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Thesis contribution 
 
This thesis contributes to the area of postpartum haemorrhage. Specifically, it 
introduces novel thinking and techniques to the fields of prevention and early 
management.  
 
The work in this thesis, including the publications, is collaboration between me and 
my supervisors. I designed the introduction and undertook the literature review. I 
wrote the first draft of the protocols for all of the included studies that my PhD thesis 
is based upon. I also located and collected all editions of the ‘Ten Teachers’ book, 
summarised the topic on postpartum haemorrhage, and extracted the illustrated 
tables and figures.  
 
I searched for and contacted the corresponding authors for the studies included in the 
histogram study described in Chapter 3. I worked on the original data from the 
studies, further analysed the data to meet the scope of the chapter, extracted the 
figures and wrote the initial discussion points.  
 
The systematic review in this thesis was completed under the supervision of 
Professor Zarko Alfirevic. The search strategy used in the systematic review was 
designed with assistance from Miss Lynne Hampson, Cochrane Search Coordinator. 
I conducted the search process in all databases, removed the duplicate articles via 
EndNote and then made an independent decision upon inclusion and exclusion of 
founded studies, designed data extraction sheet and undertook the data extraction, 
summarised the findings in form of tables, and wrote the discussion with valuable 
guidance from the supervisor. 
 
The original idea to undertake studies involving the PPH Butterfly was that of 
Professor Andrew Weeks, but I undertook all of the work for the studies, beginning 
with writing the protocol, and then running the studies and the subsequent data 
collection and analysis. However, a pressure system used in the mannequin study 
was supplied and calibrated by Mr John Porter. Although Mr Peter Watt undertook 
the designing and production of prototypes of the PPH Butterfly, I was involved in 
development of the device from the very early stages, and provided ideas and some 
utensil that contributed to the design of the device. 
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I also wrote the first draft of the published papers included in the thesis. I have gone 
through the process of submitting papers to relevant journals. I have also responded 
to reviewers’ comments and approved the final version of papers for publication. I 
have prepared all the presentations listed in the thesis and this included all posters 
and oral presentations. 
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Abstract 
 
Postpartum haemorrhage (PPH) is the most common cause of maternal mortality 
leading to an estimated 86, 000 deaths/year. The most common cause of PPH is 
failure of the uterus to contract properly (uterine atony). Several measures have been 
introduced to prevent and treat atonic PPH, but in spite of active management of the 
third stage of labour (AMTSL), maternal deaths from PPH still occur. PPH can kill 
rapidly within two hours or less. 
 
PPH has long been recognised as a dangerous complication for mothers. In order to 
optimise the prevention and treatment of PPH, different approaches have been 
introduced and modified over the last century. We reviewed the regimes used in the 
management of the third stage of labour between 1917 and 2011 as described in the 
successive editions of the ‘Ten Teachers’ books. Throughout the Ten Teachers 
series, uterotonic drugs have always been taught as being the best initial measure to 
manage PPH. However, the importance of bimanual uterine compression (BMC) has 
increased gradually, moving from third to first treatment option over the editions 
(Aflaifel and Weeks, 2012a) (Appendix A.1). 
 
The components of the AMTSL package for PPH prophylaxis have recently been 
extensively examined in clinical trials. Its effectiveness in reducing blood loss is 
now known to be almost all due to the uterotonics (Aflaifel and Weeks, 2012b) 
(Appendix A.2). However, clinical trials evaluating the efficacy of uterotonics in 
treating PPH are comparatively rare. Where present they usually compare two 
uterotonics with an absence of control group, as it is unethical to leave a bleeding 
woman untreated. A recent innovation is to model the likely outcomes in the absence 
of uterotonic therapy through histograms. This also allows an assessment of the 
efficiency of treatment by measuring the number of women who stop bleeding 
shortly after administering treatments. This model has never previously been applied 
to databases in which uterotonics were used for prophylaxis. In a secondary analysis 
of 4 large randomised trials, small secondary histogram peaks (primarily attributed 
to a treatment effect) were still present even if uterotonic therapy had not been used. 
Furthermore, the study revealed that women were commonly treated at low levels of 
blood loss (< 500 mls). It was also seen that, of those diagnosed with PPH (≥ 500 
mls), most stopped bleeding at blood losses of around 700 mls even if they did not 
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receive any uterotonic therapy. This should warn against ascribing all the effect to 
uterotonic therapy. As well as stopping spontaneously, other physical therapies may 
also have been used concurrently and may have had an effect.  
 
The evidence from the histogram study suggested that use of additional uterotonic is 
not a good surrogate for PPH in the research context. Chapter 4 reports on 
evaluations of the outcomes that are used by researchers in PPH trials. In the 121 
studies evaluated, there was a huge diversity in choosing the outcomes (PPH 
prevention). The most common was ‘Incidence of PPH ≥ 500 mls’, which was 
mentioned in 21% (25/121) of trials. The study interestingly showed that use of 
additional uterotonic was used for sample size calculation in 6% (7/121) of studies 
as a surrogate for PPH.  
 
The above findings emphasise the importance of physical measures in the early 
treatment of PPH. BMC is thought to help in treating PPH, although there are no 
clinical trials on its effectiveness. A survey was therefore conducted amongst 
obstetric care providers in the UK to look at the frequency of BMC use in clinical 
practice and the attitudes towards its use. The survey found that, although clinicians 
find BMC effective, it is rarely used as the procedure is considered to be too tiring 
and too invasive.  
 
If, however, BMC could be performed in a less invasive manner, then it could act as 
an effective low-cost treatment for those PPHs arising from atony.  
 
The thesis concludes with an investigation into a new low cost intervention that 
might contribute to the early physical management of PPH. The ‘PPH Butterfly’ is a 
new device that is designed to make uterine compression simpler, less tiring and less 
invasive. It was compared to the standard BMC in a mannequin model. The main 
objective was to compare the efficacy of the PPH Butterfly to standard BMC in 
producing sustained uterine compression. The study revealed that the PPH Butterfly 
is simple to use on a mannequin model, even among obstetric care providers with 
little experience.  It produces an equivalent amount of pressure to BMC, but neither 
method produced sustained compression over the 5 minutes of use. It also 
demonstrates the feasibility of using a mannequin model for teaching and 
performing BMC.  
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                                              Thesis summary 
 
 What is already known about postpartum haemorrhage? 
  
 
 
 How was the management of the third stage of labour developed? 
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1. Introduction  
 
The third stage of labour is referred to the period between the completed delivery of 
the baby and the placenta.  
 
"This indeed is the unforgiving stage of labour, and in it there lurks more unheralded 
treachery than in both the other stages combined. The normal case can, within a 
minute, become abnormal and successful delivery can turn swiftly to disaster" 
(Donald, 1955). 
 
Relatively little thought or teaching seems to be devoted to the third stage of labour 
compared with that given to the first and second stages. The third stage of labour is a 
risky time as uneventful, significant complications that threaten the mother’s life can 
occur in this period. The most common complication is PPH. Although maternal 
mortality rates have declined dramatically in the developed world, PPH remains a 
leading cause of maternal mortality especially in developing countries. Improving 
maternal health is Millennium Development Goals (MDG) 5. The international 
targets have been set to reduce maternal mortality by 75% between 1990 and 2015.  
The WHO 2010 report revealed a promising result in some countries, but many other 
countries made no progress and are likely to miss the target unless accelerated 
interventions are put in place (Fathalla,  2012). Globally, the maternal mortality ratio 
dropped by 45% between 1990 and 2013, this still falls far short of the MDG target 
(United Nations, 2014). Global rates of change suggest that only 16 countries will 
achieve the MDG 5 target by 2015 (Kassebaum et al., 2014).  
 
 
 
 
 
 
 
 
 
 
16 
 
2. Primary postpartum haemorrhage 
 
2.1.  Background 
 
PPH remains the most common cause of maternal mortality worldwide (Say et al., 
2014). It is estimated that, 86, 000 women die from PPH each year, which is ten 
deaths every hour. It is associated with morbidity in 20 million women per year 
(Fawcus et al., 1995; Selo-Ojeme, 2002). PPH is responsible for around 25% of 
maternal mortality worldwide (WHO, 2007a), reaching as high as 60% in some 
countries. Although the absolute risk of death is much lower in high-income 
countries (1 in 100,000 births versus 1 in 1,000 births in low-income countries 
(WHO, 2007b). PPH can also be a cause of long-term severe morbidity, and 
approximately 12% of women who survive PPH will have severe anaemia 
(AbouZahr, 2003). Additionally, women who have severe PPH and survive “near 
misses” are significantly more likely to die in the year following the PPH 
(IMMPACT, 2007). Furthermore, haemorrhage is the leading cause of admission to 
the intensive care unit. Importantly, although PPH constitutes a serious health 
burden, it is the most preventable cause of maternal mortality.  
 
The leading cause of PPH is thought to be uterine atony - the failure of the uterus to 
contract fully after delivery of the placenta. PPH resulting from uterine atony is a 
major preventable cause of maternal morbidity and mortality, especially in 
developing countries (B-Lynch et al., 2006). Morbidity and mortality due to PPH are 
largely preventable through skilled care during childbirth. However, delays in 
identifying haemorrhage, delays in transporting the woman to the appropriate point 
of care, and delays in receiving the recommended treatment all contribute to high 
rates of maternal mortality and morbidity due to PPH. In many poor countries, 
women may give birth without any assistance. Alternatively, a relative, a member of 
the community, or a traditional birth attendant (TBA), often without formal health 
training, may attend births occurring in the community. These women may not have 
access to interventions to either prevent or treat PPH (Miller et al., 2004).   
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There are different types of review in medical research such as systematic reviews 
and narrative reviews. Traditional narrative reviews differ from systematic reviews 
in several ways. Narrative reviews tend to be mainly descriptive, do not involve a 
systematic search of the literature, and therefore often focus on a subset of studies in 
an area which are chosen based on availability or author selection. An example of a 
systematic review can be seen in Chapter 4, but the current chapter is a narrative 
review as it is the most appropriate way to draw out the current knowledge about 
PPH. Different databases were searched, including PubMed, Scopus, Cochrane and 
the Web of Knowledge, using various key words (e.g. postpartum haemorrhage, 
third stage of labour, prophylaxis, treatment and prevention). The reference list of 
identified articles was also searched for additional relevant papers. 
 
This section will give an overview of the literature on PPH, including its definitions, 
the main aetiologies and risk factors, complications, prevention and available 
treatment options. It will concentrate particularly on the prevention and early 
treatment of atonic uterus as a main cause of PPH. 
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2.1.1.  Definitions  
 
Bleeding after delivery can be of two types. PPH is classified into primary (within 
the first 24 hours) or secondary haemorrhage (between 24 hours and six weeks). 
Traditionally, primary PPH is defined as a “loss of blood estimated to be more than 
500 mls per vaginam within the first 24 hours of delivery” (WHO, 1990; RCOG, 
2009). Primary PPH after caesarean section is defined as blood loss of 1000 mls or 
more (Maughan et al., 2006). PPH can be minor (500-1000 mls) or major (more than 
1000 mls). Major can be divided further to moderate (1000-2000 mls) or severe 
(more than 2000 mls) (RCOG, 2009).  
 
However, the exact definition of PPH remains problematic as the definition is 
usually based on visual estimations of bleeding. The WHO definition of 500 mls is 
increasingly becoming irrelevant, as the effect of blood loss differs from mother to 
mother. Most healthy women in the developed world can withstand a blood loss of 
more than 500 mls without any hemodynamic compromise, whereas for severely 
anaemic women even a small amount of blood loss can be fatal. This is especially 
important for mothers living in developing countries, where significant numbers of 
women have severe anaemia. Additionally, McCormick and colleagues have 
commented on the conventional definition of PPH as not clinically helpful, because 
it is often not easy to precisely assess the amount of blood a woman has lost. 
Additionally, the blood may be mixed with amniotic fluid or urine, or may be 
scattered on sponges or linens, or on the floor. In many cases, especially with slow 
trickling blood loss, PPH remains undetected, leading to an under-estimation of 
blood loss following delivery. For these reasons, a more accurate definition of PPH 
might be any amount of bleeding that causes a change for the worse in the woman’s 
condition (e.g., low systolic blood pressure, rapid pulse, signs of shock) 
(McCormick et al., 2002), which is also the preferred definition by the International 
Federation of Gynecology and Obstetrics (FIGO) latest recommendations on 
prevention and treatment of PPH (Lalonde, 2012). There are other different 
diagnostic criteria for PPH definition. These include a haematocrit drop of greater 
than 10% from the antepartum level, which necessitates blood transfusion, and 
which results in signs and symptoms of hypovolaemia (Combs et al., 1991a). 
However, changes in haemoglobin concentrations are not a clinically useful 
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definition as rapid blood loss may trigger a medical emergency prior to observation 
of a fall.  
 
2.1.2. Incidence of PPH and related maternal deaths 
 
Efforts to determine the incidence of PPH are hampered by two issues: lack of a 
universal definition of the condition as explained above, and the inaccuracy in 
clinical estimates of blood loss at delivery. Additionally, the incidence of PPH is 
different according the way in which the third stage is managed. Blood loss 
exceeding 500 mls occurs in approximately 5% of women when labour is managed 
actively with injectable oxytocics, early cord clamping and traction, and in 13–16% 
of women when managed expectantly (Khan et al., 1997; Rogers et al., 1998). 
Therefore, it has been found that the incidence of PPH varies widely, depending 
upon the criteria used to define the disorder. Examples from different population 
studies from several parts of the world, using different criteria for defining PPH, are 
demonstrated below. 
 
It is well known that PPH is a major cause of maternal mortality in both developed 
and developing countries. Globally, it is estimated that severe PPH occurs in about 
1.86% of women who give a live birth (Carroli et al., 2008).The incidence is thought 
to be much higher in developing countries where many women do not have access to 
a skilled attendant at delivery and where AMTSL may not be routine. WHO reports 
have stated that obstetric haemorrhage causes 127,000 deaths annually worldwide 
and that it is the world’s leading cause of maternal mortality. Nearly all of these 
deaths are due to PPH (WHO, 2007b). 
 
In an attempt to assess the global magnitude of PPH, depending upon the criteria 
used to define the disorder, Carroli and colleagues (Carroli et al., 2008) performed a 
systematic review of datasets from different regions around the world. They defined 
PPH (their inclusion criteria) as > 500 mls blood loss, and severe PPH (SPPH) as > 
1000 mls of blood loss. These authors, using 224 datasets, arrived at an overall 
prevalence of PPH (defined as blood loss in excess of 500 mls) of 6.09% (95% CI, 
6.06-6.11). However, when the blood loss was measured objectively, the rate was 
10.6%. The rates were about one-half of this when the method of assessment was not 
specified, consistent with the concept that blood loss is typically underestimated. 
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These authors also found the prevalence of severe PPH (defined as blood loss >1000 
mls) to be 1.86% (95% CI, 1.82-1.90). Again, the prevalence was almost doubled 
when the blood loss was measured objectively (3.04%; 95% CI, 2.90-3.17).  Most 
PPH cases were found in rural rather than in urban settings. The researchers also 
found that the rates of PPH were highest in Africa, and they attributed this partly to a 
lack of adequately skilled delivery personnel.  
 
The figure related to PPH incidence is not consistent across the world. The incidence 
differed according to the definition used, way of postpartum blood loss measured 
and the population being studied. The following is an overview on incidence of PPH 
on country bases, which would be more informative. 
 
Although pregnancy-related death is rare in the US, PPH accounts for 17% of deaths 
(Chang et al., 2003). An analysis of population-based data from the United States 
National Inpatient Sample for the years 1994-2006 found that diagnosis of PPH 
increased 26% over this period (from 2.3 to 2.9%) (Callaghan et al., 2010). Not 
surprisingly, uterine atony was the most common cause of PPH and accounted for 
most of the increase. The proportion of women diagnosed with uterine atony 
increased from 1.6 to 2.4 percent over the same interval. 
 
In the United Kingdom, although maternal deaths are extremely rare, PPH is still 
one of the most common causes of maternal mortality. The United Kingdom 
Confidential Enquiries into Maternal Deaths found that the maternal mortality rate 
due to PPH was 1.0 per 100, 000 maternities. During the three years from 2000 to 
2002, there were 10 maternal deaths from PPH out of a total of 261 maternal deaths 
(CEMACH, 2004). The maternal mortality rate for 2003-2005, calculated from all 
maternal deaths directly or indirectly due to pregnancy identified that 14 women 
died from haemorrhage; a rate of 0.66 per 100,000 maternities. Out of these 14, 2 
women died due to abruptio placenta, 3 cases due to placenta praevia and 9 women 
due to PPH (Lewis, 2007). In the triennium 2006-2008, there was a reduction in 
maternal deaths attributed to direct causes. This was mainly due to a reduction in 
deaths from thromboembolism and to a lesser extent, from haemorrhage (CEMACH, 
2011). This could be mainly due to the publication and implementation of guidelines 
that were recommended in previous reports. 
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In Africa, haemorrhage is estimated to be responsible for 30% of all maternal deaths 
(WHO, 2009). In Sub-Saharan Africa, for every 16 women, one will die of 
pregnancy and childbirth-related conditions, and PPH accounts for 25% of the 
aetiology of maternal mortality (Miller et al., 2004). Etuk and Asuquo reported that 
the death rate on account of PPH is 2.2% in a teaching hospital in Nigeria (Etuk and 
Asuquo, 1997). In Zimbabwe, in a community-based study of maternal mortality 
(Fawcus et al., 1997), it has been found that obstetric haemorrhage was the main 
contributor to one quarter of maternal deaths, with a cause-specific maternal death 
rate of 40 per 100, 000 live births. More cases of maternal mortality occurred in 
rural areas compared to urban areas. In the same study, it was found that most 
women (50%) dying from PPH died at home or in transit to, or between, institutions 
as they did not have access to any treatment before their death. The South African 
Confidential Enquiries into Maternal Deaths indicated that PPH was the third most 
common cause of death, accounting for 313 deaths in a total of 3406 in the triennium 
2002 to 2004 (Tshabalala, 2006). 
 
In another study, blood loss at caesarean delivery was measured and defined as a 
loss of  1000 mls or more, a need for blood transfusion or presence of signs and 
symptoms of hemodynamic instability (Magann et al., 2005a). The authors found 
that the incidence of PPH in non-elective caesarean (6.75%) was greater than after 
elective caesarean (4.84%, P=0.007). 
 
Combs and co-workers, in a case-control study of 9598 vaginal deliveries at Moffitt 
Hospital in San Francisco, found PPH (defined as a haematocrit drop of 10 points or 
more) in 374 cases (3.9%) (Combs et al., 1991a). In another study by the same 
authors, limited to women who underwent caesarean delivery, 196 of 3052 eligible 
deliveries were complicated by PPH, producing a rate of 6.4% (Combs et al., 
1991b). In another Australian study blood loss at vaginal delivery was calculated by 
collecting and measuring the blood in collection devices used specifically for 
vaginal birth and then weighing sheets, drapes, and sponges after delivery. PPH was 
defined as blood loss in excess of 1000 mls and/or need for blood transfusion 
because of maternal anaemia and/or hemodynamic instability. Over a 4-year period, 
13,868 of 19,476 women delivered vaginally, with a PPH rate of 5.15% (Magann et 
al., 2005b) . 
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It is very obvious that maternal death due to PPH is much more frequent in resource-
poor countries. The imbalance between resource-rich and resource-poor areas is 
thought to be from a combination of an increased prevalence of risk factors (e.g. 
grand multiparity, obstructed labour and twins), a lack of safe blood banking, no 
routine use of prophylaxis against haemorrhage, and a lack of measures for drug and 
surgical management of atony. In a secondary analysis of the multi-country survey 
on maternal and newborn health, Sheldon (Sheldon et al., 2014) found that that the 
provision of uterotonics for both prevention and treatment of PPH is widespread 
among the health facilities that participated (95.3% of women received uterotonic 
prophylaxis). High coverage of essential interventions, however, did not result in 
reduced maternal mortality in the studied facilities. The evidence is that it is mainly 
services that affect mortality (Sheldon et al., 2014) and the underlying risk factors 
and prophylaxis have little effect. For example, in clinical trials the maternal 
mortality rate is very low, even in those women having a placebo. In the South 
Africa report (Tshabalala, 2006), patient/community-related factors, lack of 
emergency transport, lack of blood for transfusion, lack of appropriately skilled 
personnel, and substandard treatment were all included among the avoidable factors.  
 
Overall, since haemorrhage can be difficult to detect, a universal definition is 
lacking, clinical estimates of blood loss are inaccurate, and there is poor recording of 
maternal deaths in remote regions, therefore the true incidence of PPH remains 
unclear. It may be even higher than the reported percentages.  
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2.1.3.  Physiology of the third stage of labour 
 
Over the course of a pregnancy, maternal blood volume increases by approximately 
50%, from 4 to 6 L and the red blood cell (RBC) volume by 32% (Pritchard, 1965). 
The plasma volume increases somewhat more than the total RBC volume, leading to 
a fall in the haemoglobin concentration and haematocrit values (haemodilution). 
This decrease is smaller in women who take supplemental iron, whereas the fall may 
be dramatic in women who do not take supplemental iron and who have limited iron 
stores or are anaemic upon becoming pregnant (Chohan, 2005). The increase in 
blood volume serves to fulfil the perfusion demands of the low-resistance 
uteroplacental unit and to provide a reserve for the blood loss that occurs at delivery. 
The increased blood volume also protects against hypotension caused by decreased 
venous return and decreased vascular tone due to high progesterone levels (Baskett, 
1999). 
 
Changes also occur in the coagulation system, with a marked increase in clotting 
factors and a decrease in fibrinolytic activity. The platelet count may fall slightly 
during pregnancy because of dilution related to the increased plasma volume and as 
a result of low-grade consumption; however, individual platelet volume is increased 
and activity is maintained (Chohan, 2005). Although uterine contraction is initially 
responsible for controlling blood loss at the placental site, clot formation and fibrin 
deposition occur rapidly and are essential in maintaining haemostasis and promoting 
involution in the days following delivery (Sleep, 1993). 
 
Early in pregnancy, the uterus grows dramatically, from an initial weight of roughly 
30-60 g and a cavity volume of 4 mls to a term weight of 700-1000 g and a capacity 
of approximately 4 L. As with the haematological and coagulation changes 
mentioned above, high levels of oestrogen promote and allow this change in the 
uterus (Chohan, 2005).
 
The initial growth of the uterus and the ultimate growth of 
the placenta and fetus require an equally impressive increase in blood flow to the 
uterus during pregnancy. At term, the estimated blood flow to the uterus is 500-700 
mls/min, which represents 10-15% of cardiac output. Most of this flow traverses the 
low-resistance placental bed (Amin  and Long, 2009). 
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2.1.3.1. Mechanisms of placental separation 
 
The physiological processes occurring during the third stage are a continuation of 
those processes occurring during the first and second stages of labour. There is an 
interplay of mechanical and haemostatic factors to separate and expel the placenta, 
and to control bleeding from the placental site. With the delivery of the placenta, the 
muscle fibres surrounding the maternal vessels contract completely to prevent 
excessive bleeding and the mother’s coagulation system is activated temporarily 
(Bonnar et al., 1970a). 
 
During the third stage of labour and following the delivery of the fetus, uterine 
contractions continue and the placenta is sheared from the underlying endometrium. 
This separation primarily occurs by a reduction in the surface area of the placental 
site as the uterus shrinks. This process is known as retraction. This myometrial 
retraction, which is a unique feature of the uterine muscle, is essential to maintain its 
shortened length following each successive contraction. In this way, the placenta is 
undermined, detached, and pushed into the lower uterine segment (Amin  and Long, 
2009). Oxytocin, a hormone secreted by the posterior pituitary gland, stimulates 
uterine contractions. Oxytocin levels increase greatly in late pregnancy and even 
more during labour and lactation. The compression of the placenta also forces the 
retro-placental blood back into the sinuses in the decidua basalis. The placenta 
attempts to force blood through the uterine sinuses, closed off by strong myometrial 
contractions. The sinuses become congested and rupture. The blood escapes from 
the ruptured sinuses, tearing the fine septae of the spongy layer off the decidua 
basalis. Consequently, the placenta shears off (Khan and EL-Refaey, 2006). 
Classical signs of placental separation include a small gush of blood with 
lengthening of the umbilical cord and a slight rise of the uterus in the pelvis, since 
the uterus contracts more effectively after the placenta is expelled. If the uterus does 
not contract normally, the blood vessels at the placental site stay open and 
haemorrhage results.  
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There are two classical methods of placental delivery which result in different 
bleeding patterns. These are the Schultze and Matthew Duncan methods, named 
after the persons who first described them (Speert, 1996). In the Schultze method, 
separation and descent occur in the central part of the placenta with the fetal surface 
protruding first, followed by the rest. As the centre of the placenta is pushed 
forward, it becomes inverted on itself forming a bag filled with blood. The Matthew 
Duncan method is characterised by detachment of the placenta edges, folding upon 
itself transversely in the passage, leading to the entire organ sliding down and out of 
the uterus sideways with the maternal side of placenta appearing first. This method 
is supposed to cause more bleeding than the Schultze method because of the slow 
separation of the placenta which allows more time for bleeding. There is however 
little relevance of this; distinction of the placental separation method appears to be 
clinically irrelevant and clinicians are incapable of predicting or changing the 
method of separation (Khan and EL-Refaey, 2006). 
 
Ultrasound studies have provided fresh insights into the mechanism of the third 
stage of labour. An ultrasonographic imaging study was performed to investigate the 
mechanism of placental delivery during the third stage of labour. Continuous real-
time ultrasound was performed during the third stage of labour in 101 normal 
deliveries (Herman et al., 2002). This study demonstrated that the process of 
placental separation is multiphasic and has three distinct phases. The first, or latent 
phase, consists of strong uterine contractions that lead to the thickening of the 
uterine muscle in all areas except behind the placenta (thus causing a shearing force 
to occur between the elastic uterine wall and the more rigid placenta). Continued 
contractions lead to gradual contracts of the retro-placental myometrium. Separation 
of the placenta commences at one of the poles and spreads slowly during the 
contraction or detachment phase until full separation occurs. This is followed by 
delivery of the placenta in the expulsion phase. The most common type of placental 
separation was ‘down-up’ separation where the process started at the lower pole. It 
rarely began from the upper pole (up-down separation). In cases of a fundal 
placenta, the separation began from either the posterior or anterior pole with the 
fundal part separating last (bipolar separation) (Herman et al., 2002). The up-down 
separation was more common in women who had a previous caesarean section, 
probably due to impaired lower uterine segment contractility (Mo and Rogers, 
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2008). The study by Herman and others (2002) also highlighted the role of 
retroplacental myometrial failure in causing retained placenta (Herman et al., 2002). 
However, the lack of contraction at the retroplacental area during early labour might 
have many benefits to the fetus. It could act as a protective mechanism to prevent 
intrapartum abruptio, and might also be protective against fetal anoxia by ensuring 
an uninterrupted maternal blood supply to the placental bed during contractions 
(Weeks, 2008).  
 
Another study using real time B-mode ultrasound described placental separation in 
three types (Goto, 1984). In Type I, which occurred in 53% of the cases, placental 
separation from its bed occurred smoothly and it slid out immediately, usually one or 
two contractions after the delivery of the baby. This type was characterised by the 
least blood loss and the shortest duration of the third stage of labour. Placental 
separation in Type II started at the marginal site and gradually progressed with each 
recurring contraction. With this type, the bleeding tended to be greater and the time 
to placental separation tended to be longer. In Type III, separation of the placenta 
began at the central part with formation of retroplacental clots resulting in an 
increase in placental size. The blood loss and the duration of the third stage were 
generally moderate. 
 
2.1.3.2.  Haemostasis 
 
When the placenta is separated from the uterine wall it leaves about 300 square 
centimetres and maybe 100 torn arteries which had been delivering around 500 mls 
of blood per minute to the placenta. This massive trauma requires both a physical 
compression of the blood vessels by the myometrial contraction, as well as vessel 
blockage by haemostasis (Hytten, 1995). Uterine muscles compress the maternal 
spiral arteries and veins of the placental bed, resulting in an obliteration of their 
lumina. Moreover, the strong myometrial contraction helps haemostasis by opposing 
the uterine walls firmly against one another and producing direct pressure on the 
placental site (Khan and EL-Refaey, 2006). The vessels supplying the placental bed 
traverse a latticework of crisscrossing muscle bundles that occlude and kink-off the 
vessels (Figure 1) as they contract and retract following the expulsion of the 
placenta. This arrangement of muscle bundles has been referred to as the "living 
ligatures" or "physiologic sutures" of the uterus (Sleep, 1993).
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After the separation of the placenta, the placental site is rapidly covered by a fibrin 
net and clots form. Coagulation at the placental site has an important role in the 
prevention of PPH after separation of the placenta. Around the time of delivery, 
many changes both in coagulation factors and fibrinolysis agents take place. There is 
consumption of platelets and blood coagulation factors (including fibrinogen) by clot 
formation and haemostasis at the placental site. This causes a decrease in the 
peripheral plasma fibrinogen levels. In a study performed by Bonnar et al., uterine 
veins samples were obtained during caesarean section in 12 patients. They found 
that the time of placental separation was accompanied by a prominent activation of 
the local clotting mechanism and a sharp increase in factor VIII (Bonnar et al., 
1970b). In another study of the coagulation and fibrinolytic systems in 15 healthy 
women during normal childbirth, there was a rapid increase in the clotting factors 
VIII and V and a decrease in plasma fibrinogen in the peripheral circulation. Within 
one hour of delivery, fibrinolytic activity returns to its non-pregnant levels, and there 
is an increase in the level of fibrin/fibrinogen degradation products. In early 
puerperium, changes promoting coagulation take place. This includes an increase in 
the fibrinogen level and a swift increase in platelet count. The level of factor VIII 
remains high (Bonnar et al., 1970a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Muscle fibres of the uterus  (Lalonde, 2012) 
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2.1.3.3. Length of the third stage of labour 
 
The length of the third stage of labour determines the amount of blood loss that 
occurs during that period, which depends on how quickly the process of placental 
separation occurs. Fifty percent of placental deliveries occur within 5 minutes, and 
90 percent are delivered within 15 minutes (Dombrowski et al., 1995). A third stage 
of labour lasting longer than 18 minutes is associated with a significant risk of PPH. 
When the third stage of labour lasts longer than 30 minutes, PPH occurs six times 
more often than it does among women whose third stage lasts less than 30 minutes 
(Odds ratio (OR) 6.2; 95% CI 4.6–8.2) (Magann et al., 2005c).  
 
There is no consensus as to the length of the third stage of labour after which the 
placenta should be called retained. In general, it has been suggested a third stage 
lasting more than 30 minutes should be considered abnormal (NICE, 2007), whereas 
the WHO manual of childbirth suggests 60 minutes to reflect the normal time of the 
third stage (WHO, 2012). The length of the third stage in those who received no 
prophylaxis during the third stage (i.e. physiological management) can be extended 
to 60 minutes (NICE, 2007).   
 
Percentage of patients with retained placenta after 30 minutes was found to be 
different between countries. It was 2.67% (2.00–6.26- range) in the developed 
countries and 1.55% (1.05–4.60- range) in the developing countries (Cheung et al, 
2011). As stated by the authors the differences may be explained by differences in 
the aetiology and risk factors of retained placenta between countries. 
 
The incidence of retained placenta also differs according to the method followed to 
manage the third stage. Incidence of retained placenta at 30 minutes has been found 
to be about 2% and 20% with active and expectant management of the third stage of 
labour respectively. When the third stage of labour lasted more than 1 hour, the 
incidence of undelivered placenta was found to be 0.7% for both active and 
physiological management (Weeks, 2008). 
  
The association between placental location and length of the third stage of labour in 
normal term singleton pregnancies was evaluated in a retrospective study, including 
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200 consecutive singleton term live vaginal deliveries following uncomplicated 
pregnancies. Patients’ charts were reviewed in order to determine the placental 
implantation site. The duration of the third stage of labour was statistically 
significantly longer (12.8 ± 9.526 minutes) in the 26 cases (13%) in which  the 
placenta was located in the fundal area of the uterus (Lurie et al., 2003). However, 
when this was studied prospectively in 201 women in labour, the association 
between prolonged third stage and fundal location of placenta was not demonstrated 
(Altay et al., 2007). The length of the third stage of labour in that study was 
approximately 2 min shorter with placentas located at the fundus compared to the 
anterior and posterior locations. The authors explained that the mechanism 
responsible for the shorter duration may be the bipolar separation of fundal placentas 
in contrast to the usual unipolar down-up separation of anterior or posterior 
placentas. Another contributing factor may be the use of oxytocin infusion for the 
management of the third stage, as oxytocin causes contraction mainly to the upper 
uterine segment, facilitating separation of fundal-located placenta. 
 
2.1.4.  Causes and risk factors  
 
Understanding the aetiology of PPH is fundamental to effectively managing the 
condition in an acute setting. There are several possible reasons for immediate PPH. 
Primary PPH is traditionally considered as a disorder of one or more of the four 
processes: uterine atony, retained clots or placental debris, genital lesions or trauma, 
and disorders of coagulation. An aide memoire is the four Ts: tone, tissue, trauma 
and thrombin. Tone refers to uterine atony, which is thought to occur in 75-90% of 
cases. Genital tract trauma is responsible for 20% of cases, and includes trauma to 
the broad ligament, uterine rupture, and uterine inversion as well as cervical, vaginal 
and perineal tears. Retained placental tissue prevents effective uterine contraction in 
10% of cases. Coagulation disorders are rare (1%) (B-Lynch et al., 2006). Causes 
and many other risk factors associated with early PPH are summarised in Table 1. 
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2.1.4.1. Aetiology of PPH 
 
2.1.4.1.1. Uterine atony 
 
Uterine atony refers to a floppy, flaccid uterus, one in which the myometrium is 
unable to contract effectively and constrict the blood vessels after the expulsion of 
the placenta leading to haemorrhage. Uterine atony is the most common cause of 
primary PPH, and accounts for 75-90% of cases of PPH (Koh et al., 2009). At term, 
more than 500-700 mls of blood enters the uteroplacental circulation every minute 
(El-Refaey and Rodeck, 2003; Amin  and Long, 2009). It is understandable that 
primary atonic PPH can be catastrophic, as over a short time of myometrial 
relaxation, fatal haemorrhage can occur. Uterine atony can occur after normal 
vaginal delivery, instrumental vaginal delivery and abdominal delivery. There are 
many recognised risk factors for uterine atony including an over-distended uterus 
caused by polyhydramnios, multiple gestations, and a large baby. Moreover,  
prolonged labour, oxytocin use in labour or chorioamnionitis and tocolytics/general 
anaesthesia can contribute to poor contractility of uterine muscle (RCOG, 2009). 
However, uterine atony may occur in women without any risk factors. About 26% of 
women who underwent hysterectomy had no identifiable risk factors (Clark et al., 
1984). In the UK, uterine atony was responsible for 53% of peripartum 
hysterectomies between February 2005 and February 2006 (Knight, 2007).  
 
2.1.4.1.2. Genital tract trauma 
 
Generally, if PPH is not due to uterine atony, genital tract trauma is likely to be the 
cause of severe bleeding. Lacerations and hematomas resulting from birth trauma 
can cause significant blood loss that can be lessened by haemostasis and timely 
repair. Trauma may result from laceration of the cervix, the vagina sidewall, the 
perineum and episiotomy, or from uterine rupture. Genital tract trauma could also be 
iatrogenic during caesarean delivery or instrumental delivery such as forceps or 
vacuum.  
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Uterine inversion is rare, occurring in 0.05 percent of deliveries. Fundal implantation 
of the placenta may lead to inversion (Gabbe et al., 2002). The condition commonly 
occurs secondary to mismanagement of the third stage of labour, especially if 
traction of the cord is applied before sufficient contractions of the uterine muscle is 
reached, and without applying effective counter pressure to the uterine fundus 
(Jeganathan and Sivanesaratnam, 2011). The inverted uterus usually appears as a 
bluish-grey mass protruding from the vagina. Vasovagal effects producing vital sign 
changes disproportionate to the amount of bleeding may be an additional clue. The 
placenta often is still attached, and it should be left in place until after reduction 
(Baskett, 2002). This cause of PPH can be fatal if not recognised and treated 
appropriately and quickly. 
 
Clinically significant uterine rupture occurs in 0.6 to 0.7% of vaginal births, and 
after caesarean delivery in women with a low transverse or unknown uterine scar 
(Chauhan et al., 2003; Landon et al., 2004). The risk increases significantly with 
previous classical incisions or uterine surgeries, and to a lesser extent with shorter 
intervals between pregnancies or a history of multiple caesarean deliveries, 
particularly in women with no previous vaginal deliveries. Compared with 
spontaneous labour, induction or augmentation increases the rate of uterine rupture 
(Landon et al., 2004). The primary signs of uterine rupture are vaginal bleeding, 
abdominal tenderness, maternal tachycardia, circulatory collapse, or increasing 
abdominal girth (ACOG, 2004). 
 
2.1.4.1.3. Retained products of conception  
 
Retained uterine products are the most common cause of delayed PPH (Roberts, 
1995; Lalonde, 2012). In normal circumstances, uterine contractions expel the 
placenta within a few minutes of childbirth. The placenta is then examined, to ensure 
it is intact. If the placenta has not been delivered within 30 minutes of childbirth the 
placenta must be retrieved (Jeganathan and Sivanesaratnam, 2011). Retained 
placenta occurs in 0.5–3% of vaginal deliveries (Weeks and Mirembe, 2002) and 
may cause inadequate uterine contraction (Oyelese and Ananth, 2010). Rates of 
retained placenta are significantly higher in developed countries, irrespective of 
whether retained placenta is defined as the length of third stage or as the need for 
manual removal (Cheung et al., 2011). Predisposed risk for retained uterine products 
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includes history of previous curettage, caesarean section or endometrial infection or 
injury, induction of labour (Golan et al., 1983; Combs and Laros, 1991; Soltan and 
Khashoggi, 1997). It has been also found a statistically significant association 
between prolonged third stage and augmented labour (Combs and Laros, 1991).  
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Table 1. Causes and predisposing factors for PPH 
 
PPH cause 
 
Aetiology process 
 
 
Clinical risk factor 
Abnormalities of uterine 
contraction  (Tone)  
 
- over distended uterus - polyhydramnios 
- multiple gestation 
- macrosomia 
- uterine muscle exhaustion - rapid labour 
- prolonged labour 
- high parity 
 
- intra amniotic infection - prolonged ROM 
 
- functional/anatomic distortion 
of the uterus 
- fibroid uterus 
- placenta previa 
- uterine anomalies 
Retained products of 
conception (Tissue) 
- retained products 
- abnormal placenta  
- retained cotyledon or 
succinturiate lobe 
- incomplete placenta at delivery 
- previous uterine surgery 
- abnormal placenta on U/S 
 
- retained blood clots  - atonic uterus 
 
Genital tract trauma 
 (Trauma)  
 
- lacerations of the cervix vagina 
or perineum 
- precipitous delivery 
- operative delivery 
 
- extensions, lacerations at  
caesarean section 
- malposition 
- deep engagement 
 
- uterine rupture - previous uterine surgery 
- induction of labour 
 
- uterine inversion  - excessive cord traction or fundal 
pressure at the 3rd stage  
 
Abnormalities of 
coagulation  (Thrombin) 
 
pre-existing states  
  - haemophilia A  
  - Von Willebrand’s Disease 
 - history of hereditary 
coagulopathies 
- history of liver disease 
 
- acquired in pregnancy 
   - ITP 
   - thrombocytopenia with pre-
eclampsia  
- DIC  
      - pre-eclampsia 
      - dead fetus in utero 
      - severe infection  
      - abruption 
      - amniotic fluid embolus 
 
 
- bruising 
- elevated BP 
- fetal demise 
- antepartum haemorrhage 
  
 - therapeutic anti-coagulation 
 
- history of blood clot 
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2.1.4.1.4. Coagulation disorders  
 
Coagulation disorders are a rare cause of PPH. Both inherited and acquired 
coagulation defects are associated with excessive blood loss postpartum. 
Fortunately, most coagulopathies are identified before delivery, allowing for 
advance planning and preventing PPH. These disorders include idiopathic 
thrombocytopenic purpura, Von Willebrand's disease, and haemophilia; patients can 
also develop HELLP syndrome (haemolysis, elevated liver enzyme levels, and low 
platelet levels) or disseminated intravascular coagulation. Excessive bleeding can 
deplete coagulation factors and lead to consumptive coagulation and disseminated 
intravascular coagulation, which promote further bleeding. Risk factors for 
disseminated intravascular coagulation include severe pre-eclampsia, amniotic fluid 
embolism, sepsis, placental abruption, and prolonged retention of a fetal demise 
(Pritchard, 1959; Alamia and Meyer, 1999). 
 
Although PPH due to coagulation problems is categorised under thrombin, recent 
studies suggest that acquired fibrinogen deficiency, rather than thrombin generation, 
could be the main coagulation defect associated with obstetric bleeding (de Lloyd et 
al., 2011). In addition, fibrinogen levels could act as a prognosis factor for the 
severity of PPH, as it has been found that the level of fibrinogen during the first hour 
was the only parameter independently and significantly associated with the 
worsening of bleeding during PPH. Fibrinogen level < 2g/dl measured in the course 
of obstetric haemorrhage has been found to have a positive predictive value of 100% 
for progression to severe PPH (Charbit et al., 2007).  
 
2.1.4.2. Identified risk factors for PPH 
 
Although PPH often occurs in women with no identifiable risk factors several 
studies have identified risk factors for this condition (Combs et al., 1991a; Combs et 
al., 1991b; Magann et al., 2005a; Magann et al., 2005b; Sheiner et al., 2005). 
Antenatal risk factors include increasing maternal age, high body mass index, parity 
and other medical conditions such as type II diabetes, and connective tissue 
disorders (B-Lynch et al., 2006). It is appropriate that women with these 
predisposing risk factors should deliver in a hospital with adequate facilities to 
manage PPH.  
35 
 
In a study involving 666 PPH cases out of 154,311 deliveries, significant risk factors 
were: failure to progress during second stage of labour (OR 3.4; 95% CI 2.4-4.7), 
placenta accreta (OR 3.3; 95% CI 1.7-6.4), lacerations (OR 2.4; 95% CI 2.0-2.8), 
instrumental delivery (OR 2.3; 95% CI 1.6-3.4), large for gestational age (OR 1.9; 
95% CI 1.6-2.4), hypertensive disorders (OR 1.6; 95% CI 1.2-2.1), induction of 
labour (OR 1.4; 95% CI 1.1-1.7) and augmentation of labour with oxytocin (OR 1.4; 
95% CI 1.2-1.7) (Sheiner et al., 2005). There has been a long-standing debate over 
the association between prolonged labour and PPH. It is unclear whether this is due 
to a primary myometrial problem, causing the uterus to contract inefficiently both 
before and after delivery, myometrial acidaemia, or the association of both with 
increased fetal size. There is also an association with the use of oxytocin infusions in 
labour but randomised trials of intrapartum oxytocin show no effect on PPH rates 
(Saunders et al., 1989; Sosa et al., 2011). 
 
Previous history of PPH is considered as a significant risk factor for PPH in 
subsequent pregnancies. A population-based study was conducted in New South 
Wales to investigate the occurrence and recurrence of PPH in 125,295 women over a 
period from 1994 to 2002. Among the participating women, 5.8% had PPH in their 
first pregnancy and 14.8% of these women had PPH in their second consecutive 
pregnancy which represents a 3-fold increased risk of PPH. The rate of PPH in 
women who had PPH in their first two consecutive pregnancies was 21.7% in their 
third consecutive pregnancy. Furthermore, the rate of PPH in the third pregnancy in 
women who had a first pregnancy with PPH and a second uncomplicated pregnancy 
was 10.2% (Ford et al., 2007). 
 
 A major risk factor for PPH is a history of antepartum haemorrhage (Breathnach 
and Geary, 2009) including placenta praevia (Figure 2) or placental abruption, 
(Figure 3). The anatomical and physiological limitations of the lower uterine 
segment cause ineffective uterine contraction to prevent PPH after separation of the 
placenta from its bed. Implantation of the placenta in the lower segment (placenta 
praevia) makes haemorrhage much more likely. Invasive placenta can be life 
threatening. Classification is based on the depth of invasion and can be easily 
remembered through alliteration: placenta accreta adheres to the myometrium, 
placenta increta invades the myometrium, and placenta percreta penetrates the 
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myometrium to or beyond the serosa (Gabbe et al., 2002). If the placenta invades the 
myometrium (placenta increta), there is no clear cleavage line and attempts to 
remove the placenta can cause it to tear. The remaining fragments and opened 
sinuses will lead to severe haemorrhage. Risk factors include advanced maternal 
age, previous invasive placenta or caesarean delivery, and placenta praevia (Wu et 
al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Placenta praevia (A) minor placenta praevia (B) major placenta 
praevia (Baker and Kenny, 2011) 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 3. Abruptio placenta (premature separation of placenta). Two types of 
bleeding, revealed and concealed haemorrhage (Baker and Kenny, 2011) 
 
 
 
 
 
 
 
 
 
B. Revealed haemorrhage  
A. Concealed haemorrhage  
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In a study conducted at the King Edward Memorial Hospital, Perth, Australia, over a 
4-year period, where the PPH rate was 5.15% among women who delivered 
vaginally, the identified risk factors were Asian race, maternal blood disorders, prior 
PPH, history of retained placenta, multiple pregnancy, antepartum haemorrhage, 
genital tract lacerations, macrosomia (> 4 kg), and induction of labour, as well as 
chorioamnionitis, intrapartum haemorrhage, still birth, compound fetal presentation, 
epidural anaesthesia, prolonged first/second stage of labour, and forceps delivery 
after a failed vacuum (Magann et al., 2005b). 
 
Hypertensive disease of pregnancy has been linked to severe PPH caused by atony.  
This can explained in two ways. Firstly, preeclampsia can result in 
thrombocytopenia, platelet dysfunction, and disseminated intravascular coagulation. 
In addition, magnesium sulfate, used routinely in patients with preeclampsia and 
eclampsia, has the side effect of compromising postpartum uterine contractility. 
Chorioamnionitis has repeatedly been shown to result in a poorly contractile uterus, 
likely in part due to inflammation. Caesarean delivery, often performed after a 
prolonged labour, may predispose a patient to uterine atony as a result of uterine 
muscle fatigue or impaired contraction at the site of the uterine incision (Bateman et 
al., 2010). 
 
2.1.5.  Complications and prognosis 
 
If PPH does occur, the outcomes depend on many factors, for example, how healthy 
the woman is when she has PPH (particularly her haemoglobin level), how soon a 
diagnosis is made, and how quickly effective treatment is provided after PPH begins. 
Importantly, the immediate prognosis depends on the rate and the amount at which 
the blood is lost. 
 
PPH can lead to number of problems. Most PPH complications, particularly in 
Europe and the US, are well tolerated by women. However, in many parts of the 
world, especially in low-resource countries, the loss of 500 mls of blood can be a 
serious threat to health due to the high prevalence of severe anaemia. In low-income 
countries, poor nutritional status, lack of easy access to treatment, and inadequate 
intensive care and blood bank facilities are additional contributing factors that lead 
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to the high morbidity and mortality rates in these countries. Severe anaemia is a 
common consequence of postpartum bleeding and affects about 12% of the 14 
million women with severe PPH each year (AbouZahr, 2003). Anaemia may cause 
weakness and fatigue; these symptoms may make maternal care of the newborn 
more difficult. Postpartum anaemia also increases the risk of postpartum depression 
(Corwin et al., 2003). Hospitalisation may be prolonged, and the establishment of 
breastfeeding may be affected. A blood transfusion may improve the anaemia and 
shorten the hospital stay, but it carries risks of transfusion reaction and infection 
especially of viral infections such as human immunodeficiency virus (HIV) and 
hepatitis B (Ekeroma et al., 1997). Access to safe blood is not universal, and PPH 
can sometimes strain the resources of the best blood bank. Severe PPH, retained 
placenta, and uterine inversion may require emergency anaesthetic services. Any 
exploration or instrumentation of the uterus increases the risk of sepsis. 
 
Other significant morbidities associated with PPH include hypovolaemia shock, 
disseminated intravascular coagulopathy, renal failure, hepatic failure and adult 
respiratory distress syndrome (Bonnar, 2000), multiple organ failure, need for 
surgery including dilatation and curettage, and, rarely, hysterectomy. In the most 
severe cases, haemorrhagic shock may lead to anterior pituitary ischemia with delay 
or failure of lactation (postpartum pituitary necrosis or Sheehan's syndrome) (Willis 
and Livingstone, 1995; Sert et al., 2003). Hysterectomy and other surgical 
procedures to reduce blood flow to the uterus and their subsequent consequences in 
fertility have to be considered as consequences of PPH, although it is difficult to 
quantify their burden. 
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2.2. Prevention of primary PPH 
 
PPH is one of the few obstetric complications with an effective preventive 
intervention. The aims of intervention are to prevent death, and to reduce i) the 
volume of blood loss, ii) the need for manual removal of placenta, iii) the need for 
transfusion, and iv) the need for medical or surgical treatment of PPH.  
 
The United Nation’s MDG5, to reduce maternal mortality by 75% by 2015, cannot 
be reached without the successful management of PPH (WHO et al., 2007; United 
Nations., 2008). Maternal deaths due to PPH are most common during the first seven 
days after the birth of the newborn. The majority of these deaths occur within 1-4 
hours of delivery (Kane et al., 1992). Thus, immediate management is necessary to 
prevent morbidity from PPH. Different preventive measures may either increase the 
woman’s chance of survival or prevent conditions caused by PPH. These measures 
can be applied during the antenatal period, in labour or during the third stage of 
delivery.  
 
 
2.2.1.  Reducing the risk of PPH antenatally and during labour 
 
Ideally, prevention of PPH starts in the antenatal clinic by identifying mothers with 
risk factors for PPH. Attempts have been made to identify women at risk of atonic 
PPH based on historical or clinical factors, allowing steps to be taken to prevent it in 
this high-risk group of women. However, it has been found difficult to accurately 
predict PPH, because only 41% of women with an identified risk factor go on to 
develop PPH (Sherman et al., 1992). It is therefore widely accepted that the most 
effective strategy to reduce maternal mortality from PPH is to provide preventive 
management for all women during childbirth (RCOG, 2009). Each woman should be 
assessed for the likelihood of developing PPH before labour and risk reduction 
should be implemented. This includes the detection and treatment of anaemia, and 
the development of a birth plan to ensure the provision of adequate shifts and 
resources to manage a woman who develops PPH. Referral to a tertiary centre 
should be recommended for high-risk patients.  
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2.2.1.1. Detection and correction of anaemia 
 
A review of associated factors, as demonstrated above, shows an association of PPH 
with anaemia. Anaemia increases the risk both by reducing the woman’s tolerance to 
blood loss and through a direct effect on the myometrium (Allen, 1997). Women 
with moderate anaemia are less able to cope with PPH, leading to increased 
postpartum morbidity. It is therefore essential to diagnose and treat anaemia so that 
blood haemoglobin is optimised before delivery (Lewis G. and Drife J., 2001). This 
is especially important in the developing countries, where the prevalence of anaemia 
in pregnancy is high. Haemoglobin increase is best achieved with iron prophylaxis 
throughout pregnancy. Special consideration should be given to women with 
religious objections to receiving blood products. Those patients should have efforts 
made to maximize their haemoglobin prior to the time of delivery, including use of 
intravenous iron if necessary (Litton et al., 2013). They should also be advised of 
alternative blood products and those products that they find acceptable should be 
clearly defined. 
 
2.2.1.2. Care during early labour (first and second stages) 
 
When women present in labour it is sensible to identify women who may be at 
increased risk of excessive bleeding, if they have not been recognised antenatally. 
Such identification allows these patients to have an access to medical facilities 
where trained staff, blood banking, laboratories, and radiographic expertise exist to 
accurately manage PPH. For women with identifiable risk factors, consideration 
should be given to extra precautions such as IV access and cross-matching of blood. 
The second stage should be short and delivery assistance should commence when 
indicated.  
 
Routine episiotomy is associated with a 27% increase in PPH at normal birth and so 
should be used cautiously for delivery (Combs et al., 1991a; Stones et al., 1993; 
Carroli and Mignini, 2009). Avoidance of unnecessary episiotomies may contribute 
to the reduction in blood loss after delivery. As in one randomised controlled trial 
(RCT) of routine versus selective episiotomy, in which blood loss was evaluated 
after childbirth, significantly less blood loss occurred in women allocated to a 
restrictive episiotomy policy (House et al., 1986). Moreover, a systematic review of 
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RCTs showed that compared with routine use, restrictive episiotomy involved less 
posterior perineal trauma (Risk ratio (RR) 0. 67; 95% CI 0.49-0.91), less suturing 
(RR 0.71; 95% CI 0.61-0.81) and fewer healing complications (RR 0.69; 95% CI 
0.56-0.85). The only disadvantage shown in the restrictive use of episiotomy was an 
increased risk of anterior perineal trauma (RR 1.84; 95% CI 1.61-2.10). There was 
no difference in severe vaginal or perineal trauma, dyspareunia or urinary 
incontinence (Carroli and Mignini, 2009). Therefore, it is advisable to perform 
selective episiotomy for medical and obstetric reasons only and assist the woman in 
the controlled delivery of the baby’s head and shoulders to help to prevent tears. 
 
2.2.2.  Care during the third stage of labour 
 
For effective PPH prevention, special attention should be given to the third stage of 
labour. The correct management of the third stage of labour plays an important role 
in the prevention of PPH. Different methods for prevention have been developed for 
intrapartum care to reduce maternal morbidity and mortality due to PPH. Whatever 
procedures are to be used to prevent PPH, all should be explained to the woman and 
her family, providing support and reassurance throughout. 
 
There are two broad approaches to the clinical management of the third stage of 
labour: expectant and active management. In the following section the different 
methods of third stage management are reviewed including AMTSL and its 
components. 
 
2.2.2.1. Active versus expectant management of the third stage of labour 
 
Physiological management, also known as conservative, is where the umbilical cord 
is not clamped or cut until it has stopped pulsating. Placental separation from the 
uterine wall occurs without intervention and signs of placental separation are 
awaited and the placenta is delivered spontaneously or aided by gravity or nipple 
stimulation (Prendiville et al., 2009). Some women and practitioners prefer 
expectant management of the third stage of labour, since it is seen as more 
physiological and avoids uncomfortable procedures shortly after birth when the 
mother wishes to concentrate on the baby.  
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Evidence based research has shown that there are feasible and low cost interventions 
that can prevent PPH. Active management is where the physician facilitates the 
separation and delivery of the placenta and enhances the efficacy of uterine 
contractions to shorten the third stage of labour (Maughan et al., 2006). The original 
definition of AMTSL was intramuscular administration of 10 IU of oxytocin, 
controlled cord traction (CCT) and early cord clamping (Spencer, 1962). Placental 
delivery is facilitated by use of the Brandt-Andrews manoeuvre (Figure 4), which 
involves applying firm traction on the umbilical cord with one hand while the other 
applies suprapubic counter-pressure. Giving a uterotonic drug to prevent PPH 
promotes strong uterine contractions and leads to faster retraction and placental 
separation and delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Brandt-Andrews manoeuvre for cord traction (Anderson and Etches, 
2007) 
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The effects of active and expectant management of the third stage of labour were 
compared in four high quality randomised trials (two were conducted in the United 
Kingdom and one each in the United Arab Emirates and Ireland) (Prendiville et al., 
1988; Begley, 1990; Khan et al., 1997; Rogers et al., 1998). It is not easy to compare 
these studies as different uterotonic drugs (oxytocin, ergometrine, either drug, or 
both drugs) with different dosages and routes of administration were used. Despite 
this, their results are informative. The results of all the four studies demonstrated 
that AMTSL was associated with a reduction in PPH (up to 70%), and with a 
reduction in the length of the third stage of labour, suggesting a clear benefit of 
AMTSL over expectant management in reducing PPH. According to Prendiville and 
colleagues, AMTSL involves giving a prophylactic uterotonic, early cord clamping 
and CCT to deliver the placenta (Prendiville et al., 1988). The most recent Cochrane 
systematic review compared active versus expectant management of labour in seven 
studies (involving 8,247 women), and found that AMTSL in hospitals with mixed 
levels of PPH risk reduces the risk of PPH > 1000 mls (RR 0.34; 95% CI 0.14-0.87, 
three studies, and 4,636 women), but the evidence was of very low quality. In the 
subgroup of women at low risk of excessive bleeding, there were similar findings 
(RR 0.31; 95% CI 0.05-2.17, two studies, 2941 women), except there was no 
significant difference identified between groups for severe haemorrhage or maternal 
Hb less than 9 g/dl (at 24 to 72 hours). Overall the authors stated that active 
management showed a significant decrease in primary blood loss greater than 500 
mls, and mean maternal blood loss at birth, maternal blood transfusion and 
therapeutic uterotonics during the third stage or within the first 24 hours, or both. 
The review concluded that active management also increases the risk of side effects 
such as postnatal hypertension, after pains and return to hospital due to bleeding. 
The trials included in this review used syntometrine
® 
or ergometrine in their 
intervention arm which could explain the occurrence of these adverse outcomes. 
AMTSL is also associated with a reduction in the birth weight which may reflect a 
reduction in the neonate blood volume due to early cord clamping (Begley et al., 
2015). 
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The implementation of AMTSL remains controversial, despite the evidence of its 
efficacy in randomised trials (Vivio and Williams, 2004). This might be because 
there are variations in the components of active management. For example several 
types of AMTSL are described: uterotonic, with CCT and fundal massage 
(FIGO/ICM, 2004) or uterotonic, with early cord clamping and CCT (Prendiville et 
al., 1988). There are also differences in the timing of cord clamping: this can be 
immediately after the delivery of the baby or within a set time after the childbirth. 
Timing the initiation of CCT is also an issue, with some waiting for signs of 
placental separation and others not (Begley et al., 2015). Examples of the variation 
in practice of AMTSL in different organisation/countries are shown in Table 2. 
 
These recommendations; however, are not exactly followed in practice when the 
policy of AMTSL is assessed. For example, three settings included in the table 
below namely Egypt, Kenya and Uganda were assessed for their existing policy of 
AMTSL as a primary step of a multicentre trial on the effect of AMTSL with and 
without CCT conducted in 8 countries (Gulmezoglu et al., 2012). All the three sites 
practised CCT, intramuscular or intravenous oxytocin 10 IU, but the timing of 
administration was different. In Kenya, cord clamping was described as delayed, 
whereas other sites were practising immediate cord clamping, which was not 
recommended in Egypt. Uterine massage after placental delivery was part of routine 
management in about 50% of cases in Egypt. In Kenya and Uganda, uterine massage 
is part of the AMTSL recommendation (Table 2) but it was not practiced.  
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Table 2. Recommendations for AMTSL according to the organisation/country, 
(FIGO= International Federation of Gynaecology and Obstetrics, ICM= 
International Confederation of Midwives, WHO = The World Health Organisation, 
RCOG= Royal College of Obstetrics and Gynaecology, ACOG= The American 
College of Obstetricians and Gynaecologists, NICE= The National Institute for 
Health and Clinical Excellence, MOHP= Ministry of Health and Population). 
Organisation/ 
country 
Oxytocin 
Cord 
clamping 
Time of 
oxytocin 
CCT 
Uterine 
massage 
Cord 
drainage 
FIGO/ICM 
(FIGO/ICM, 
2003) 
Yes ─ 
Within one 
minute after 
delivery of 
baby 
Yes 
Yes 
 
─ 
RCOG 
(RCOG, 2009) 
Yes 
5 or 10 
IU IM 
Early- 
only when 
indicated 
  ─ ─ 
NICE 
(NICE, 2007) 
 
Yes 10IU 
IM 
Early ─ Yes ─ ─ 
WHO 
(WHO, 2006) 
Yes 
10 IU 
Delayed 
(at around 
3 minutes) 
Within one 
minute after 
delivery of 
baby 
Yes Yes ─ 
WHO              
(WHO, 2007a) 
Yes 
10 IU 
Delayed 
(at around 
3 minutes) 
Within one 
minute after 
delivery of 
baby 
Yes Yes ─ 
WHO 
(WHO, 2012) 
Yes 
10 IU 
(IV/IM) 
Delayed 
(1-3 
minutes) 
─ Optional No ─ 
Egypt 
(MOHP, 2001) 
Yes  (5 
IU) IM 
Delayed 
At the time of 
the delivery 
of the anterior 
shoulder 
Yes ─ ─ 
SOGC 
(Leduc et al., 
2010) 
Yes 10IU 
IM 
Delayed 
After delivery 
of  the 
anterior 
shoulder 
─ ─ No 
Kenya 
(Kimathi et al., 
2002) 
Yes 5 IU ─ 
After delivery 
of baby 
 
 
Yes Yes ─ 
Uganda 
(Armbruster,  
2007) 
Yes ─ 
Within one 
minute after 
delivery of 
baby 
 
 
Yes 
Yes 
 
─ 
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Furthermore, evidence of the variation was also seen in a survey, involving 14 European 
countries designed to ascertain and compare policies for management of the third stage of 
labour following vaginal delivery (Winter et al., 2007). The result showed considerable 
differences in policies for managing the third stage of labour both between and within 
countries. Policies for using uterotonics for the management of the third stage were 
widespread, but the oxytocic agents, timing, clamping of and cutting the umbilical cord 
and the use of CCT differed widely. Overall, 90% (1052/1175) of units surveyed 
recommend uterotonic prophylaxis, 66% (770/1175) recommend early cord clamping and 
41% (481/1175) recommend CCT (Winter et al., 2007).  
 
There is no consensus on the optimal time for cord clamping. Delayed umbilical cord 
clamping is recommended for improved maternal and infant health and nutrition outcomes. 
Delayed umbilical cord clamping (not earlier than 1 min after birth) should be understood 
as the lower limit period supported by published evidence. WHO recommends that the 
umbilical cord should not be clamped earlier than is necessary for applying cord traction to 
reduce PPH and speed delivery of the placenta (WHO, 2012), which the guideline 
development group clarified would normally take around 3 min. 
 
Huge numbers of studies have been conducted examining different aspects of routine 
management of the third stage of labour. However, in spite of all the previous work on 
AMTSL, there remains confusion amongst clinicians over the optimal AMTSL packages 
to balance the benefits and harms. There is also frequent disagreement over in which order 
the components of AMTSL should be given. For example, in case of uterotonic the type, 
doses, time, as well as the route of administration, remain controversial. It is suggested that 
the prophylactic administration of uterotonic will reduce bleeding and the risk of severe 
haemorrhage. However, active management is associated with a number of unpleasant side 
effects (e.g. nausea, vomiting, and hypertension). Additionally, in specific developing 
countries the feasibility of widespread of active management requires consideration of the 
costs, the storage and distribution needs of drugs, the availability of skilled birth 
attendants, and the quality of the health services.  
 
The FIGO and the ICM recommend that skilled birth attendants provide AMTSL for all 
vaginal births (FIGO/ICM, 2003). The WHO, however, recently recommended that all 
women should be offered uterotonics, but not the whole package of the active management 
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(WHO, 2012). The recommendations were against uterine massage and early cord 
clamping as being one of practices of AMTSL, rather CCT was left to the preference of the 
woman and healthcare provider. In the absence of a skilled birth attendant who can provide 
all of the components of AMTSL, the WHO, FIGO, and ICM recommend that oxytocin 
(10 IU) or misoprostol (600 mcg orally) should be given by a health worker trained in its 
use to prevent PPH.  Oxytocin is preferred to other uterotonic drugs where its use is 
feasible (Mathai et al., 2007; WHO, 2012).  
The different components of the AMTSL have been investigated to find out the effect of 
different practices on the reduction of postpartum blood loss and the possible adverse 
effects. These included the type and timing of administration of the uterotonics and the 
timing of cord clamping, uterine message and whether to apply cord traction for placental 
delivery or not. The following section will discuss these components and other different 
measures used to prevent PPH. 
 
2.2.2.2. Type of drug used for the prevention of PPH 
 
The routine prophylactic administration of an uterotonic agent is an integral part of the 
AMTSL. There is a variation in the clinical opinion about which is the most effective 
uterotonic and its appropriate route of administration (parenteral IV/IM, sublingual, oral, 
or rectal). An ideal uterotonic agent should produce quick, strong and sustained uterine 
contractions without any significant adverse effects. Uterotonic agents are divided into 
three categories: oxytocin, ergot alkaloids and prostaglandins. There are several published 
Cochrane systematic reviews about the use of various uterotonic drugs in the third stage of 
labour for PPH prevention (McDonald et al., 2004; Liabsuetrakul et al., 2007; Su et al., 
2012; Tuncalp et al., 2012; Westhoff et al., 2013). 
 
A. Uterotonic drugs 
 
I. Prophylactic oxytocin (Syntocinon®, Pitocin®) 
 
Oxytocin is a hormone which causes contraction of the myometrium and the myoepithelial 
cell of the breast. It has been showed that the hormone is synthesised in the hypothalamus, 
then transported to the posterior pituitary for storage, and stimulates uterine activity (Dale, 
1909). Blair Bell first reported its efficacy in the treatment of PPH (Blair Bell, 1909). In 
1953 Vincent DuVigneaud was able to identify the structure of oxytocin and synthesise the 
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hormone a year later (Francis and Francis, 1956 ). He gained a Nobel Prize for this work. 
The mode of action of oxytocin involves stimulation of the upper uterine segment to 
contract in a rhythmical fashion which constricts spiral arteries and decreases blood flow 
through the uterus.  Its effect is seen with within 2-3 minutes lasting for up to 60 minutes 
when given by intramuscular route. It acts within less than a minute after intravenous 
administration, with the uterine response subsiding within 1 hour of cessation of IV 
administration. Metabolism of oxytocin is via the liver and its excretion is through the 
renal and hepatic routes. Because of the structural similarity between oxytocin and 
vasopressin, oxytocin has an anti-diuretic effect; therefore, prolonged infusion can cause 
water intoxication, particularly if given in a large volume of electrolyte-free solution, so 
that hyponatraemia, confusion, convulsions, coma and cardiac failure may occur 
(Breathnach and Geary, 2009).  
 
Several studies have provided evidence on the effectiveness of routine prophylactic 
administration of an oxytocic in AMTSL for reducing PPH. The most recent Cochrane 
review included 10,806 women in 20 trials with considerable variation in the doses and the 
route of administration. It found a clear benefit of the use of oxytocin in the third stage of 
labour compared to no uterotonic (Westhoff et al., 2013). Oxytocin use was associated 
with a lower incidence of PPH > 500 mls (RR 0.53; 95% CI 0.38-0.74; six trials, 4203 
women) and less need for therapeutic uterotonics (RR 0.56; 95% CI 0.36-0.87, four trials, 
3174 women). When compared to ergot alkaloids, prophylactic oxytocin was superior to 
ergot alkaloids in preventing PPH greater than 500 mls (RR 0.76; 95% CI 0.61-0.94; five 
trials, 2226 women). Use of prophylactic oxytocin was associated with fewer side effects 
compared with use of ergot alkaloids. However, the authors stated that there is limited 
high-quality evidence supporting a benefit of prophylactic oxytocin over ergot alkaloids. 
However, the use of prophylactic oxytocin was associated with fewer side effects, 
specifically nausea and vomiting, making oxytocin the more desirable option for routine 
use to prevent PPH. The finding that oxytocin decreases the risk of PPH by about 60% 
(RCOG, 2009), and the need for therapeutic oxytocics, compared with no uterotonic 
(Westhoff et al., 2013), means that  oxytocin is now the drug of choice to be given 
routinely as a part of the AMTSL to all mothers (RCOG, 2009).  
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Some of the known disadvantages are that oxytocin has a short half-life (mean 3 minutes); 
it is not very heat stable (stable at temperatures up to 25°C) so requires refrigeration, it 
needs parenteral administration with sterile equipment and to be given by skilled 
personnel. These obstacles restrict the use of oxytocin in many low-resource settings and 
home births where delivery is usually conducted by an unskilled birth attendant.  
 
The solution for some of the oxytocin known problems can be achieved by using oxytocin-
Uniject. The oxytocin-Uniject device is a plastic, nonreusable, disposable syringe prefilled 
with a single dose of 10 IU of oxytocin. The oxytocin is enclosed in a sealed blister, and a 
permanent needle is attached (Strand et al., 2005). Introduction of the Uniject may 
facilitate the application of the AMTSL, particularly in the developing countries, thus 
reducing maternal mortality due to PPH. A study conducted in Angola found that Uniject 
showed a marked reduction in the rate of blood loss ≥ 500 mls (316/782 (40.4%) vs. 
67/814 (8.2%), p <0.001) (Strand et al., 2005). Tsu and co-workers conducted two separate 
studies in Indonesia and Vietnam on the use of oxytocin in prefilled Uniject injection 
devices for managing third-stage labour (Tsu et al., 2003; Tsu et al., 2009). These studies 
reveal that the use of the device is easier and more practical than the traditional way using 
a needle, syringe and ampoule. Midwives, with the use of a prefilled injection device, 
overcame many of the barriers cited by midwives with regard to the use of oxytocin in 
ampoules, such as trying to break ampoules and fill syringes in a hurry. This device 
enabled midwives to deliver the correct dose of oxytocin in the third stage of labour in a 
safe and timely way. Use of such an injection device for oxytocin may increase the 
acceptability and practice of AMTSL in primary level facilities.  
 
The timing of oxytocin administration also differs greatly between clinicians, as various 
professionals use oxytocic immediately after the delivery of the baby. In the AMTSL, it is 
has been recommended to administer relevant drugs at the delivery of the anterior 
shoulder. The administration of uterotonic prior to placental delivery raised the concerns 
that this could inhibit the delivery of the placenta. However, available data propose that 
immediate administration of oxytocic does not lead to greater need for manual removal of 
the placenta (Rajan and Wing, 2010; Begley et al., 2015). The impact of early 
administration on blood loss remains uncertain. There was no difference in the incidence 
of PPH between women who had oxytocin immediately after the delivery and those who 
had oxytocin after the delivery of the placenta (56/745 [7.5%] vs. 72/741 [9.7%], P=0.15) 
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(Jackson et al., 2001). The most recent Cochrane review of the timing of prophylactic 
uterotonics found that timing of the administration of oxytocin either before or after the 
expulsion of the placenta did not have any significant effect on the rate of PPH, the length 
of the third stage of labour or the rate of placental retention (Soltani et al., 2010). This 
review included a small number of trials and investigated only intravenous infusion of the 
oxytocin. Therefore, the authors recommended further studies to examine different routes 
of administration and different maternal and neonatal outcomes.   
 
The dose of oxytocin has not been directly subjected to study, but it has been noted that 
administration of 5 IU intravenous bolus of oxytocin can result in profound hypotension 
due to a decrease in the resistance of vascular smooth muscles, (Figure 5) (Weeks, 2010). 
Therefore, oxytocin should be given preferably as a small volume infusion. It is 
recommended to use 5 IU oxytocin as a slow intravenous injection and replace it with a 
continuous infusion of 20 IU oxytocin in 500 mls crystalloid solution to maintain uterine 
contraction. It has been stated that administration of 10 units of oxytocin intramuscularly 
or 20 units diluted in 500 mls of normal saline to be given as an intravenous bolus appear 
to be the most effective drug doses (Maughan et al., 2006). Owing to its short plasma half-
life for a sustained effect, IV infusion is preferred because it provides a steady flow of the 
drug (FIGO/ICM, 2003; Lalonde, 2012). 
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Figure 5. Systemic vascular resistance, mean arterial pressure and cardiac output 
represented as means vs. time (seconds). Arrow indicates timing of 5 unit oxytocin 
bolus (Weeks, 2010) 
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II. Oxytocin agonist (Carbetocin) 
 
Carbetocin is a synthetic oxytocin analogue structurally modified to possess long-acting 
agonist properties. It was first described in 1987 (Atke and Vilhardt, 1987). The clinical 
and pharmacological characteristics of carbetocin are similar to those of naturally 
occurring oxytocin. The drug binds to oxytocin receptors present on the uterine smooth 
muscle, causing rhythmic contractions of the uterus, increased frequency of existing 
contractions, and increased uterine tone by releasing calcium ions. Carbetocin can be 
administered by intravenous or intramuscular route. It has been found that an 
intramuscular dose of carbetocin acts for a longer time than intravenous carbetocin. The 
uterine activity for an IM injection persisted for approximately 120 minutes and for 
intravenous injection for about 60 minutes (Hunter et al., 1992). This can be explained by 
the time required for the absorption of carbetocin into the circulation from the 
intramuscular site. Oxytocin requires repeated injections or an infusion of several hours, 
with a variability of the administered doses; carbetocin has 4-10 times longer half- life 
(about 40 minutes) than oxytocin given in a single injection (Hunter et al., 1992). The 
optimal dosage of carbetocin used in the third stage of labour is 100 mcg (Boucher et al., 
1998).  
 
The efficacy of carbetocin in the AMTSL has been investigated following vaginal and 
caesarean deliveries. Some evidence demonstrates similarity in PPH prevention between 
carbetocin and oxytocin (5 IU) following caesarean section. The evidence also suggests 
that 100 mcg intravenous carbetocin could significantly reduce the use of additional 
uterotonic agents (Attilakos et al., 2010). A RCT compared the efficacy of 100 mcg 
intramuscular carbetocin against a 2-hour 10 IU oxytocin IV infusion, for reducing the 
incidence and severity of PPH in women at risk of PPH who underwent vaginal delivery. 
Although the result showed reduced need for additional uterotonic, uterotonic intervention 
was clinically indicated in 37 of the women (44.6%) who received carbetocin compared to 
49 of the women (63.6%) given an IV oxytocin infusion (P <0.02). The study found 
insufficient evidence in terms of the benefit of carbetocin over oxytocin for preventing 
PPH (Boucher et al., 2004).  
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In a Cochrane review includes 11 studies (2,635 women) (Su et al., 2012). The review 
compared carbetocin with oxytocin (IV), syntometrine
®
 (IM) or placebo. Carbetocin was 
administered as 100 mcg IV in all the trials. Six trials compared carbetocin with oxytocin; 
four of these were conducted with women undergoing caesarean deliveries, one was for 
women following vaginal deliveries and one did not state the mode of delivery clearly. Use 
of carbetocin resulted in a statistically significant reduction in the need for therapeutic 
uterotonics (RR 0.62; 95% CI 0.44-0.88; four trials, 1173 women) compared to oxytocin 
for those who underwent caesarean section, but not for vaginal delivery. Compared to 
oxytocin, carbetocin was associated with a reduced need for uterine massage following 
both caesarean delivery (RR 0.54; 95% CI 0.37-0.79; two trials, 739 women) and vaginal 
delivery (RR 0.70; 95% CI 0.51-0.94; one trial, 160 women). Carbetocin also resulted in a 
lower risk of PPH (≤ 500 mls) compared to oxytocin in women who underwent caesarean 
delivery (RR 0.55; 95% CI 0.31-0.95; three trials, 820 women). Comparison between 
carbetocin and syntometrine
®
 showed a lower mean blood loss in women who received 
carbetocin compared to syntometrine
®
 (Mean difference (MD) -48.8 mls; 95% CI -94.8 to 
-2.9; four trials, 1030 women). There was no statistically significant difference in terms of 
the need for therapeutic uterotonic agents, but the risk of adverse effects such as nausea 
and vomiting were significantly lower in the carbetocin group: nausea (RR 0.24; 95% CI 
0.15-0.40; four trials, 1030 women); vomiting (RR 0.21; 95% CI 0.11-0.39; four trials, 
1030 women). The incidence of postpartum hypertension was also significantly lower in 
women who received carbetocin compared to those who received syntometrine
®
. Overall, 
the authors concluded that there is evidence to suggest that 100 mcg of intravenous 
carbetocin is more effective than oxytocin for preventing PPH in women undergoing 
caesarean deliveries, but more studies are needed to validate this finding (Su et al., 2012).  
 
Adverse events reported by at least 10% of women who received prophylactic intravenous 
carbetocin following caesarean delivery include headache, tremor, hypotension, flushing, 
nausea, abdominal pain, itching and a feeling of warmth. Uncommon or sporadic adverse 
events are  tachycardia, sweating, dizziness, chest pain, vomiting and a metallic taste in the 
mouth (Rath, 2009). 
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III. Ergot alkaloids 
 
John Stearns was the first to highlight the use of ergots for PPH in 1882. Oral 
administration of aqueous ergot extract is associated with dramatic and very strong 
contractions of the uterine musculature. This was demonstrated by Moir in 1932 who 
described it as the ‘John Stearns effect’ (Dunn, 2002).  In 1935, Dudley and Moir isolated 
the pure crystallised substance from the water soluble extract of ergot that was responsible 
for the ’John Stearns effect’ and they called it ’ergometrine’ (Dudley and Moir, 1935). The 
drug is known under different names in different countries. The Americans call their 
preparation ergonovine, in the UK it is named ergometrine and the Swiss use the name 
ergobasine. Ergot alkaloids (ergometrine and methyl ergometrine) are usually given 
intramuscularly or intravenously, although the oral route is also possible. The most 
common type of ergot alkaloid is methyl ergometrine; this ergometrine was the first 
uterotonic drug used in the early 1950s. It is known to increase the tone of the uterine 
muscles via stimulation of myometrial alpha adrenergic receptors. It prevents haemorrhage 
by compressing the myometrial blood vessels through fast (less than a minute) rhythmic 
contraction of the myometrium and long-lasting tetanic contractions. The onset of action is 
2-5 minutes after intramuscular injection of the standard dose (0.25 mg of ergometrine). Its 
mean plasma half-life is 30 minutes and the clinical effect continues for 3 hours. The 
metabolism is by the hepatic route. The drug is both heat- and light-sensitive therefore it 
should be stored at temperatures below 8°C, away from light but should also be protected 
from freezing (Lalonde, 2012). 
 
For the AMTSL, ergot alkaloids were compared to no uterotonic agent in a Cochrane 
systematic review. Parenteral administration of ergot alkaloids significantly decreased the 
mean blood loss and the risk of PPH > 500 mls (RR 0.38; 95% CI 0.21-0.69). On the other 
hand, more treated women had elevated blood pressure (RR 2.60; 95% CI 1.03-6.57), 
vomiting (RR 11.81; 95% CI 1.78- 78.28) and after pain requiring analgesia (RR 2.53; 
95% CI 1.34-4.78) (Liabsuetrakul et al., 2007). Other side effects include nausea, 
vomiting, headache, dizziness and increased blood pressure (Breathnach and Geary, 2009). 
Additionally, ergometrine was found to be associated with increased risk of coronary 
artery spasm (Carey, 1993). As ergot alkaloids mediate their action via stimulation of the 
α-adrenergic receptors which can result in vasoconstriction, the drug is contraindicated in 
women with hypertension, pre-eclampsia, heart disease, and peripheral vascular disease 
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(Breathnach and Geary, 2009). Most studies used intramuscular ergometrine. However, the 
one study that used the intravenous route reported that 0.5 mg intravenous ergometrine 
was associated with a significant increase in the incidence of manual removal of the 
placenta (3%) compared to the physiological management of the third stage of labour 
(0.1%) (Begley, 1990). The one trial that examined the oral route showed no significant 
benefit of ergot alkaloid over a placebo, and concluded therefore that oral ergometrine is 
not an alternative to oxytocin in the management of the third stage of labour (deGroot, 
1996). Overall the evidence suggests that although ergometrine is effective at PPH 
prophylaxis, oxytocin is much better tolerated. 
 
In 1961, the intramuscular combination of oxytocin and ergometrine was studied 
tocographically. The author found that the combination of both drugs resulted in the 
strength and duration of action of ergometrine, and the speed of oxytocin (effective within 
2.5 minutes) (Embrey, 1961). Syntometrine
®
, consisting of 5 units of oxytocin and 0.5 mg 
of ergometrine, has been, therefore, designed to take advantage of the rapid onset of action 
of oxytocin with the longer action of ergometrine. The Cochrane review of the 
prophylactic use of syntometrine
®
 versus oxytocin found that syntometrine
®
 reduced the 
occurrence of PPH > 500 mls (OR 0.82; 95% CI 0.71-0.95) but not of PPH > 1000 mls 
(OR 0.78; 95% CI 0.59-1.04). Syntometrine
®
 was associated with significantly more risk 
of side effects such as hypertension (OR 2.81; 95% CI 1.17-6.73) and vomiting (OR 4.92; 
95% CI 4.03- 6.00) (McDonald et al., 2004). Therefore, although oxytocin would appear to 
be marginally less effective than syntometrine
®
, it is generally recommended as a first-line 
treatment due to its low rate of side effects and greater stability in light and heat. 
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IV. Prostaglandins 
 
4.1 Intramuscular prostaglandins  
 
Prostaglandins are found in most tissue and organs including decidua, fetal membranes and 
placenta. Synthetic prostaglandins have strong uterotonic properties and are used widely in 
obstetric and gynaecological practice for cervical ripening, induction of labour and 
termination of pregnancy. They are available in different forms of preparations according 
to their use: injectable, tablet or gel. They include prostaglandin 15-methyl-PGF2α, 
(Dinoprost
®
) and its analogue (Carboprost, Hemabate
®
), prostaglandin E2 analogue 
(Dinoprostone, Sulprostone [Nalador
®
]) and prostaglandin E1 analogues (Misoprostol and 
Gemeprost).  
 
Prostaglandin F2α and prostaglandin E2 are mainly used for the treatment of PPH and the 
data on their application for PPH prophylaxis is very limited. In the Cochrane review for 
prostaglandins for preventing PPH, when compared with no uterotonic, injectable 
prostaglandins resulted in less mean blood loss (MD -224ml; 95% CI -420.35 to -27.60 
ml), and shorter duration of the third stage of labour, compared to conventional uterotonics 
(MD -1.25 minutes; 95% CI -1.42 to -1.08 minutes) (Tuncalp et al., 2012). However, 
concerns about its safety, costs and availability restrict its appropriateness over other 
conventional injectable uterotonics for routine prophylactic management of the third stage 
of labour and especially in low-resource settings. Owing to its vasoconstrictive and 
bronchoconstrictive effects, intramuscular prostaglandins were also found to commonly 
cause vomiting, nausea, abdominal pain and diarrhoea and bronchospasm (Tuncalp et al., 
2012). Contraindications include cardiac and pulmonary disease. The nature of other side-
effects (nausea, vomiting and diarrhoea) could affect the immediate relationship between 
the mother and her newborn baby in the early hours after delivery. Furthermore, the drug is 
both light- and heat-sensitive and must be kept refrigerated at 4°C. Overall, although 
injectable prostaglandins appear to be superior to placebo, they were not preferable to 
conventional uterotonics in the management of the third stage of labour. Injectable 
prostaglandins are therefore restricted to use for treatment of PPH rather than for 
prophylaxis (Bohlmann and Rath, 2013). 
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V. Misoprostol 
 
Misoprostol (15-deoxy-16-hydroxy-16-methyl, PGE1) is a synthetic form of prostaglandin 
E1 analogue. The drug was initially developed for the prevention of peptic ulcers induced 
by non-steroidal anti-inflammatory drugs as it has mucosal protective properties 
(Silverstein, 1998). Misoprostol selectively binds to the myometrial EP-2/EP-3 prostanoid 
receptors, thereby promoting uterine contractility. It is metabolised via the hepatic route. 
Misoprostol can be given orally, sublingual buccally, vaginally, intraumbilically and 
rectal. After oral administration, misoprostol is rapidly absorbed and converted to its 
pharmacologically active metabolite, misoprostol acid. It appears in the serum within 2 
min and reaches peak levels after 20 min (Abdel-Aleem et al., 2003). Oral or sublingual 
misoprostol shows promising results when compared with placebo in reducing blood loss 
after delivery (Tuncalp et al., 2012). A study conducted in rural India has revealed the 
efficacy of misoprostol tablets for prevention of PPH. Over 1600 low-risk women were 
randomly selected to receive oral misoprostol (600 mcg) or placebo at the time of delivery 
(Derman et al., 2006). Blood was collected for the first hour postpartum. In the 
misoprostol group, the risk of PPH (> 500 mls) was halved, and the risk of severe PPH 
was reduced by 80%. The authors conclude that "oral misoprostol is safe, effective, and 
inexpensive ($1.00 per 600 mcg dose) for women giving birth in low-resource settings". 
Finding that misoprostol is inexpensive, easy to administer and stable at room 
temperatures, in the management of the third stage of labour, misoprostol is potentially the 
most crucial uterotonic to be used in low-recourse settings (Parsons et al., 2007; Mousa et 
al., 2014). Additionally, although other prostaglandins (prostaglandin E2 and 
prostaglandin F2α) can cause myocardial infarction and bronchospasm, misoprostol does 
not (Ulmann and Silvestre, 1994). However, its use in obstetrics and gynaecology is still 
off-label in many countries over the world and until recently, it was not approved by the 
Food and Drug Administration (FDA) for use in pregnant women. In spring 2002, FDA 
made new changes to the misoprostol label; the statement that misoprostol is 
contraindicated in pregnancy has been removed and a labour and delivery section has been 
added.  
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The drug poses some unpleasant adverse effects. The most common side effects associated 
with the postpartum administration of misoprostol are shivering and pyrexia which are 
known to be dose- and route -related (Hofmeyr et al., 1998; Hofmeyr et al., 2009; Elati and 
Weeks, 2012). Higher rates of shivering and fever are associated with oral and sublingual 
routes of administration, as compared with rectal administration (Chong et al., 2004). In 
terms of misoprostol dose-related side effects, meta-analysis results indicated that during 
the third stage of labour, the risk of pyrexia increased 3 fold with 400 mcg misoprostol and 
six fold with 600 mcg misoprostol when compared with placebo (Hofmeyr and 
Guemezoglu, 2008). However, misoprostol side effects are transient (resolving within 12 
hours or less) (Durocher et al., 2010).  
 
The WHO currently recommends the use of oxytocin rather than misoprostol for the 
prevention of PPH as an integral part of the AMTSL. Nevertheless, in settings where 
active management is not being practiced or the birth attendants are of limited skills, they 
recommend the use of misoprostol (WHO, 2012). In their review, the Bellagio expert 
group found that misoprostol prophylaxis using an oral or sublingual dose of 600 mcg is 
more effective than placebo at preventing PPH in community births (RR 0.59; 95% CI 
0.41-0.84), but not in hospital settings (RR 1.23; 95% CI 0.86-1.74) (Alfirevic et al., 
2007). Therefore, they recommended a single dose of 600 mcg of oral or sublingual 
misoprostol and that it should not be repeated for 2 hours. According to the latest 
Cochrane review on the use of misoprostol in the prevention of PPH in a community 
setting it has been concluded that misoprostol has been effective and safe (Tuncalp et al., 
2012). This consistent with the most recent WHO Essential Medicine List which approved 
“misoprostol for prevention of PPH in setting where oxytocin is not available or cannot be 
safely used” (WHO, 2011).  
 
There is now a tendency towards community distribution of misoprostol by healthcare 
workers. Some suggested that oral misoprostol can be given by birth attendants at home 
birth without additional equipment (Rajbhandari et al., 2010). Oral misoprostol could be 
the only option in home births in low-resource settings. There is currently an effort toward 
self-administration of misoprostol as it might contribute to reducing PPH at a home 
delivery. This has been implemented and subjected to a study in a placebo-controlled trial 
(MamaMiso) carried out in Uganda. The main aim of the study was to assess the 
effectiveness and safety of antenatal administration of misoprostol tablets (600 mcg) for 
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self-administration immediately following home delivery for the prevention of PPH 
(Weeks, 2012).  
 
B. Other pharmacological measures 
 
I. Tranexamic acid  
 
Tranexamic acid is a synthetic preparation that is derived from the amino acid lysine. It 
acts as an antifibrinolytic agent that produces its antifibrinolytic effect via the reversible 
blockage of lysine-binding sites on plasminogen molecules and prevents binding of 
plasminogen and plasmin to fibrin (Dunn and Goa, 1999). The drug is valuable in a wide 
range of haemorrhagic conditions as it found to decrease blood loss as well as 
postoperative blood loss and the need for blood transfusion in a number of different 
surgeries (Katsaros et al., 1996; Dunn and Goa, 1999). A systematic review of RCTs of 
antifibrinolytic agents in different types of elective surgery (e.g. cardiac, vascular, liver 
transplantation and orthopaedic) has found that  tranexamic acid reduced the risk of blood 
transfusion by approximately 39%, and reduced the transfused blood volume by 1.1 units 
in the patients who required blood transfusion (Henry et al., 2007).  
 
In the field of obstetrics and gynaecology, it has been concluded that tranexamic acid 
reduces menstrual blood loss with no evidence of adverse side-effects (Lethaby et al., 
2000). It is therefore widely used for women’s menorrhagia. During the delivery of the 
placenta, the fibrinolytic system is activated leading to an increase in the plasminogen 
activators and fibrin degradation products with an increased rate of degradation of 
fibrinogen and fibrin. This activation can last from 6 to ten hours postpartum, which may 
contribute to increased haemorrhage (Astedt, 1987). In the context of preventing PPH 
during the third stage of labour, beside the currently used prophylactic uterotonic, 
intravenous tranexamic acid could be used to reduce the blood loss. A Cochrane review of 
using tranexamic acid for preventing PPH found that the drug decreases postpartum blood 
loss after vaginal birth and after caesarean section in the dosage of 1 g or 0.5 g IV (RR 
0.51; 95% CI 0.36-0.72; two studies, 453 women) (Novikova and Hofmeyr, 2010). 
However, the authors recommended further investigations to confirm the efficacy and 
safety of this regimen for preventing PPH. 
 
61 
 
An additional advantage of using tranexamic acid is its cost-effectiveness. In one study on 
total hip arthroplasty, prophylactic tranexamic acid preoperatively was found to save blood 
transfusions and money (47 Euros per patient) (Johansson et al., 2005). However, the drug 
is not free from side effects. Tranexamic acid was associated with gastrointestinal 
symptoms with diarrhoea, nausea and vomiting occurring in about 10% of patients. 
Hypotension, blurred vision, thrombosis, renal cortical necrosis and retinal artery 
obstruction are rare complications of tranexamic acid (Astedt, 1987).  
 
II. Traditional Chinese medicine 
 
Traditional Chinese Medicine (TCM) is an ancient medical system in China that has been 
used for many centuries. TCM combines the use of medicinal herbs, acupuncture, food 
therapy, massage and therapeutic exercise. TCM has specific theories for concepts of 
disease prevention, aetiology, systems of diagnosis and treatment which are vital to its 
practice (Fulder, 1996). TCM treatment consists typically of complex prescriptions of a 
combination of different components. The combination is based on the Chinese diagnostic 
patterns (that is inspection, listening, smelling, inquiry, and palpation) and follows a 
completely different rationale than many Western drug treatments (Liu et al., 2001). 
Typical treatment in TCM is based on one or several herbs, which are taken from plants, as 
the basic drug for a disease. 
 
 In the context of preventing PPH, TCM has its own approach and has been used for 
thousands of years. The traditional way to use TCM in preventing PPH is to orally take a 
“decoction”, a water extraction of mixed herbs, immediately after delivery. However, 
some TCM is also given in the form of an injection. In a special TCM formulation for 
PPH, each herb has some special function; some herbs act to improve the blood flow, some 
to stop bleeding, and some for uterine relaxation. For example, modern pharmacological 
research has demonstrated that Yimucao or Leonorus (known in England as Chinese 
motherwort), has an ergonovine-like action, acting directly  on the uterus (Jin, 2003), 
leading to contraction of uterine musculature (Yang et al., 2001), and causing ischemia in 
the uterine muscular tissue (Zhang and Wang, 2002).  
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In clinical practice, TCM may be used alone, or combined with conventional medicine, for 
example, injecting Yimucao alone or injecting Yimucao with oxytocin. Lin and others 
conducted a multi-centre study on the effect of motherwort injection in preventing PPH 
after caesarean section, compared with oxytocin alone or in combination. The study was 
designed as a randomised and single blind multi-centre research. Three groups of 
participants were divided as follows: 147 cases were given motherwort; 144 cases were 
given motherwort and oxytocin, 149 cases were given oxytocin alone. The incidence of 
PPH was 32.0% (47/147) in the motherwort group, 11.1% (16/144) in the motherwort and 
oxytocin group, and 18.8% in (28/149) in the oxytocin alone group. When comparing the 
lowest rate of postpartum blood loss in the group of motherwort plus oxytocin, and the 
highest rate in the motherwort group, this displayed a statistical difference (P<0.01). The 
authors concluded that combining motherwort and oxytocin is safe and effective in 
preventing PPH at caesarean section (Lin et al., 2009). 
 
2.2.2.3. Management of umbilical cord 
 
A. Early versus late umbilical cord clamping 
 
Clamping and cutting of the umbilical cord at delivery is by far the oldest and most 
frequently used 3
rd
 stage intervention in humans. The cord is usually clamped in two 
places and cut between the two clamps, making it easy for the birth attendant to apply 
CCT, and promoting quick delivery of the placenta. In that strategy, the umbilical cord is 
usually clamped shortly after childbirth, this is in general carried out in the first 30 seconds 
after birth, regardless of whether the cord pulsation has stopped or not (McDonald and 
Middleton, 2008). After delivery of the baby, the placenta continues to function and the 
cord blood continues to flow carrying oxygen to the newborn. So as long as the cord 
remains unclamped, the average transfusion to the newborn is 19 ml/kg birth weight, 
corresponding to 21% of the neonate’s final blood volume (Hutton and Hassan, 2007). 
Around 75% of the transfusion occurs in the first minute of infant life. The transfusion rate 
in the first minute can be increased by the use of intravenous uterotonics (to 89%), or by 
holding the newborn 40 cm below the level of the placenta (Yao et al., 1968).  
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The optimal timing of cord clamping has been subject to debate for many years. There are 
differences in the rate and timing of clamping of the cord in the current packages of 
AMTSL, as clamping of the umbilical cord can be done immediately after delivery of the 
baby, or within a set time after the childbirth. In a survey of 14 European countries that 
compared  policies of  management of the third stage of labour, the rate of early cord 
clamping varied from 17% (4/23) of units in Denmark to 90% (98/109) in France (Winter 
et al., 2007).  
 
Several reviews have concentrated on the potential advantages and risks of late versus 
early clamping of the umbilical cord. Hutton and Hassan, (2007) have noticed that early 
cord clamping has been proposed as a main cause of anaemia in infancy (Hutton and 
Hassan, 2007). In contrast, late clamping has been shown to possess some potential 
benefits in preterm babies in terms of a decreased need for blood transfusion and a lower 
risk of intraventricular haemorrhage (Rabe et al., 2004). Late cord clamping can be 
advantageous for the infant by improving their iron level, which may be of clinical value, 
particularly in infants with poor nutritional condition in low-income sittings (van Rheenen 
and Brabin, 2006).  
 
The effects of delayed cord clamping on infant health beyond the neonatal period were 
subjected to study in low- and middle-income countries. Results from meta-analyses 
showed that delayed cord clamping results in higher levels of serum ferritin at 3–6 months 
of age (Hutton and Hassan, 2007). A similar result was found in a high-income country 
(Sweden) where higher mean ferritin concentration (117 mcg/L vs 81 mcg/L, P<0.001) 
and a lower prevalence of iron deficiency (1 (0.6%) vs 10 (5.7%), P=0.01) were found at 4 
months of age among infants who had delayed cord clamping, compared to early cord 
cutting (Andersson et al., 2011). Some may argue that the high blood volume in the 
circulation of  the infant that results from delayed cord clamping can harm the baby as it 
might result in overloading the neonatal blood volume and consequently increase the 
likelihood of respiratory distress, polycythemia (Hutton and Hassan, 2007) and increase 
the risk of jaundice requiring phototherapy (Neilson, 2008). However, no significant 
differences were found between the effects of delayed versus early umbilical cord 
clamping on postnatal respiratory symptoms, polycythaemia, or hyperbilirubinaemia 
requiring phototherapy (Andersson et al., 2011). 
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Despite all of this evidence, the policy of early cord clamping has still been the dominant 
one. A survey involving 14 European countries, designed to ascertain and compare 
policies for management of the third stage of labour following vaginal delivery, revealed 
that 66% (770/1175) of surveyed maternity units recommend early cord clamping (Winter 
et al., 2007). Most importantly, the result from meta-analysis (McDonald et al., 2013)  
comparing early and deferred cord clamping showed that delaying cord clamping does not 
seem to increase the risk of PPH [severe PPH (RR 1.04; 95% CI 0.65-1.65) or for PPH of 
500 mls or more (RR 1.17; 95% CI 0.94-1.44)] and has no effect on the length of the third 
stage of labour.  
 
B.  Controlled cord traction 
  
Cord traction was first described by Brandt (1933) and Andrews (1940) and introduced 
into routine obstetric practice as the Brandt-Andrews manoeuvre (Spencer, 1962). In 1962, 
the term CCT was introduced by Spencer as a modification which aims to facilitate the 
separation of the placenta once the uterus contracts, and thus shorten the third stage of 
labour. The procedure of CCT is applied while the uterus is contracting, after delivery of 
the baby, by elevating the uterus suprapubically while maintaining steady traction on the 
cord (Spencer, 1962). CCT for delivery of the placenta was thought to be an effective 
technique in decreasing the incidence of PPH, and retained placenta, as well as further 
need of uterotonic (Khan et al., 1997). However, a recent large multi-centre controlled trial 
examined the effect of AMTSL with and without CCT on severe PPH (blood loss equal or 
> 1000 mls) which included 12,163 subjects in the CCT group. Gulmezoglu and 
colleagues followed a simplified package in the experimental group for the management of 
the third stage of labour, where all women received an oxytocin injection, the cord was 
clamped around 1–3 min after delivery of the baby and placental delivery was allowed to 
occur with the aid of gravity and maternal effort by encouraging women to cough or push 
after noting the signs of placental separation. Measurement of the blood loss was through 
the use of the gravimetric method. The primary (non-inferiority) outcome was blood loss 
of 1000 mls or more (severe haemorrhage). The study findings suggest that omission of 
cord traction results in very little, if any, increased risk of severe haemorrhage, the blood 
loss of 1000 mls or more had a RR of 1.09 (95% CI 0.91-1.31) and the upper 95% CI limit 
crossed the pre-stated non-inferiority margin. Additionally, uterine inversion occurred in 
one case of the full package group. Uterine inversion is a rare but a life-threatening 
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condition. It occurs secondary to strong cord traction during the delivery of the placenta, 
especially if traction is applied before sufficient contractions of the uterine muscle are 
reached, and without applying effective counter-pressure to the uterine fundus. As CCT 
requires high levels of manual skills, it is used in limited settings with trained birth 
attendants in order to apply it safely (Gulmezoglu et al., 2012). The study provides the 
largest evidence so far on the effect of CCT as part of AMTSL. CCT adds only marginally 
to the beneficial effect of the full package. The rate of manual placental removal was a 
significantly higher in the simplified package group (153 cases in the simplified package 
and 105 women in the full package (RR 1.45; 95% CI 1.14-1.86). In the Cochrane review 
the results revealed that there was no significant reduction in severe PPH (blood loss > 
1000 ml), but a small reduction was observed in PPH (blood loss > 500 ml) and mean 
blood loss with CCT (Hofmeyr et al., 2015). The reviewers stated that the routine use of 
CCT can be omitted from the 'active management' package without increased risk of 
severe PPH, they therefore, did not encourage any changes in the current practice in terms 
of training in CCT skills for birth attendants who do not have formal training. The review 
authors stated that “the results of their review are dominated by the large WHO trial, but 
are consistent with the results of the other included smaller trials”. 
 
C.   Placental cord drainage 
 
Placental cord drainage involves immediate unclamping of the previously clamped and cut 
umbilical cord after delivery of the baby from the maternal side. This will allow drainage 
of blood freely from the placenta into a container. Sharma et al., was the first one to carry 
out placental cord drainage in a caesarean section and the technique could be named 
Sharma’s method (Sharma et al., 1995; Sharma et al., 2005). It has been proposed by 
Wood and Roger (1997) that drainage of placental blood can result in reduction of placenta 
bulk, allowing adequate contraction and retraction to the uterine muscle, hence facilitating 
quick delivery of the placenta (Wood and Rogers, 1997). Some clinicians believe that 
placental cord drainage enhances the delivery of the placenta and lessens complications of 
the third stage of labour. According to the Cochrane review (Soltani et al., 2011) cord 
drainage reduced the length of the third stage of labour (MD -2.85 minutes, 95% CI -4.04 
to -1.66) and reduced the average amount of blood loss (MD -77.00 ml, 95% CI -113.73 to 
-40.27). Sharma argues that fetomaternal haemorrhage and discomfort or pain during the 
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third stage can also be affected by the amount of residual blood in the placenta (Sharma et 
al., 2005).  
 
It could be argued that deferred cord clamping would have similar effects to that of 
placental cord drainage, as both methods include draining blood from the placenta. The 
result from meta-analysis (McDonald et al., 2013) comparing early and deferred cord 
clamping showed that delaying cord clamping does not seem to increase the risk of PPH. 
 
D. Umbilical vein injection 
 
In 1826, Mojon and Asdrubali first described umbilical vein injection (UVI) for the 
treatment of retained placenta (Mori et al., 2012). Several studies and systematic reviews 
have examined the use of intraumbilical oxytocics for the treatment of retained placenta to 
prevent PPH (Gazvani et al., 1998; Weeks et al., 2010). The Cochrane review of UVI of 
saline solution plus oxytocin demonstrated no clear evidence of its effectiveness in the 
management of retained placenta (Nardin et al., 2012). The result however is borderline 
and the NICE guidelines in the UK have recommended the use of umbilical oxytocin for 
the treatment of retained placenta (NICE, 2007). The WHO in its latest recommendations 
says that there is insufficient evidence to recommend an intraumbilical vein injection of 
oxytocin to treat retained placenta (WHO, 2012).  
 
Routine UVI has been suggested as an alternative way of managing the third stage of 
labour, as it directs the treatment to the placental bed and uterine wall, resulting in an 
earlier uterine contraction and placental separation (Neri et al., 1966). It also allows higher 
doses to be used with a reduction in systemic side-effects. Different studies have been 
published on the use of an UVI of oxytocin as a prophylactic method in reducing blood 
loss during the third stage of labour (Ghulmiyyah et al., 2007; Tehseen et al., 2008; 
Gungorduk et al., 2010). The use of UVI with AMTSL significantly reduced postpartum 
blood loss, as women in study group who received UVI oxytocin lost 234 mls of blood, 
while the control group lost 276 mls (P=0.001). It also shortened the mean duration of the 
third stage; 2.59 minutes in the study group and 7.67 minutes in the control group 
(p<0.001) (Tehseen et al., 2008). Balanced against this is a need for training in the 
technique and a possible higher cost of materials. Use of UVI of saline alone or in 
combination with oxytocin, has been proposed for third stage management (Ghulmiyyah et 
al., 2005). However, according to the latest Cochrane review it is not recommended during 
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the third stage of labour to routinely use oxytocin or any other uterotonics with normal 
saline via UVI until new evidence is available (Mori et al., 2012). The authors encourage 
further research to show the effectiveness of oxytocin with normal saline via UVI. 
 
2.2.2.4. Uterine manipulation 
 
A. Fundal squeezing 
 
Crede’s manoeuvre is a method that has been advocated to separate the placenta after 
delivery. However, there is complete disagreement to its benefits because it has been found 
to cause shock (Claassens, 1957). The procedure of fundal pressure is performed by 
placing one hand on the uterine fundus and squeezing the uterus between the thumb and 
fingers to facilitate placental separation and expel the placenta through the birth canal. 
Although effective, this manoeuvre produces great pain and if performed incorrectly, can 
lead to haemorrhage and uterine inversion. It is generally no longer recommended in 
national guidelines.  
 
B. Uterine massage 
 
Following delivery, uterine massage can be used for a variety of purposes. For example, it 
can be used to ensure that there is no undiagnosed twin after delivery of a baby or 
assessing or simulating uterine contractility. The joint statement of the FIGO and ICM 
(FIGO/ICM, 2003) recommend routine massage of the uterus after delivery of the placenta 
as one component of AMTSL (Table 2). In contrast, in their published comprehensive 
guidelines on intrapartum management in 2007, NICE did not include uterine massage in 
its guidelines (NICE, 2007). Uterine massage involves placing a hand on the woman’s 
lower abdomen and stimulating the uterus by rhythmic massage or squeezing movements. 
Massage is thought to reduce postpartum bleeding through stimulation of myometrial 
contraction, probably by stimulating the release of local prostaglandin (Abdel-Aleem et al., 
2011) .  
 
Uterine massage is economical and requires no access to medication or other specialised 
services, and can be used in any birth location even at home birth.  It is noticed that there 
are very few studies that assess the effectiveness of this method. Abdel-Aleem and others 
conducted the first RCT aimed to evaluate the effect of persistent uterine massage on 
blood loss after delivery. The 200 subjects were randomly selected to receive routine 
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AMTSL (oxytocin 10 IU IV. or IM, immediate cord clamping and CCT) with uterine 
massage every 10 minutes for the first 60 minutes, or active management without uterine 
massage. The trial demonstrated a significant reduction in blood loss by 78 mls and a 80% 
reduction in the need for additional uterotonics in the massage group, compared to the non-
massage group. There was no significant reduction in the rate of PPH (4/98 (5%) vs., 
8/102 (7%) (Abdel-Aleem et al., 2006). Another trial which recruited 1,964 women was 
conducted in Egypt and South Africa. Women in the second study were randomly 
allocated to 1 of 3 treatment groups: intramuscular oxytocin, sustained uterine massage, or 
both treatments before delivery of the placenta. Blood loss within 30 minutes of delivery 
was recorded. The trial showed that uterine massage alone was associated with more blood 
loss within 30 minutes after delivery compared with treatment with oxytocin with or 
without massage. In the latest Cochrane review Hofmeyr et al., (2013) stated that “the 
results of the review are inconclusive, and should not be interpreted as a reason to change 
current practices” (Hofmeyr et al., 2013). They suggested the need for a larger study to 
show the effect of uterine massage.  
 
Recently, a multi-centre study in China evaluated the effect of uterine massage after 
delivery of the placenta (Chen et al., 2013). The study included 2,340 women and the 
participants received oxytocin plus uterine massage or oxytocin only. The placenta was 
delivered by CCT in both groups. The incidence of blood loss of 400 mls or more at 2 
hours after delivery was not significantly different between the two groups (143/1,170 
[12.2%] compared with 144/1,170 [12.3%]; RR 0.99, 95% CI 0.88-1.13). 
 
In summary, uterine massage is not recommended as an intervention to prevent PPH in 
women who have received prophylactic oxytocin, as it may cause maternal discomfort, 
requires a dedicated health professional, and may not lead to a reduction of blood loss. 
However, surveillance of uterine tonus through abdominal palpation is recommended in all 
women for early identification of postpartum uterine atony (WHO, 2012). 
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C. Uterine compression 
 
Chantrapitak and colleagues recently addressed ‘lower uterine segment compression’ 
(LUSC) as a new manoeuvre for prevention of PPH (≥ 500 mls) after vaginal delivery. The 
subjects (686 women) were divided into two groups and both groups received standard 
therapy for PPH prevention with IV oxytocin 10 IU, delayed cord clamping (within 3 
minutes) and CCT. After delivery of the placenta, uterine massage was done for all 
subjects. In the experimental group, the authors added the manoeuvre of lower uterine 
segment compression for 10 minutes. LUSC were done by two ways depending on the 
women’s condition. If the woman had thick abdominal wall (obese, primigravida), the first 
technique was used by placing one hand (or both) on the abdomen to compress the lower 
uterine segment as hard as the mother could tolerate it. The second way was used in 
mothers with a thin abdominal wall (slimmer women, multipara) where one hand 
compressed the fundus and the other hand compressed the lower uterine segment. The 
result showed that LUSC significantly reduced the rate of PPH (2.9% vs. 6.8%; RR 0.43, 
95% CI 0.21-0.90, p = 0.02). The amount of blood loss was also reduced by 29.26 mls, p = 
0.012 (Chantrapitak et al., 2011).  
 
2.2.2.5. Nipple stimulation 
 
Early suckling or nipple stimulation is thought to increase uterine contractility. A cluster 
RCT was carried out to examine the effect of suckling immediately after birth on the 
frequency of PPH and mean blood loss after delivery (Bullough et al., 1989), involving 
2104 mothers in the early suckling group and 2123 subjects in the control group. In that 
study early suckling was not found to reduce the rate of PPH of 500 mls or more (OR, 
0.93; 95% CI 0.75-1.17). The frequency of PPH was 7.9% in the suckling group and 8.4% 
in the control group, with mean blood losses of 258 mls and 256 mls respectively. Early 
suckling should still be encouraged because it promotes bonding and breastfeeding and 
may help to maintain uterine tone.  
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2.2.3. Care after delivery of the placenta 
 
It is advisable after delivery of the placenta to routinely inspect the vulva, vagina, 
perineum, and anus to identify genital lacerations, to routinely inspect the placenta and 
membranes for completeness, and to monitor the woman for vaginal bleeding and uterine 
hardness every 15 minutes for at least the first two hours. The palpation of uterus is to 
check that the uterus is well contracted, with massage being performed as needed, to keep 
the uterus well-contracted and firm (FIGO/ICM, 2004; Hofmeyr et al., 2008).  
 
 
2.3. Third stage blood loss estimation and diagnosis of PPH 
 
Mortality reports have found that the majority of PPH deaths involve delayed and 
substandard care in the diagnosis and management of PPH (Berg et al., 2005; Lewis, 
2007). A timely and precise diagnosis of PPH is therefore essential, allowing prompt 
initiation of appropriate interventions, drugs, surgery, and referral when necessary (Prata 
and Gerdts, 2010). Several studies assessed the amount of blood loss during childbirth 
using different methods: the mean blood loss reported was approximately 400 to 600 mls 
and 1000 mls after vaginal and caesarean deliveries, respectively. Clinicians were seen to 
more commonly underestimate than overestimate the volume of blood lost (Stafford et al., 
2008). Estimation of blood loss during the third stage of labour still presents a great 
challenge to most practitioners. Since haemorrhage is a major cause of maternal mortality, 
methods to precisely measure blood loss and PPH are required. Over several years, 
different techniques have been used for the estimation of postpartum blood loss, including 
visual estimation, direct measurement, gravimetric, photometry and others.  
 
In practice, blood loss after delivery is seldom measured and it is not clear whether 
measuring blood loss improves the care and outcome for the women. One study (Zhang et 
al., 2010) found that even if the blood loss was measured it does not affect the incidence of 
PPH. 
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I. Visual estimation 
 
Visual estimation is the most frequently used method for estimation of blood loss after 
child birth (Tourne et al., 2004). Although repeated studies have shown the inaccuracy of 
the visual estimation method, it is still used. It has been long recognised that actual blood 
loss was higher than visually estimated blood loss during vaginal births (Brant, 1967), with 
studies finding that visual estimates are about 30-50% of actual blood losses (Razvi et al., 
1996; Chua et al., 1998). Importantly, this inaccurate estimation rises with increasing 
blood loss (Brant, 1967; Duthie et al., 1991). In clinical practice, underestimation may 
result in delaying or deterring the recognition and diagnosis of PPH. The accuracy of 
estimated blood loss was found to be independent of the age or clinical experience of the 
healthcare provider (Meiser et al., 2001; Dildy et al., 2004). Interestingly, several studies 
demonstrate that the inaccuracy of visual estimation method of blood loss can be improved 
with staff teaching and by quantification of blood loss using calibrated under-buttocks 
drapes for blood collection (Dildy et al., 2004; Bose et al., 2006). 
 
II. Direct measurement 
 
Direct measurement is one of the oldest methods used to precisely determine the amount 
of blood loss during child birth. Several types of drapes were used in various studies to 
assist with direct blood collection. This method has many advantages as it requires only 
containers for collection and a graduated container for measuring. Women can give birth 
in any position or location. It still needs some estimation of blood that may be on gloves, 
linens, gowns or other materials. One limitation is that it is not possible to avoid all other 
forms of fluid, such as amniotic fluid or urine. If those fluids are unintentionally collected, 
the results may be erroneous. In a study in rural India it was found that the calibrated-drape 
estimation of blood loss is more accurate than visual estimation for PPH; a specially 
designed blood collection drape was used to estimate postpartum blood loss. The assessed 
blood loss by visual estimation was 33% less than the drape measurement and the 
correlation between the drape determination and photospectrometry was 0.92, proving its 
accuracy (Patel et al., 2006).  
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III. Gravimetric (measurement by weight) 
 
The gravimetric method of blood loss estimation is an alternative objective techniques 
used in calculating postpartum blood loss. It involves the weighing of collected blood lost 
during childbirth along with materials such as all contaminated linens, pads, towels, or 
swabs on a sensitive scale and then deducting the known dry weights of these materials to 
find out the actual amount of blood loss (Lee et al., 2006). However, other types of fluid, 
such as amniotic fluid or urine that are present at the time of delivery cannot be avoided or 
discriminated from the blood during the process of weighing; this would affect the final 
results of the actual amount of blood loss. In addition, the weighing must be done quickly 
to minimise evaporation loss. This method can be easily taught, but is both time-
consuming and labour-intensive (Schorn, 2010). In a prospective cohort study comparing 
visual estimation versus gravimetric measurement of postpartum blood loss, there was a 
significant difference between the calculated amounts of blood loss using a sensitive 
gravimetric machine. Both healthcare providers’ (physicians and obstetric nurses) visual 
assessment had a tendency to underestimate the loss on average by 30% (Al Kadri et al., 
2011). Again this study shows that the background knowledge and experience of the 
assessing healthcare provider did not affect the accuracy of the estimation. Schorn has 
stated that a combination of direct measurement and gravimetric methods are the best 
method to be used in the estimation of blood loss (Schorn, 2010). 
 
IV. Photometry 
 
A photometric technique (also known as the alkaline haematin method) involves the 
conversion of blood pigment to alkaline haematin. This technique is considered as the gold 
standard for measuring blood; other methods are compared against it to determine 
accuracy (Schorn, 2010). Chua et al., (1998) have taken blood collected from a 
gynaecologic surgery and simulated postpartum conditions by pouring this blood onto 
sanitary pads and towels (Chua et al., 1998). These pads and towels were collected and 
given to a laboratory technologist who did not know the original measured amount of 
blood. The blood loss measured in the laboratory showed an error of between 0% and 
9.4%. Although photometric methods are considered the most accurate technique for 
estimation of blood loss, the procedure poses several limitations. For example, the method 
is not cheap, it needs specialised equipment, and a formula is required after the meter 
reading is obtained. Furthermore, errors can occur at any stage of blood collection: 
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extraction of blood from the pads, conversion of haemoglobin to alkaline haematin, or 
during the time of comparison in the spectrophotometer. The availability of highly skilled 
personnel with laboratory equipment is also necessary (Schorn, 2010). 
 
V. Miscellaneous methods 
  
There are other different techniques used in estimation of blood loss, but none have been 
found to be practical or reliable methods (Schorn, 2010). The measurement of the diameter 
of the inferior vena cava by ultrasound was one of these methods. Performing this 
technique in traumatised patients in the emergency room has shown that there was a 
significant association between the diameter of the inferior vena cava and the amount of 
blood loss. The diameter of the inferior vena cava was smaller with large blood loss and 
was present before the development of other signs of shock, the decreased size in the 
inferior vena cava was observed when the blood loss was > 450 mls (Lyon et al., 2005). 
Another method is comparing haemoglobin drawn at the last prenatal visit before birth 
with post-delivery haemoglobin (day 3 and 10 weeks postpartum). However the result was 
not significant as there was no correlation, especially between haemoglobin levels at 10 
weeks postpartum and estimated blood loss (Palm and Rydhstroem, 1997).  
 
Overall, underestimation of blood loss at delivery can lead to a delay in the diagnosis, and 
consequently the treatment, of PPH. Overestimation of blood loss can also have significant 
implications such as unnecessary cross-matching of blood, wasting valuable time and 
resources. One confounding factor could be the flow rate over time. Therefore, it is well 
acknowledged that the best definition and diagnosis of PPH should be made on a clinical 
basis. The diagnosis of PPH can be based on the status of the physiological response to the 
circulating blood volume loss (Bose et al., 2006). Moreover, since there is insufficient 
evidence to recommend quantification of blood loss over clinical estimation the WHO 
currently strongly recommend diagnosis of PPH to be based on clinical parameters (WHO, 
2009). So the birth attendant should be aware of excessive bleeding that leads to 
development of symptoms such as pallor, headache, weakness, palpitations, excessive 
sweating, restlessness, confusion and coma and/or results in signs of shock due to 
hypovolemia, for example, hypotension, tachycardia, oliguria, and low oxygen saturation 
(less than 95%).   
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There is no single gold standard method that could be used for measuring postpartum 
blood loss. Researchers usually are left to use methods that are cheap, feasible and easy to 
teach. For research purpose, it can be recommended that combining two methods would be 
ideal to reduce errors and increase accuracy when measuring postpartum blood loss. 
Combining the gravimetric method along with direct blood measurement can be proposed 
as appropriate blood loss estimation technique. This would be a cheap method and increase 
the accuracy of blood loss estimation. 
 
2.4. Treatment of established PPH 
 
As mentioned above, PPH is an unpredictable emergency condition that if uncontrolled 
can very quickly lead to maternal death. In one series, almost one third (32%) of deaths 
occurred within 24 hours after delivery, with one fifth of all deaths occurring within 1-4 
hours of delivery (Kane et al., 1992). Thus, in the absence of timely and appropriate 
action, a woman could die within a few hours.  
 
Once the diagnosis of the primary PPH is established, the condition requires early 
recognition of its cause, immediate control of the bleeding source by multiple interventions 
(medical, mechanical, invasive-non-surgical and surgical procedures), and rapid 
stabilisation of the mother’s condition. Most importantly, a multidisciplinary approach 
must be employed. The practical management of PPH may be considered as having at least 
four components: communication with all relevant professionals; resuscitation; monitoring 
and investigation; and measures to arrest the bleeding. All of these components must be 
initiated and progressed simultaneously for optimal patient care.  
 
2.4.1. General measures  
 
Women should be assessed carefully to find out the cause of bleeding and they should be 
resuscitated if they develop signs and symptoms of haemorrhagic shock. The first action 
should be to call for help and to alert an experienced obstetrician, followed by resuscitation 
of the patient and, assessment of the uterine tone to rule out the possibility of retained 
products of conception, genital tract trauma and coagulopathy. Bladder evacuation and 
keeping a catheter in place is very important as a distended bladder could be the only cause 
of uterine atony and PPH. While investigating the aetiology of PPH and treating the cause, 
resuscitation and volume replacement should immediately take place. The haematologist 
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and blood transfusion laboratory should be notified. Anaesthesia should be also notified to 
be ready for surgical interventions once needed. A baseline investigation should be 
ordered, such as a complete blood count, as well as prothrombin time and partial 
thromboplastin time (RCOG, 2009). 
 
Communication "Call for help" 
 
Because emergency situations create opportunities for errors in care, it is essential that 
obstetricians and other maternity care providers work together to develop systems within 
their units to address the coordinated management of woman experiencing PPH. Early 
involvement and communication of all appropriate obstetric staff, including experienced 
midwives, a member of the team to record events, fluids, drugs and vital signs, as well as 
porters for delivery of specimens/blood, senior staff (including anaesthesia team), and 
laboratory specialists including a consultant clinical haematologist, are fundamental to the 
management of PPH. 
 
 Resuscitation 
 
A, B and C – assess airway, breathing and evaluate circulation  
Immediate resuscitation of hypovolemia should be achieved with large bore IV cannula 
and IV fluids. A high concentration of oxygen (10-15 litres/minute) via a facemask should 
be administered, regardless of maternal oxygen concentration. If the airway is 
compromised owing to an impaired conscious level, anaesthetic assistance should be 
sought. Blood samples should be taken and sent for diagnostic tests, including ABO/RH 
grouping and cross matching, full blood count, coagulation screen, urea and electrolytes. 
 
 Fluid replacement 
 
A total volume of 3.5 litres of warmed solution should be infused as rapidly as possible. In 
the 2012 WHO recommendations, the treatment of PPH using isotonic crystalloid is 
recommended in preference to the use of colloid for the initial IV fluid (WHO, 2012). 
However the RCOG guidelines state that the nature of fluid infused is of less importance 
than rapid administration and warming of the infusion. The woman needs to be kept warm 
using appropriate measures. 
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Blood transfusion 
 
Women diagnosed with massive PPH may need rapid RBCs which improve the blood’s 
oxygen-carrying capacity. Therefore, it is recommended that women with known risk 
factors for PPH should not be delivered in a hospital without a blood bank on site 
(CEMACH, 2004). If fully cross-matched blood is unavailable by the time that 3.5 litres of 
clear fluid have been infused, the best available alternative should be given. It is 
recommended that if transfusion is needed before type-specific or cross-matched blood can 
be obtained, if possible type-O, Rh-negative blood should be utilised because of the future 
risk of Rh sensitisation; however if not readily available Rh-positive blood should not be 
withheld if clinically required (Fuller and Bucklin, 2007). 
 
Platelets are also needed to help coagulation. Massive haemorrhage will lead to a rapid 
decrease in the fibrinogen levels and hypofibrinogenaemia will increase the severity of 
uterine bleeding. Fresh frozen plasma can increase fibrinogen and replace clotting factors. 
Cryoprecipitates provide a more concentrated form of fibrinogen as each 40 mls raises the 
fibrinogen level by 10 mg/dl (Rajan and Wing, 2010). 
 
A new thrombelastometry system (ROTEM
®
) is available for early diagnosis of 
coagulation disorders. It can be used in the laboratory or at the patient’s bedside. The 
FIBTEM
® 
test of the ROTEM
®
 can be used to assess the fibrinogen level. It might be 
helpful in identifying fibrinogen deficiency early in the PPH leading to its rapid correction 
(Huissoud et al., 2009). 
 
Monitoring and investigation 
 
Close monitoring of vital signs is critical (temperature, pulse and automated blood pressure 
recording [every 15 minutes]). Fluid replacement and the use of blood and blood products 
should be strictly monitored. Bladder catheterisation is very important as a distended 
bladder could be the only cause of uterine atony. It further assists to monitor the urine 
output. The full blood count will include an estimation of haematocrit and platelet count. 
The clotting screen should include prothrombin time, thrombin time, partial 
thromboplastin time and fibrinogen assay. 
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2.4.2.  Life-saving procedures 
 
 In achieving a definitive treatment for PPH, there may be delays due to the need for 
transfer to a higher-level facility or, if already in such a facility, obtaining blood and 
surgery. A variety of mechanical measures have been developed to deal with this situation 
such as BMC, aortic compression and the pneumatic anti-shock garment. 
 
1. Bimanual compression (BMC) 
 
Bimanual compression of the uterus is an emergency procedure used to stop PPH caused 
by uterine atony. It is of two types internal and external. 
 
It is thought that internal bimanual compression might be more effective than external 
bimanual compression in controlling blood loss, but it can only performed if the mother 
has had adequate anaesthesia (Billington and Stevenson, 2007 ).   
 
a. External bimanual compression  
 
This method, illustrated in Figure 6, is performed by applying the left hand on the fundal 
area of the uterus while the right hand is applied on the abdominal wall just below the 
umbilicus. The objective of this technique is to produce pressure on the blood vessels of 
uterus through the abdominal wall so as to diminish the bleeding and achieve haemostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. External bimanual compression (Lalonde, 2012) 
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b. Internal bimanual compression  
 
Internal bimanual compression is usually applied when the uterus continues to bleed after 
the placenta has spontaneously or manually delivered. For this method, adequate 
anaesthesia is required. Under aseptic conditions, the right hand is inserted into the vagina, 
making a fist that faces upward in the anterior fornix. The left hand is applied on the 
abdominal wall just behind the uterus to push it firmly in the direction of the symphsis 
pubis (Figure 7). Similar to the external method, the aim of this technique is to compress 
the blood vessels of the uterus through the abdominal wall in order to diminish the 
bleeding and achieve haemostasis as well as well uterine contractility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The technique of internal bimanual uterine compression for uterine atony 
(Anderson and Etches, 2007) 
 
BMC of the uterus is used by many healthcare professionals in emergencies, and in 
environments where there is no medical support such as home birth or in the case of severe 
bleeding in any setting. It is generally used as a stop-gap measure to maintain homeostasis 
until the arrival of medical help and further implementation of pharmacological or surgical 
measures. 
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2. Compression anti-shock garments 
 
The non-pneumatic anti-shock garment (NASG), shown in Figure 8, is a first-aid 
compression garment device made of neoprene and a hook-and-loop fastener comprising 
lower-extremity segments, a pelvic segment, and an abdominal segment, which includes a 
foam compression ball that goes over the uterus (Miller et al., 2007). The NASG reverses 
shock by compressing the lower-body vessels and, decreasing the container size of the 
body, so circulating blood is directed mainly to the core organs: the heart, lungs, and brain. 
It also compresses the diameter of pelvic blood vessels, thus decreasing blood flow (Lester 
et al., 2011). In preliminary pre-intervention/intervention trials in tertiary facilities in 
Egypt and Nigeria, the NASG was shown to significantly improve shock (Miller et al., 
2010), decrease blood loss, reduce emergency hysterectomy for atony, and decrease 
maternal mortality and severe maternal morbidities associated with obstetric haemorrhage 
(Turan et al., 2011). The NASG offers considerable potential for use in low-resource 
settings as it is simple to apply, reusable and relatively inexpensive (US$160 per garment) 
(Weeks, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Picture of compression anti-shock garments fully applied on the patient 
(Miller et al., 2008) 
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3. Aortic compression 
 
Another life-saving intervention is aortic compression, illustrated in Figure 9. It is carried 
out when there is heavy postpartum bleeding, whatever the cause. It may be considered at 
several different points during management of PPH. Aortic compression does not prevent 
or delay any of the other steps to be taken to clarify the cause of PPH and treat it. 
Circulating blood volume is restricted to the upper part of the body and, thereby, to the 
vital organs. Blood pressure is kept higher, blood is prevented from reaching the bleeding 
area in the pelvis, and volume is thus conserved. The manoeuvre is carried out by placing 
the left hand just above and to the left of the woman's umbilicus. Before exerting aortic 
compression, the femoral artery should be felt for a pulse using the index and third fingers 
of the right hand. Once the aorta and femoral pulse have been identified, the clinician 
should slowly lean over the woman and increase the pressure over the aorta to seal it off. 
Absence of femoral pulsation is an indication that the compression is effective (Lalonde, 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Compression of abdominal aorta and palpation of femoral pulse (Lalonde, 
2012) 
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2.4.3. Stopping the bleeding 
 
As stated above, the causes for PPH relate to one or more of ‘the four Ts’: tone, tissue, 
trauma and thrombin. Establishing the cause of haemorrhage is an essential step towards 
correcting the problem. For a patient who delivers vaginally, once the placenta is 
delivered, excessive bleeding should prompt careful exploration of the placenta and genital 
tract. This will usually allow an assessment of the first 3 aetiologies, but a clinical 
examination may not be able to diagnose a coagulation abnormality. In the following 
section, PPH management will be reviewed according to its cause. 
 
A. Tone 
 
Uterine tone and size are assessed by resting one hand on the fundus and palpating the 
anterior aspect of the uterus. A bimanual examination may facilitate this assessment. If the 
uterus is large and boggy to palpation, then the bleeding is likely to be caused by uterine 
atony. Because uterine haemostasis depends on myometrial contraction, atony is treated 
initially by BMC and massage, followed by drugs that promote uterine contraction.  
 
B. Tissue 
 
If the placenta has not been delivered within 15-30 minutes of childbirth or in cases where 
retained placental fragments are suspected, the uterus must be emptied (Tamizian and 
Arulkumaran, 2002).  
 
WHO recommend use of oxytocin and CCT before commencing UVI (WHO, 2009). If the 
UVI is bypassed, or not successful, adequate regional anaesthesia or general anaesthesia 
should be ensured; current haemostatic parameters should be reassessed with cross-
matched blood available, broad spectrum antibiotics administered and an oxytocin drip (40 
IU oxytocin in 500 mls of 0.9% saline) should be started before attempting manual 
removal of the placenta (Rajan and Wing, 2010). The best way to remove retained 
products is to approach transvaginally, finding the line of cleavage then gently separating 
the placental parts from the uterus, sweeping the fingers in a side-to-side motion. After this 
has been completed, the uterine cavity should again be checked to ensure it is empty 
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(Tamizian and Arulkumaran, 2002). If the line of cleavage cannot be found, then invasive 
placenta should be considered. The most common treatment for invasive placenta is 
hysterectomy (Wu et al., 2005).  
 
C. Trauma 
 
In order to gain effective control of the bleeding, the injured area should be sutured, 
starting at the apex of the tear. If the apex cannot be reached, the suture should be started 
as close to the apex as possible, then, once the remainder of the tear has been 
approximated, place traction to reach the previously hidden apex. If there is extensive 
trauma to the vaginal wall, with multiple lacerations, bruising and oozing repairs, a vaginal 
pack can be used to provide haemostasis and maintained for 12-24 hours (Tamizian and 
Arulkumaran, 2002).  
 
In case of uterine inversion every attempt should be made to replace the uterus quickly 
(Watson et al., 1980). The Johnson method of reduction begins with grasping the 
protruding fundus (Figure 10A) with the palm of the hand with fingers directed towards 
the posterior fornix (Figure 10B). The uterus is returned to its position by lifting it up 
through the pelvis and into the abdomen (Figure 10C). Once the uterus is reverted, 
uterotonic agents should be given to promote uterine tone and to prevent recurrence. If the 
initial attempts to replace the uterus fail or a cervical contraction ring develops, 
administration of tocolytic therapy or general anaesthesia may allow sufficient uterine 
relaxation for manipulation. If these methods fail, the uterus will need be replaced 
surgically (Beringer and Patteril, 2004). 
 
Uterine rupture is a rare, life threatening emergency that requires laparotomy for surgical 
repair of the defect or hysterectomy. Surgical repair is used for simple scar dehiscence or a 
small tear. Major tears, however, with uncontrolled haemorrhage will require a 
hysterectomy (Jeganathan and Sivanesaratnam, 2011).  
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D. Thrombin  
 
In patients who have not responded to the usual measures to treat PPH, and in those who 
are not forming blood clots or are oozing from puncture sites, coagulation defects should 
be suspected. Evaluation should include a platelet count and measurement of prothrombin 
time, partial thromboplastin time and fibrinogen level. The ROTEM
®
 diagnostic system 
can also assist in the bedside rapid diagnosis. Management consists of treating the 
underlying disease process, supporting intravascular volume, serially evaluating 
coagulation status, and replacing appropriate blood components (Price et al., 2004).  
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Figure 10. Reduction of uterine inversion (Johnson method) (A) the protruding 
fundus is grasped with fingers directed toward the posterior fornix. (B, C) the uterus 
is returned to position by pushing it through the pelvis and into the abdomen with 
steady pressure towards the umbilicus (Anderson and Etches, 2007) 
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2.4.4. Medical treatment of atony 
 
If initial interventions fail to control PPH, a stepwise progression of medical therapy is 
carried out, using available uterotonics to facilitate the contraction of the uterus. Different 
uterotonic agents can be used in treatment of atonic PPH.  The early medical treatment of 
uterine atony involves the administration of oxytocin or ergometrine. Despite extensive 
and extended use of injectable uterotonics over the last few decades, there have been no 
clinical trials comparing oxytocin and ergometrine for treatment of uterine atony. 
 
The WHO recommends 20-40 IU in 1 litre of intravenous fluid at 60 drops per minute, and 
10 IU intramuscularly as first-line treatment. Ergometrine (with or without oxytocin) and 
intramuscular prostaglandin F2α (carboprost) are considered a valid alternative (WHO, 
2009; Tuncalp et al., 2013) . If there is not adequate uterine tone with oxytocin, the second 
line agent used will depend on the medication’s side effects and contraindications. 
Methylergonovine may be used, with a typical dose of 0.2 mg administered intramuscular 
and repeated 2-4 hrs later for a maximum of 5 doses (1 mg) in a 24-hour period, as long as 
the patient does not have hypertension or preeclampsia (Lalonde, 2012; Tuncalp et al., 
2013).  
 
Prostaglandin F2α is considered as the third line for the management of PPH in a uterus 
unresponsive to oxytocin or ergometrine (WHO, 2009). However, there were no trials 
comparing it with other uterotonics. Carboprost can be administered intramyometrially or 
intramuscularly in a dose of 0.25 mg; this dose can be repeated 3 times every 15 minutes 
for a total dose of 2 mg (Lalonde, 2012). The use of intramuscularly administered PGF2α 
in uncontrollable atonic PPH has been shown to be a valuable life-saving medical tool in 
critical cases (Toppozada et al., 1981). The direct intramyometrial route has a rapid onset 
of action and can be achieved under direct vision during caesarean section or 
transabdominally or transvaginally after vaginal delivery (Jacobs and Arias, 1980). The 
peak plasma concentration of the intramuscular route is achieved at 15 minutes and at less 
than 5 minutes for the intramyometrial injection. Carboprost has been proven to control 
haemorrhage in up to 88% of patients (in 208 of 237 cases) if used alone or in combination 
with other uterotonic agents (95%). In cases where it is not effective, chorioamnionitis or 
other risk factors for haemorrhage are often present (Oleen and Mariano, 1990). The use of 
prostaglandin E2 analogue (sulprostone) in the treatment of PPH was associated with 
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cardiac arrest in three participants and therefore, it was voluntarily withdrawn by the 
manufacturers (Sharma and El-Refaey, 2003). 
 
Misoprostol could be an appropriate alternative when parenteral prostaglandin is not 
available or when it is contraindicated. Misoprostol is effective in the treatment of PPH, 
but side effects may limit its use (Hofmeyr et al., 2005). It can be administered 
sublingually, orally, vaginally, and rectally with doses ranging from 200 to 1,000 mcg 
(Hofmeyr et al., 2005). Oral misoprostol produces the fastest and strongest uterotonic 
effect, but with the most side effects including shivering, pyrexia, and diarrhoea (Chong et 
al., 2004). The authors of the latest Cochrane review for treatment of PPH concluded that 
the available evidence was not enough to support the use of misoprostol instead of 
oxytocin and ergometrine as a first line treatment of PPH (Mousa et al., 2014). Further 
recent research has shown that a single dose of misoprostol 800 mcg administered 
sublingually is a safe and effective treatment for PPH, due to uterine atony in women who 
have received oxytocin prophylaxis, as well as those who have received no oxytocin 
prophylaxis during the third stage of labour (Blum et al., 2010; Winikoff et al., 2010). In 
home births without a skilled attendant, misoprostol may be the only technology available 
to control PPH. Studies on treatment of PPH found that misoprostol significantly reduces 
the need for additional interventions (Prata et al., 2005). There is evidence that misoprostol 
provides no added benefit when given simultaneously with other injectable uterotonic 
drugs for the treatment of PPH, and therefore misoprostol as an adjunct treatment with 
oxytocin for PPH is not recommended (Widmer et al., 2010).  
 
The questions relating to the management of women with major primary PPH 
unresponsive to uterotonic therapy remain largely unanswered. In the absence of RCTs, 
clinicians are left to make their own judgement on the best combination of surgical, 
radiological and/or pharmaceutical interventions that should be used to control the 
bleeding (Mousa and Alfirevic, 2007).  
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2.4.5. Other pharmacological interventions 
 
Haemostatic drugs, including tranexamic acid and recombinant activated factor VII 
(rFVIIa) have been used for the treatment of intractable haemorrhage. 
 
Tranexamic acid may have a role in the control of PPH, particularly where coagulation is 
compromised. The drug is potentially attractive for PPH management as it would provide 
an alternative way of achieving haemostasis and reducing bleeding irrespective of whether 
it came from uterine atony or lacerations (Weeks, 2010). However, Searle et al., (2008) 
raised theoretical concerns regarding its use in women with severe PPH as they can 
develop disseminated intravascular coagulation, and tranexamic acid would theoretically 
increase the damaging microvascular thrombosis that occurs in this process (Searle et al., 
2008). In addition, rapid intravenous administration of tranexamic acid can also cause 
hypotension, thus exacerbating the hypotensive effects of PPH.  
 
There is currently an ongoing randomised, double-blind, placebo-controlled trial among 
women with a clinical diagnosis of PPH (WOMAN trial), coordinated by the London 
School of Hygiene and Tropical Medicine (University of London), which aim to reliably 
determine the effect of the early administration of tranexamic acid on death, hysterectomy 
and other morbidities (surgical interventions, blood transfusion and risk of non-fatal 
vascular events), in woman with PPH (Shakur et al., 2010). 
 
The use of rFVIIa as a haemostatic agent for refractory PPH has been described in a 
number of case reports (Bouwmeester et al., 2003; Segal et al., 2003). The mode of action 
of this agent involves enhancement of the rate of thrombin generation, leading to 
formation of a fully stabilised fibrin plug that is resistant to premature lysis. Reported 
cases involve haemorrhage unresponsive to numerous conventional treatments including 
hysterectomy and pelvic vessel ligation, where use of this agent was remarkably successful 
at arresting seemingly intractable bleeding within a matter of minutes. Doses of 60–120 
mcg/kg intravenously were used. 
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2.4.6. Surgical methods 
 
The surgical procedures that can be applied in case of PPH are of two types, non-invasive 
or invasive measures: 
 
2.4.6.1. Surgical non-invasive measures 
 
Uterine tamponade 
 
Active attempts have been made to introduce conservative procedures to control bleeding, 
and importantly to avoid hysterectomy including the use of uterine packing and uterine 
tamponade. Uterine packing applies these principles, making it a popular technique for 
over a century, whereas the balloon tamponade is a more recent development.  
 
Uterine packing, using “several yards of wide gauze” placed inside the uterine cavity, fell 
out of favour in the 1950s as it was thought to conceal haemorrhage and cause infection 
(Eastman, 1950). However, this technique re-emerged in the 1980s and 1990s after these 
concerns were not confirmed. Surgeons found that, whether uterine packing was used early 
or late in patient management for the control of PPH, it was a safe, quick, and effective 
way to create haemostasis (Maier, 1993). It is particularly useful in the developing 
countries. It is important to note the fundal level at the time of packing. If, on subsequent 
examinations, the fundus seems to have moved higher then there may be ongoing 
haemorrhage. Broad-spectrum antibiotics should always be used prophylactically to 
prevent septic complications (Rajan and Wing, 2010). To remove the pack, some 
practitioners administer an anxiolytic. Oxytocin, administered for 12-24 hours after the 
pack is removed, provides adequate muscle contraction, thus preventing the re-initiation of 
bleeding (Drucker and Wallach, 1979). 
 
Internal tamponade can also be achieved using an intrauterine balloon. Examples of 
balloon catheters are the Foley catheter, Rush catheter, SOS (Surgical Obstetric Silicone) 
Bakri catheter, and the Sengstaken-Blakemore balloon. Balloon catheters can also be made 
using a sterile rubber glove or condom attached to a rubber urinary catheter (Figure 11) 
(Georgiou, 2009). The general idea is to insert a sterile balloon into the uterine cavity, then 
fill the balloon with warm water to see if additional pressure can control the patient's 
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haemorrhage. The Sengstaken-Blakemore tube, Foley catheter and Bakri balloon have the 
advantage of providing an outflow tract for the continuous bleeding (Majumdar et al., 
2010). 
 
 
Figure 11. Distal component of tamponade balloons (Georgiou, 2009) 
 
Bakri first published the concept of intrauterine balloon technology in the management of 
PPH secondary to placenta praevia accreta during caesarean section (Bakri, 1992; Bakri, 
1999). The Bakri ‘SOS’ balloon was described as having a capacity of up to 500 mls of 
saline achieving a pressure and tamponade effect to control the bleeding. In 2001 Bakri 
and his colleagues (Bakri et al., 2001), demonstrated that the tamponade balloon was 
effective in controlling PPH originating from the placental site of the lower uterine 
segment (five women with PPH caused by low-lying placenta/placenta previa) and 
bleeding from the implantation site of cervical ectopic pregnancy (one woman with 
cervical pregnancy).  
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In addition to the Bakri balloon, there are other designed uterine balloons such as the 
EbbTM balloon and BT-Cath
®
 (Figure 12) (Georgiou, 2012). The BT-Cath
®
 is a soft 
silicone balloon tamponade catheter that provides direct uterine pressure to control PPH. 
The BT-Cath
®
 also has a lumen allowing intrauterine blood drainage. This allows timely 
confirmation of the tamponade effectiveness. The intrauterine drainage port is flush with 
the top of the inflated balloon (no tubing protruding from the balloon) allowing placement 
near the uterine fundus (http://www.utahmed.com/btcath.htm, 2012). 
 
In 1994, Katesmark and colleagues described the use of a Sengstaken-Blakemore tube 
(generally used for tamponade of acute upper gastrointestinal bleeding due to oesophageal 
varices) to control PPH (Katesmark et al., 1994). Warm saline was used to fill the balloon 
until it was visible at the cervical canal-using approximately 300 mls of fluid. Johanson 
and co-workers (Johanson et al., 2001), described the same process using a Rusch balloon 
catheter, a type of urologic hydrostatic balloon catheter. In two cases of failed medical 
therapy for PPH, where the catheter had been tried, further surgical interventions were 
avoided. The balloon was inserted into the uterine cavity and inflated through the drainage 
port, using approximately 400-500 mls of warm saline.  
 
Although there is no evidence to direct how long the balloon should be left inside, it is 
recommended to be maintained for 12-24 hours. The previously started oxytocin infusion 
should be continued and broad spectrum antibiotics should be given to decrease the 
patient's risk of sepsis.  
 
A successful tamponade demonstrates decreased or minimal bleeding after balloon 
inflation, thus terminating the need for surgical treatment (Doumouchtsis et al., 2008). 
Uterine balloons have proved very popular with success rates of 81% for the Sengstaken-
Blackemore tube and 59% success for Rusch balloon (Majumdar et al., 2010). Therefore, a 
uterine balloon tamponade is considered an important tool for the treatment of PPH. But it 
is important to note that the effectiveness of different tamponade methods have only been 
described in case series. RCTs are unlikely to be conducted as the cases which need 
uterine tamponade are relatively rare. 
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Figure 12.  Uterine specific balloons. The Bakri balloon and the BT-Cath
®
 are single 
balloon devices. The Ebb balloon is designed for one balloon in the uterine cavity (Ut) 
and the other within the vagina (Va). *Drainage channel for each balloon system. Bar 
= 5 cm (Georgiou, 2012) 
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2.4.6.2. Invasive surgical interventions  
 
If conservative non-surgical treatment has failed, other surgical options are available. 
These include selective arterial embolisation, a variety of compression suture techniques, 
selective arterial ligation and, as a final option, hysterectomy. The choice of the type of 
surgical intervention depends on several factors, the most important being the experience 
of the surgeon. Other factors include parity and desire for future children, the extent of the 
haemorrhage, the general condition of the woman, and the availability of equipment, 
especially in case of radiological embolisation. 
 
1. Selective arterial embolisation (radiological embolisation) 
 
Selective radiological embolisation of the bleeding vessel may be an option in centres 
where interventional radiologists are available and the bleeding is not life threatening.  It is 
a less invasive intervention and involves insertion of a catheter through the femoral artery 
into the aorta and then to the uterine arteries. Gel foam (gelatin) pledgets are the most 
commonly used material in cases of emergency embolisation with a potential for 
recanalisation three weeks later (Pelage et al., 1999). The uterine artery is the most 
commonly embolised vessel, followed by the pudendal, hypogastric, obturator, vaginal and 
cervical arteries (Vegas et al., 2006). Pelage and colleagues evaluated the role of selective 
arterial embolisation in 35 patients with unanticipated PPH (Pelage et al., 1999). Bleeding 
was controlled in all except one who required hysterectomy for re-bleeding five days later. 
All women who had successful embolisation resumed normal menstruation. Fever, 
contrast media renal toxicity, and leg ischaemia are rare but reported complications of this 
procedure (ACOG., 1998). Unfortunately, the efficacy of selective arterial embolisation is 
often limited to a small number of hospitals where a trained, available interventional 
radiologist is present (Tamizian and Arulkumaran, 2002). It is less effective in the 
presence of disseminated intravascular coagulation and placenta accreta (Rouse, 2013). 
When embolisation is successful, the patient can rapidly recover without undergoing 
additional surgery. The procedure has many advantages, including minimal morbidity and 
low complication rates, shorter hospital stay, preservation of fertility and the fact that it 
can be carried out under local anaesthesia (Ledee et al., 2001). 
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2. Compression sutures 
 
Haemostatic uterine suturing or uterine compression sutures have been used to control 
PPH. The technique was introduced in 1997 as a type of vertical brace suture (Figure 13). 
It works by opposing the anterior and posterior walls of the uterus. The original technique 
was the B-Lynch suture, created by Dr. B-Lynch, a British Obstetrician and 
Gynaecologist. Single or multiple stitches may be inserted at the same time and, according 
to the shape, they may be called the brace suture (B-Lynch et al., 1997), square sutures 
(Cho et al., 2000) or simple brace (Hayman et al., 2002).  
 
In his 2007 article, Baskett offers results of a 7-year study of compression sutures, all done 
at the time of caesarean delivery, showing that compression sutures were able to control 
bleeding in 23 of 28 (82%) of women, thereby preventing hysterectomy. Of these women, 
7 were able to have subsequent uncomplicated term pregnancies (Baskett, 2007). The 
usefulness of the B-Lynch suture is attributed to its simplicity, safety, ability to preserve 
life, the uterus and fertility (Somunkiran et al., 2007). Despite the effectiveness of uterine 
compression sutures, unexpected occlusion of the uterine cavity with subsequent 
development of infection (pyometra) has been reported (Ochoa et al., 2002), and uterine 
necrosis was also documented (El-Hamamy and B-Lynch, 2005). 
 
 
Figure 13. Uterine compression using B-Lynch suture for treatment of atonic uterus 
(B-Lynch et al., 2006) 
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3. Ligation of arterial blood supply  
 
Of the uterus-sparing options, arterial ligation is one of the most frequently used 
worldwide. Ligation of the uterine artery or its main supply internal iliac artery may be 
considered in selected cases. Bilateral uterine artery ligation, as first described by O’Leary 
and O’Leary (OLeary and OLeary, 1966; OLeary and OLeary, 1974), consists of a mass 
ligation of the uterine vessels (including arteries and veins) and the myometrium at the 
level of the lower uterine segment. The procedure is considered one of the most effective 
surgical measures to control PPH as its occlusion reduces 90% of the uterine blood flow. 
Despite this percentage, an adequate blood supply is still available (Gilstrap and Ramin, 
1994). The technique is easy to perform, associated with minor morbidity and has shown 
to be successful (not requiring hysterectomy) in 80-96 % of cases (O'Leary, 1995; Morel et 
al., 2011). Incomplete ligation is the most common cause of persistent bleeding and failure 
of the method (Fargeaudou et al., 2010; Zwart et al., 2010). Fears regarding uterine 
compromise with subsequent pregnancies have been proven unfounded as a number of 
women have become pregnant after undergoing uterine ligation (Shah and Wright, 2009). 
 
Systematic pelvic devascularisation, including additional ligation of the internal iliac 
arteries, has been advocated as an effective measure for controlling intractable PPH and 
preventing maternal death (Joshi et al., 2007; Mukherjee and Arulkuman, 2009). 
Unfortunately, this procedure has a low success rate (estimated at 40%), mostly attributed 
to the late stage at which the ligation is attempted and that it is frequently complicated by 
hematoma formation and tissue oedema that obscure the anatomy (Tamizian and 
Arulkumaran, 2002). In a case-series including 88 patients with a therapeutic internal iliac 
artery ligation (IIAL) mainly due to uterine atony, genital tract injury and placenta praevia, 
IIAL failed to arrest haemorrhage in nearly 40% of cases requiring subsequent 
hysterectomy (Joshi et al., 2007). IIAL is more difficult to perform and not more effective 
compared to other conservative operative procedures for controlling PPH, requires 
advanced surgical skill, and carries an increased risk of venous, ureteral and nervous 
damage. Complications of this procedure can be severe, including ischemic damage to the 
pelvis, and decreased blood flow to the gluteal muscles (Tamizian and Arulkumaran, 
2002). As shown by numerous case reports and small case series, IIAL has no adverse 
effect on subsequent fertility or pregnancy outcome (Sziller et al., 2007). 
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4. Hysterectomy 
 
Porro in 1876 was the first to describe caesarean hysterectomy to prevent death from 
uterine haemorrhage (Mousa and Alfirevic, 2007). Hysterectomy is the last line of 
treatment available for treating PPH. It is only used for haemorrhage unresponsive to other 
management attempts mentioned above, as it removes the patient's option to bear 
additional children (Yucel et al., 2006). Some clinicians go immediately for hysterectomy 
as a life-saving procedure. The subtotal hysterectomy (also called supra-cervical) has 
become a preferable procedure, as it is quicker, associated with less blood loss, and carries 
a reduced need for further blood transfusion (Chanrachakul et al., 1996). However, if the 
bleeding source is in the lower segment of the uterus, a total hysterectomy is needed 
(Tamizian and Arulkumaran, 2002). Unfortunately, both subtotal and total hysterectomies 
completed for PPH are associated with high rates of maternal mortality (Yucel et al., 
2006). 
 
Conclusion 
 
PPH is a major contributing factor for maternal morbidity and mortality. PPH has 
numerous causative factors, which makes its occurrence and severity difficult to predict. 
The exact definition of PPH and consequently its incidence are continuing to be a matter of 
debate, and there is currently no single, satisfactory definition for PPH. It is agreed that the 
failure of the uterus to contract properly is the most common cause of primary PPH.  
AMTSL is able to decrease the rate of PPH and the duration of the third stage of labour. 
The role of AMTSL in preventing PPH is thought to be attributed to oxytocin. However, 
preventing deaths from PPH require more than this. It requires skilled attendants, the 
availability of uterotonic drugs (including purchase, cold chains and long-term storage) 
and most importantly good quality health facilities. There still exists a significant amount 
of uncertainty regarding the optimal mode of prevention and management of PPH. Hence, 
a more robust approach to the prevention of PPH and a new method of treatment may be 
needed. 
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A hundred years of the third stage: 
 development in the management of the third stage of labour as described 
by Ten Teachers 
 
1. Background 
 
As mentioned before, the third stage of labour is recognised as being the most dangerous 
time of childbirth for the mother. Many of today’s obstetricians were brought up believing 
that ‘active management’ of the third stage (oxytocics, early cord clamping and CCT) was 
the only safe way to deliver the placenta. However, recent studies have shown that 
although prophylactic oxytocics are beneficial, early cord clamping is of no benefit (and 
could be harmful), and CCT has little benefit (Aflaifel and Weeks, 2012b). We therefore 
sought to place these changes in context through a historical study of obstetric practice 
over the last century. 
 
The undergraduate textbook ‘Obstetrics by Ten Teachers’ has been a favourite with 
students, lecturers and practitioners for many generations. First published in 1917 as 
‘Midwifery by Ten Teachers’ (Berkeley et al., 1917), the book was renamed ‘Obstetrics by 
Ten Teachers’ in 1966 (Clayton et al., 1966). New editions have been published every 3 to 
8 years, giving 19 editions over the last century. Throughout these years, each book has 
been written by 10 leading obstetricians from the British Isles with the authors chosen by 
the senior editor. Famous previous editors include Stanley Clayton, George Pinker, 
Geoffrey Chamberlain, and Stuart Campbell. With a complete absence of references in the 
text, the series provide an excellent example of ‘eminence-based’ medicine and gives a 
fascinating insight into changes in labour ward culture over the last century. 
 
2. Methods  
 
In this study, we reviewed the regimes that were recommended for the management of the 
third stage of labour between 1917 and 2011 as described in the successive editions of the 
‘Ten Teachers’ books. Copies were obtained from the Harold Cohen library of the 
University of Liverpool and from interlibrary loans as necessary. Teaching on the routine 
management of the third stage of labour and the treatment of atonic PPH were tabulated 
and graphically displayed (Appendixes B.1 and B. 2). 
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3. Results 
 
Routine third stage management (Figure 1) 
 
Routine third stage management is focussed on reducing blood loss and achieving rapid 
and complete delivery of the placenta. Changes over the last century are shown in Figure 
1. 
 
From 1917 until 1972, the ten teachers taught students to give uterotonic drugs and deliver 
the placenta through maternal effort. The cord was clamped only after the baby had cried 
vigorously, cord pulsations had stopped and the umbilical vein had collapsed (the authors 
describe their concern about depriving the neonate of 60-90 mls of blood if the cord was 
clamped immediately). The first uterotonic available was liquid extract of ergot, which 
was given after the delivery of the placenta either orally as “one teaspoonful in a wine-
glass of water” or by hypodermic injection. In the late 30s the intramuscular injection of 
ergometrine was also recommended as an alternative. In 1948, oxytocin injection was first 
described, at first on its own and then from 1966 in combination with 500 mcg 
ergometrine as syntometrine
®
. In the mid-50s, the timing of the administration was 
changed from after placental delivery to immediately after delivery of the baby. 
 
Although the use of uterotonic drugs in various forms have been used ever since the first 
edition as mentioned above, the practice of early cord clamping and CCT only became 
routine after the AMTSL package was popularised in the mid-sixties.  
 
The 1966 edition was the first to separate management options into conservative and active 
methods. In the active method, ergometrine or syntometrine
®
 is given “after delivery of the 
anterior shoulder”. The placenta is then actively delivered by the Brandt-Andrew method 
or, more recently, using CCT. In the Brant-Andrew method, the cord is held taut whilst the 
placenta is extracted by upward pressure on the uterus with the palmer surface of the 
fingers. In CCT however, the birth attendant pushes the uterine fundus upwards with one 
hand while the other hand applies continuous traction on the umbilical cord to extract the 
placenta. 
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The textbook also taught that, as part of the active management package, the cord should 
be cut early. However, this advice only lasted 14 years until the 1980 edition when the 
early cord clamping was dropped from the teaching, and the teaching became that cord 
clamping should be delayed for few minutes (unless neonatal resuscitation was needed). 
This was the recommended practice until 2011 when the authors reverted to their 
recommendation of early cord clamping. The position of the newborn baby whilst the cord 
is being clamping was also the subject of interest for the teachers from 1966. Initially they 
recommended placing the baby below the level of placenta to facilitate blood flow to the 
baby. But from 1980 onwards, the authors preferred to keep the baby at the same level as 
the placenta and advised against ‘milking the cord’ to force the blood from the placenta to 
the baby. 
 
The treatment of atonic PPH (Figure 2)  
 
Throughout the ‘Ten Teachers’ series, uterotonic drugs have always been taught as being 
the best initial treatment for atonic PPH, with ergot derivatives as the drug of choice. From 
the earliest edition until 1942, a combined dose of ergotin and pituitary extract was 
recommended, although it changed in 1942 to intravenous or intramuscular ergometrine. 
The drug was always given after delivery of the placenta. However, with the increasing 
availability in hospitals of anaesthesia, surgical procedures and blood transfusion transfer 
to a facility became important. From 1955, ergometrine was advised to be given before 
delivery of the placenta if the patient was located outside of a well-equipped hospital. It 
was argued that this would either cause expulsion of placenta, or stop the bleeding by 
contracting the uterus around the placenta so that she can be transferred to hospital for a 
manual removal of placenta. Since 1948, the teachers have recommended a repeat dose of 
uterotonic if the first was unsuccessful. The standard drug was ergot, but others have 
included transabdominal intramyometrial ergometrine (1961-1972) and oxytocin (1948). 
From 1995 onwards the choice of uterotonics increased to include IV syntometrine
®
, 
oxytocin infusion, prostaglandin F2α (IM or directly into the uterine muscle), and 
misoprostol.  
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Aside from drug therapy, uterine massage (sometimes in combination with squeezing the 
uterus through the abdominal wall) has always been taught as the first line non-drug 
intervention. Early alternatives include a 180°F intrauterine douche (with dettol in 1938-
1942), and external or intra-abdominal aortic compression. The importance of BMC has 
increased gradually, moving from third to first option over the editions. Throughout the 
century, the importance of its early use was stressed in the event of severe bleeding. 
 
Hysterectomy is usually kept as the last line of treatment, but a number of physical 
methods have been taught to try to avoid this. In early editions, packing the uterus was 
suggested (1917-1935). This technique returned in the 2000 edition along with balloon 
tamponade and arterial embolisation as alternatives to arterial ligation. In 2011 uterine 
compression sutures were also recommended as a further alternative to hysterectomy. 
 
4. Discussion 
 
The ‘Ten Teachers’ collection provides an intriguing insight into the history of medical 
care in pregnancy through the last 100 years. Although only a snapshot of the teaching 
from a single textbook, it has provided us with the opinions of some of the most respected 
obstetricians of their day. It is therefore likely to be representative of medical student 
teaching generally at that time, especially in the first half of the century when ‘Ten 
Teachers’ was one of very few textbooks available. 
 
An examination of a century of practice provides us with three lessons. First, with 
scientific evidence absent for much of the century, the management practices have tended 
to ebb and flow according to the experts’ opinion and cultural acceptability. This is most 
clearly seen with the use of CCT for routine delivery of the placenta. However, the 
recommendations regarding the timing of cord clamping are also of interest. Throughout 
the century, right up until the latest edition, teachers have taught that the cord should be 
clamped only after the baby stopped crying and the cord stopped pulsating (although the 
option of early cord clamping was introduced in the 1960s as part of the active 
management). This teaching persisted up to the most recent edition when the teaching 
changed and students were taught to clamp the cord early. Oddly, the authors reverted to 
their recommendation of early cord clamping in the 2011 edition, it comes just at a time 
when there is a widespread change back to delayed cord clamping again, led by national 
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and international evidence-based guidelines (WHO, FIGO and the RCOG), demonstrating 
the well-recognised disconnect between ‘evidence-based’ and ‘eminence-based’ medicine. 
 
Second, the change in teaching shows clearly a lowering of the threshold for invasive 
therapies. As safe anaesthetics and antibiotics became available, so invasive therapies 
could be introduced at a much earlier stage for life saving. Hysterectomy for controlling 
severe haemorrhage was not mentioned in the first half of the century, presumably because 
the mortality from the surgery was so high that it was not worth attempting in a woman 
who is already severely shocked from haemorrhage. In the 1966 edition, however, it was 
introduced as a possible life-saving operation. This was only made possible with the 
introduction of blood transfusions, a technique that allowed women to be resuscitated 
before this high-risk surgery. Finally, several recent ‘innovations’ are found to simply be 
rediscoveries of old technologies that have been used successfully in the past but went out 
of fashion. This is seen with ‘delayed’ cord clamping as outlined above and uterine 
packing (although the tamponade is usually done now by an intrauterine balloon).  
 
This review highlighted two important points. The first is that, throughout the century 
uterotonics were always used to start with in prophylaxis or in treatment. The other 
important point is the increasing importance of BMC, seen by it moving from third to first 
option in the management pathway. The following chapter will evaluate the effectiveness 
of uterotonics in treatment of PPH by examining histograms from large clinical trials. 
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Figure 1. Routine third stage management (im= intramuscular; imm= intramyometrial; iv= intravenous) 
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Figure 2. The treatment of atonic PPH (E= Ergometrine; Ox= Oxytocin; E/OX= Syntometrine; PG= prostaglandin; im = intramuscular; 
iv= intravenous; imm= intramyometrial) 
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Chapter 3 
Blood loss histogram 
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The use of histograms to assess the efficacy of uterotonic treatment for 
postpartum haemorrhage: a feasibility study. 
 
1. Background  
 
PPH is a major killer of women worldwide, but its treatment has largely been 
developed empirically. There are, understandably, few randomised trials to assess 
the efficacy of treatments. Experts have often, therefore, had to rely on expert 
opinion and cohort studies to assess the efficacy of various therapies. 
 
Given that an atonic uterus is thought to be the most common cause of PPH, the 
standard management of PPH starts with the administration of a dose of uterotonic, 
even if the mother has received a prophylactic dose of the same or other uterotonic. 
There is little evidence behind this treatment strategy. However, the finding that a 
single dose of a uterotonic markedly reduces both the mean blood loss and rates of 
PPH (Liabsuetrakul et al., 2007; Tuncalp et al., 2012; Westhoff et al., 2013) justifies 
the use of uterotonics as the first-line treatment option. Furthermore, it is reasonable 
to use oxytocin as first-line treatment for PPH as it has fewer side effects than other 
uterotonics (McDonald et al., 2004). Recent research has shown that a single dose of 
misoprostol 800 mcg administered sublingually can be used for atonic PPH in 
women who have received oxytocin prophylaxis, as well as those who have received 
no oxytocin prophylaxis (Blum et al., 2010; Winikoff et al., 2010). It is not known, 
however, whether oxytocin treatment has benefits over placebo alone due to the 
ethical imperative to provide treatment for all women. Furthermore, recent evidence 
from double-blind RCTs suggests that concurrent treatment with two drugs (i.e. 
misoprostol in addition to oxytocin, or an oxytocin infusion in addition to an 
oxytocin bolus) has little or no benefit (Widmer et al., 2010; Sheehan et al., 2011). A 
question remains therefore over the absolute efficacy of uterotonic therapies. 
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The technique of evaluating the effect of an intervention by measuring a size of a 
post-intervention response in continuously collected data is widely used in 
laboratory experiments, but rarely in epidemiology. With accurate measurement of 
blood loss however, the same principles can be applied to large blood loss datasets. 
In this situation, the response to uterotonic treatment is seen on blood loss 
histograms as a ‘post-treatment peak’, which represents the number of mothers who 
responded to the treatment. This was seen in a recent secondary analysis of 2 large 
RCTs, (Blum et al., 2010; Winikoff et al., 2010) where Weeks and others measured 
the size of the post-treatment peaks to compare the effect of misoprostol and placebo 
on women who had received oxytocin prophylaxis or none (Weeks et al., 2014). 
This showed that although both misoprostol and oxytocin were effective therapies, a 
second dose of uterotonics seems to be less effective in stopping the bleeding if the 
women had already received oxytocin prophylaxis. It is not known however whether 
this data can be replicated in other data sets, or whether the same attenuation of 
efficacy is seen following misoprostol or ergometrine prophylaxis. 
 
We therefore explored the data sets from large randomised studies in which 
participants have been managed according to an explicit protocol for the prophylaxis 
and treatment of PPH, and who have had their postpartum blood loss measured.  
 
The objectives of this research were therefore: (1) to explore whether post 
treatment peaks are routinely seen in postpartum blood loss histograms and whether 
the peaks are only seen in treated women. (2) To evaluate the efficacy of different 
uterotonic drugs in the treatment of PPH by measuring the size of the post-treatment 
peak on the blood loss histogram. 
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2. Methods 
 
This study sought to examine the databases of all clinical trials of postpartum 
haemorrhage prophylaxis of over 1000 women which included individual patient 
data on measured blood loss, type of prophylaxis used and type of treatment used. 
In order to identify suitable studies, we searched the Cochrane library database 
including Cochrane Central of Controlled Trials (CENTRAL), the Embase, the Ovid 
version of Medline, the Web of Knowledge and Scopus for relevant RCTs, using 
different keywords and medical subject headings (MeSH) without language 
restrictions. Examples of used MeSH and keywords are ‘postpartum haemorrhage’, 
any intervention used for PPH prevention such as ‘oxytocin’, ‘ergometrine’, 
‘misoprostol’, ‘carbetocin’, ‘oxytocin analogues’, ‘prostaglandin’. Wildcards were 
used to improve the sensitivity of the search.  
 
Titles and abstracts of 4170 papers were identified initially; removal of duplicates 
resulted in 1975 articles. Several types of studies were assessed as not eligible for 
inclusion into the study, such as research on cost effectiveness or hemodynamic 
effect of drugs or the assessment of drug side effects within population. Conference 
abstracts, non-randomised, observational and retrospective studies were also not 
included. These further exclusions left 125 papers for review and nineteen fulfilled 
the study inclusion criteria described above. These studies’ principal investigators 
were contacted by email to request their original data for secondary reanalysis. The 
protocol of the study was emailed to those who initially agreed to participate, and 
the datasets from 4 studies were obtained for analysis (Figure 1). The characteristics 
of these studies are summarised in Tables 1 and 2. The dataset for each randomised 
trial was divided into groups according to the type of prophylaxis used. The reported 
final blood loss for each woman was categorised into 100 mls increments from 0-
2000 mls, according to the definition of PPH in the included studies. The percentage 
of women in every increment was obtained by dividing the number of women in 
each increment by the total number of women within the study arm from which 
women extracted. This process was repeated for each group (graphically displayed 
in a histogram). 
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In order to assess whether the peaks seen in the histogram had occurred as a result of 
the treatment administered, a second graph was produced containing only the data 
for those women who received treatment with a uterotonic. This allowed an 
assessment of whether any fluctuation in the histogram was due to uterotonic 
treatment. Women with missing data on total blood volume were excluded.  
 
All studies received ethical approval prior to recruitment to the individual 
randomised trials and the data upon which this analysis was based had already been 
published. No further ethical approval was therefore sought for this secondary 
analysis of data. 
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Figure 1. Flow diagram of included studies  
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3. Results  
 
All of the included studies compared prophylactic misoprostol (either alone or in 
addition to other uterotonic) with another uterotonic or placebo in women having a 
vaginal birth. Two of the included studies were conducted in primary healthcare 
centres in India and compared 600 mcg of oral misoprostol either with ergometrine 
(Chandhiok et al., 2006) or with placebo (Derman et al., 2006), in low risk women. 
The two other trials were placebo-controlled, double-blind trials which examined the 
effect of the additional administration of 400 mcg of sublingual misoprostol to a 
routine prophylactic uterotonic. One was conducted in Nigeria (Fawole et al., 2011) 
and the other was multi-country (Hofmeyr et al., 2011).  
 
1. Chandhiok, 2006 
 
Chandhiok and colleagues (2006) investigated whether oral misoprostol 
administered by paramedical workers from rural primary health centres in India was 
effective at preventing PPH. The researchers used prophylaxis with 600 mcg 
misoprostol or ergometrine in low risk women undergoing vaginal delivery. The 
blood loss was collected and measured for 1 hour after delivery (or 2 hours for those 
bleeding was persisting). In this study, there was a low incidence of PPH (<1%) in 
both groups, but a significant reduction was noticed in median blood loss after 
delivery (100 mls vs. 200 mls; p <  0.001) in the misoprostol arm (Figure 2). In the 
misoprostol arm 2 small peaks were seen consisting of 4 women who were treated 
with uterotonic. The first peak was at a total blood loss 600-900 mls and the other 
was at 1200-1300 mls (Figure 3). 
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Figure 2. Histogram showing the main study results in the Chandhiok trial 
(2006). The red line represents the blood loss in all participants in the 
methergine group. Whilst the blue line shows the blood loss distribution for all 
women included in the misoprostol arm. The study definition of PPH was > 500 
mls; increments were therefore defined so that “500 mls” was included with the 
400-500 range
0%
10%
20%
30%
40%
50%
60%
P
e
rc
e
n
ta
g
e
 o
f 
w
o
m
e
n
Blood loss in mls
Misoprostol group (All)
Methergine group (All)
112 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Histogram showing blood loss distributions of women in the 
Chandhiok trial (2006) who were randomised to receive misoprostol. The blue 
line shows the distribution for all women who received misoprostol prophylaxis, 
whilst the dotted line represents the blood loss in the subgroup of women who 
received treatment 
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Figure 4. Histogram showing blood loss distributions of women in the 
Chandhiok trial (2006) who were randomised to receive methergine. The blue 
line shows the distribution for all women in the methergine arm, whilst the 
dotted line represents the blood loss in the subgroup of women who received 
treatment 
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In the methergine group, 4 women were diagnosed with PPH and of these, only 2 
women received treatment. Two others, with a total blood loss between 600 and 800 
mls, did not receive a uterotonic but stopped bleeding spontaneously (Figure 4). The 
treatment peaks of similar size were noted in misoprostol and methergine groups.  
 
In this study, very few women had a PPH, and all settled quickly with maximum 
blood loss of 1200-1300 mls. No women with a blood loss of < 500 mls received 
treatment and almost all those diagnosed with PPH had treatment. 
 
2. Derman, 2006 
 
The second study was a RCT conducted by Derman and co-workers (2006). This 
was a placebo-controlled trial of 600 mcg oral misoprostol for the prevention of PPH 
conducted in rural India. Oral misoprostol was associated with a significant 
reduction in the rate of PPH ≥ 500 mls (12.0% to 6.4%, p < 0.0001) and severe PPH 
≥ 1000 mls (1.2% to 0.2%, p < 0.0001). Misoprostol was also associated with a 
decrease in mean postpartum blood loss (262.3 mls to 214.3 mls, p<0.0001). This is 
shown graphically in the histogram in Figure 5. 
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Figure 5. Histogram showing the main study results in the Derman trial (2006). 
The red line represents the blood loss in all participants in the placebo group, 
whilst the blue line shows the blood loss distribution for all women included in 
the misoprostol arm. The study definition of PPH was 500 mls or more; 
increments were therefore defined so that ‘500 mls’ was included with the 500-
599 mls range 
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Despite the frequency of PPH in both study groups (6.4% in the misoprostol group 
and 12.0% in the placebo group), very few women with PPH received treatment (2 
in misoprostol group and 6 in the placebo arm). In addition, some women with blood 
loss < 500 mls received treatment (Figures 6 and 7). In the misoprostol arm, both 
treated women had final blood losses of under 500 mls, whilst all of those with a 
PPH of over 500 mls stopped bleeding spontaneously without receiving further 
uterotonic therapy. In the placebo arm, one woman received treatment despite a final 
blood loss of only 200 mls. The remaining 5 treated women all had blood losses of 
over 500 mls. However, of 97 women with PPH in the placebo arm, only 5 women 
(5%) received treatment - the remainder stopped spontaneously without the need for 
oxytocic therapy. 
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Figure 6. Histogram showing blood loss distributions of women in the Derman 
trial (2006) who were randomised to receive misoprostol. The blue line shows 
the distribution for all women who received misoprostol prophylaxis, whilst the 
dotted line represents the blood loss in the subgroup of women who received 
treatment 
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Figure 7. Histogram showing blood loss distributions of women in the Derman 
trial (2006) who were randomised to receive placebo. The blue line shows the 
distribution for all women in the placebo arm, whilst the dotted line represents 
the blood loss in the subgroup of women who received treatment 
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3. Hofmeyr and Fawole 
 
The two final studies compared the use of misoprostol and placebo in addition to 
routine uterotonic prophylaxis (Fawole et al., 2011; Hofmeyr et al., 2011). These 
two studies were double-blind, placebo-controlled multicentre randomised trials 
undertaken in hospitals to investigate the administration of 400 mcg sublingual 
misoprostol to augment routine AMTSL to prevent PPH. In both studies the 
measurement of blood loss was for one hour after delivery. Neither trial found any 
significant difference in the primary outcome of blood loss of 500 mls or more 
within 1 hour of randomisation: misoprostol 40 (6.1%) versus placebo 42 (6.4%) 
(Fawole et al., 2011) and misoprostol 22 (4.0%) versus placebo 35 (6.3%) (Hofmeyr 
et al., 2011). This can be also seen graphically in the histograms in Figures 8 and 11. 
 
In both studies, the majority of women who received treatment had blood losses of 
under 500 mls (Figures 9, 10, 12 and 13). As with the previous studies, small 
secondary peaks were seen in all study arms, despite many women within the 
secondary peaks not having received uterotonic therapy. 
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Figure 8. Histogram showing the main study results in the Fawole trial (2011). 
The red line represents the blood loss in all participants in the placebo arm, 
whilst the blue line shows the blood loss distribution for all women in the 
misoprostol arm. The study definition of PPH was 500 mls or more; increments 
were therefore defined so that ‘500 mls’ was included with the 500-599 mls 
range 
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Figure 9. Histogram showing blood loss distributions in women in the Fawole 
trial (2011) who were randomised to receive misoprostol. The blue line shows 
the distribution for all women in the misoprostol arm, whilst the dotted line 
represents the blood loss in the subgroup of women who received treatment 
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Figure 10. Histogram showing blood loss distributions of women in the Fawole 
trial (2011) who were randomised to receive placebo. The blue line shows the 
distribution for all women in the placebo arm, whilst the dotted line represents 
the blood loss in the subgroup of women who received treatment 
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Figure 11. Histogram showing the main study results of the Hofmeyr trial 
(2011). The red line represents the blood loss in all participants in the placebo 
group, whilst the blue line shows the blood loss distribution for all women 
included in the misoprostol arm. The study definition of PPH was 500 mls or 
more; increments were therefore defined so that ‘500 mls’ was included with 
the 500-599 mls range 
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Figure 12. Histogram showing blood loss distributions in women in the 
Hofmeyr trial (2011) for those randomised to receive placebo. The blue line 
shows the distribution for all women in the placebo arm, whilst the dotted line 
represents the blood loss in the subgroup of women who received treatment 
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Figure 13. Histogram showing blood loss distributions in women in the 
Hofmeyr trial (2011) for those women randomised to receive misoprostol. The 
blue line shows the distribution for all women in the misoprostol arm, whilst the 
dotted line represents the blood loss in the subgroup of women who received 
treatment 
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4. Discussion 
 
This exploratory study examined the distribution of blood loss for women during the 
third stage of labour using histograms. All of the included studies compared the 
prophylactic effect of oral or sublingual misoprostol (either alone or in addition to 
routine uterotonic) with placebo or another uterotonic in preventing PPH during 
vaginal birth.  
 
The only previous description of this methodology is a study examining the data 
from 2 large randomised trials conducted by Gynuity Health Projects in which 
40,403 women were recruited and had intrapartum blood loss measured. Those with 
blood loss over 700 mls were randomised to receive 800 mcg sublingual misoprostol 
or 40 IU intravenous oxytocin. In a secondary analysis similar to this one, no peak 
was seen for non-treated cases, but clear peaks were measurable for those who 
received either oxytocin or misoprostol (Weeks et al., 2014). The size of the 
treatment peak was attenuated by the use of oxytocin prophylaxis. The data analysed 
here is from smaller studies which were examining the effect of prophylaxis on 
blood loss. The time at which treatment was initiated was left to the clinical team 
and the histograms thus represent ‘real life’ care. Whilst it cannot be stated that the 
uterotonic treatment was given immediately before bleeding stopped, the final blood 
loss represents the maximum blood loss at which it could have been given. The 
treatment graphs are therefore conservative examples, representing the highest blood 
loss at which uterotonic treatment could have been used. This is in contrast to the 
Gynuity PPH management studies. In those, there were rigorous diagnostic and 
treatment protocols which were necessary because they were specifically examining 
PPH treatment, and so the accuracy of the diagnosis, randomisation and initiation of 
treatment were critical.  
 
The peak that appeared in the graphs represents the total blood loss a woman had 
lost. An important finding from this study is that presence of a peak was not specific 
for treated cases. A secondary peak was noted in many of the histograms and 
contains many women who did not receive uterotonic treatment. In the Chandhiok 
study for example the group who received ergometrine for prophylaxis but did not 
receive any treatment still had a small secondary peak at a blood loss of around 600-
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800 mls (Figure 4). This could reflect the effect of other therapies rather than 
uterotonics in treating PPH such as BMC or/and uterine massage. The presence of 
this peak should caution against the over-interpretation of histogram data and 
ascribing the presence of treatment peaks to uterotonics alone. 
 
Although postpartum blood loss was objectively measured in all of the included 
studies, the use of oxytocic therapy was not consistent in the use of therapy only at 
the traditional blood loss cut off of 500 mls. In the studies of Fawole (2011) and 
Hofmeyr (2011) the vast majority of uterotonic therapy was given to women with a 
final blood loss of under 500 mls. This reflects reality, where the decision to initiate 
therapy is based not only on the volume of blood lost, but also on the speed of the 
blood flow, the underlining cause of the bleeding and the woman’s clinical 
condition. Thus a severely anaemic woman with a prolonged labour who has a gush 
of blood postnatally would rightly be given treatment immediately, even though the 
final blood loss might amount to only 200 mls in total. Although this reflects usual 
practice, it limits the use of the histogram analysis to studies with a very clear and 
rigorously enforced protocol for the uterotonics use. 
 
Of more concern is the number of women who bled over 500 mls but did not receive 
uterotonic therapy. This again reflects clinical practice where underestimation of 
blood loss is common, especially if the woman is otherwise healthy, and there is a 
slow trickle of blood thought to be coming from vaginal lacerations. This surprise 
finding provides a fascinating insight into clinical practice in PPH treatment. 
 
The implications of these findings are that: a) in prophylaxis trials, the rate of 
uterotonic use appears to be a poor surrogate for PPH; b) the recommendations to 
treat PPH at 500 mls may not be commonly used in clinical practice, and needs to be 
reviewed; and c) the size of the histogram ‘treatment peaks’ are not a good indicator 
of the efficiency of uterotonics, unless the clinicians follow a very strict treatment 
protocol (which may not reflect clinical practice). 
 
Furthermore, it appears that vaginal blood loss in women having a PPH commonly 
stops spontaneously even without uterotonic therapy. This presents a dilemma for 
clinicians. Whilst reassuring, it is impossible to predict who will spontaneously stop 
bleeding and who will continue bleeding to life-threatening levels. In addition, PPH 
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causes significant problems through postpartum anaemia and the use of uterotonics 
is likely to hasten the cessation of bleeding. Understandably therefore, clinicians 
tend to use uterotonics frequently and at very early stages to prevent progression. 
 
In summary, the findings from this study do not support the routine use of histogram 
analysis to assess the efficiency of uterotonic therapy. The analysis of histograms 
should be limited to PPH treatment studies in which strict protocols are used for the 
timing and nature of PPH treatment. Even then, the finding of a secondary peak in 
untreated women in these studies should warn against ascribing all the effect to 
uterotonic therapy; other physical therapies may also be used concurrently and may 
also have an effect. 
 
In addition, the analysis of these histograms provide further insights into clinical 
practice, with clinicians frequently using uterotonic therapies even when the volume 
of the blood loss is low. This demonstrates how uterotonic use in practice is often 
not linked with the standard 500 mls definition of PPH - this is important both for 
researchers and for those producing clinical guidelines. 
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Table1.  Methodological details of included studies
Study 
Participants risk of 
PPH 
Study type Setting Prophylaxis received PPH definition and  measurement 
Chandhiok, 2006 1200 – low risk 
Cluster 
randomised 
30 peripheral 
health centres 
from 5 states in 
India 
Intervention: 600 mcg of 
oral misoprostol (600)  
Control: (600) an 
intramuscular injection of 
0.2 mg of methergine 
(88.5%) or oral tablet of 
0.125 mg methergine 
(9.7%) 
PPH was defined as > 500 mls 
bleeding. A calibrated blood 
collection drape (BRASS-V) was 
used to measure blood loss for 1 
hour after delivery (and for 2 
hours if bleeding persisted)  
Derman, 2006 1620- low risk RCT 
Four primary 
health centres 
areas in rural 
India 
Intervention: A single 
oral dose of 600 mcg of 
misoprostol (812) 
 
Control: Placebo (808) 
PPH was defined as ≥ 500 mls 
bleeding and  was assessed using a 
polyurethane blood collection 
drape  for 1hour after delivery 
(and for 2 hours if bleeding 
persisted) 
Fawole,  2011 1345- not specified RCT 
6 hospitals in 
Nigeria 
Intervention: A 
sublingual dose of 400 
mcg of misoprostol (672) 
Control: A placebo (673).  
Both arms also received 
standard active 
management of the third 
stage of labour (oxytocin 
or ergometrine)  
PPH was defined as ≥ 500 mls 
bleeding and was assessed using a 
low-profile plastic bedpan for a 
period of 1 hour  
Hofmeyr, 2011 1103- not specified RCT 
4 hospitals in 
South Africa, 
Uganda, and 
Nigeria 
Intervention: A 
sublingual dose of 400 
mcg of misoprostol (547)  
Control:  A placebo 
(556). Both arms also 
received standard active 
management of the third 
stage of labour (oxytocin 
or ergometrine) 
PPH was defined as ≥ 500 mls 
bleeding and was assessed using a 
low-profile plastic bedpan for a 
period of 1 hour or until bleeding 
stopped 
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Table 2. Study outcomes from included studies 
 
 
*Data on total blood loss were not available for one woman.
Study 
Number of women with 
PPH 
Uterotonic given Additional interventions used 
 
Chandhiok, 2006 
Total: 9 
Intervention: 4 (0.7%) 
Control: 5 (0.8%) 
Total: 6 
Intervention: 4 
Control: 2 
Type: Methergine and 
oxytocin injection 
 Manual removal of placenta (30 women in the methergine 
group) 
 One woman in the intervention group lost > 1000 mls of blood. 
Uterine exploration was carried out and a blood transfusion 
administered 
Derman, 2006 
Total: 149 
Intervention: 52 (6.4%) 
Control: 97 (12.0%) 
Total: 10* 
Intervention: 3 
Control: 6 
Type: Methergine, oxytocin  
and carboprost injection 
 One in the intervention group and 8 in the placebo arm had 
surgical interventions (repair of perineal, cervical, and high 
vaginal lacerations, manual removal of placenta) 
 One women in the placebo group received bimanual uterine 
compression alongside medical treatment 
Fawole,  2011 
Total: 82 
Intervention: 40 (6.08%) 
Control: 42 (6.36%) 
Total: 259 
Intervention: 162 
Control: 97 
Type: Methergine and 
oxytocin injection 
 Manual removal of placenta (23 in misoprostol group, 27 in 
placebo group) 
Hofmeyr, 2011 
Total: 57 
Intervention: 22 
Control: 35 
Total: 58 
Intervention: 31 
Control: 27 
Type: : Methergine oxytocin  
and syntometrine injection 
 Manual removal of placenta (32 in misoprostol group, 33 in 
placebo group) 
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Chapter 4 
Clinical outcomes in studies evaluating intervention to 
prevent PPH 
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Choice of outcomes in randomised trials and systematic reviews evaluating 
interventions for postpartum haemorrhage prevention: a systematic review 
 
1. Background  
 
PPH remains a concern as it is considered to be a major cause of maternal mortality in both 
low- and high-income countries. Prevention of PPH is therefore of great importance in order 
to improve women's healthcare and to save lives. It is well-recognised that some research 
designs are more powerful than others in their ability to answer research questions about the 
effectiveness of interventions. This concept has given rise to the notion of hierarchy of 
evidence (Akobeng, 2005). The ranking has an evolutionary order, moving from simple 
observational methods at the bottom, through to increasingly rigorous methodologies at the 
top. Systematic reviews of RCTs, with or without meta-analysis, usually appear at the top of 
the hierarchy as they can provide the most powerful forms of evidence. RCTs are the most 
valid scientific method for evaluating interventions. This is because the processes used during 
the conduct of a RCT minimise the risk of confounding factors influencing the results. The 
results of RCTs are used to inform decisions (Guyatt and Rennie, 2002; Akobeng, 2005). In 
order for the results of RCTs to be useful, they should measure outcomes that are relevant to 
both patients and the healthcare professionals involved in making clinical decisions about an 
individual patient, group, or population. To support the implementation of effective methods 
of intervention in clinical practice, it is important to carry out a clinical appraisal of 
systematic reviews including their most important outcomes, whether or not these endpoints 
were measured in a consistent way, and whether the studies were adequately powered to 
detect the clinical benefits of the interventions being studied. Evidence-based comparisons of 
interventions can therefore be challenging because of the diversity of outcomes in RCTs.  
 
Outcomes in clinical trials 
 
Interventions used in healthcare may have various beneficial and harmful effects. These are 
known, in clinical practice and research, as outcomes. It is therefore critically important that 
the right outcomes are evaluated in clinical research in general, and in RCTs and systematic 
reviews in particular.  
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The primary outcome is an integral component of the research question. It should be 
explicitly stated and described, because it reflects the objective of the trial, and determines 
the sample size required (Moher et al., 2001). There is usually only one primary outcome, 
which should relate to the research question. In some situations, more than one primary 
outcome can be measured, in order to assess treatments more comprehensively. This can be 
useful if it is unclear which single primary outcome would best answer the research question. 
  
Most trials also measure secondary outcomes, in order to evaluate other beneficial or harmful 
effects of treatments. These must be clearly stated and described in the study protocol and 
report (International Conference on Harmonisation, 1999). They should be selected 
judiciously, because as the number of secondary outcomes increase, the more likely it 
becomes that one will show a statistically significant result due to chance alone (Pocock, 
1997). 
 
There are tens of thousands of research studies which might provide the evidence needed to 
make well-informed decisions about healthcare. The task of working through all this material 
is overwhelming. Studies that describe their findings in different ways, make it difficult, if 
not impossible, to draw out the relevant information. Systematic reviews aim to identify, 
evaluate and summarise the findings of all relevant individual studies, thereby making the 
available evidence more accessible to decision makers. When appropriate, combining the 
results of similar studies gives a more reliable and precise estimate of an intervention’s 
effectiveness than one study alone (Sacks et al., 1987). Systematic reviews adhere to a strict 
scientific design based on explicit, pre-specified and reproducible methods. Because of this, 
when performed well, they provide reliable estimates about the effects of interventions so that 
their conclusions are defensible. They clearly depict what is known about a particular 
intervention, but also demonstrate where knowledge is lacking (Petticrew, 2003). This can 
then be used to guide future research (Brown et al., 2006).  
 
Recently, there has been much concern regarding the selection of outcome measures in 
clinical trials as evidence generated from clinical trials guides the changes in clinical practice 
(COMET, 2012). The Cochrane Handbook for Systematic Reviews of Interventions (Higgins 
and Green, 2011), states that a review question should specify not only the interventions and 
participants of interest but also the types of outcomes of interest. The Handbook also 
discusses some of the issues associated with drawing conclusions about outcomes found in a 
systematic review. The Handbook states that in addition to considering the strength of 
130 
 
evidence underlying any conclusions that are drawn, “reviewers should consider all of the 
potentially important outcomes of an intervention when drawing conclusions, including ones 
for which there may be no reliable data from the included trials. They should also be cautious 
about any assumptions they make about the relative value of the benefits, harms and costs of 
an intervention. Including all important outcomes in a review will highlight gaps in the 
primary research and encourage researchers to address these gaps in further studies”. 
 
It can be difficult to know which outcomes should be measured in RCTs. Some groups 
advocate the development of core outcome sets, a minimum set of outcomes that should be 
measured, and reported, in all clinical trials involving a given condition (COMET, 2012). 
There were however no robust recommendations about which outcomes to measure in RCTs 
of PPH, which is a condition of considerable global importance.  
 
Our aims were to assess whether the absence of a core set outcomes for RCTs of PPH 
prevention meant that certain outcome measures were measured less frequently than others, 
and whether there was non-uniformity between studies in terms of outcomes selected.  
 
We have also examined the consistency of primary outcome reporting within systematic 
reviews of PPH prevention. The reason for choosing only primary outcomes from systematic 
reviews is that they reflect the key research question (objective) of the review, whilst the 
secondary outcomes are, as a rule, hypothesis generating.   
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2. Objectives 
 
A. To assess which outcomes had been measured in clinical trials of PPH prevention 
and: 
1. Systematically collect and organise these outcomes (primary and secondary). 
2. Examine the clarity of stating primary and secondary outcomes within the trials. 
3. Rank the outcomes in order of those most commonly used in RCTs (primary and   
secondary). 
4. Determine whether there was consistent selection of primary outcomes. 
5. Assess frequency of reporting of sample size calculations (SSC) and find out the 
percentage of primary outcomes that underpin SSC. 
 
B. To assess which outcomes had been measured in systematic reviews of PPH 
prevention and: 
1. To systematically identify and analyse the primary outcomes reported in systematic 
reviews of PPH prevention. 
2. To rank these outcomes in order based on the frequency of reporting. 
 
C. Compare the choice of primary outcomes between systematic reviews and RCTs 
evaluating intervention for PPH prevention. 
 
Study design: a systematic review of RCTs and systematic reviews on the outcomes used in 
routine third stage management for prevention of PPH. 
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3. Methods 
 
Criteria for considering reviews for inclusion 
 
1. Study type and participants: in this study, we included all published RCTs and 
systematic reviews (all Cochrane and non-Cochrane systematic reviews) of interventions 
used in the routine management of the third stage of labour with the primary aim to prevent 
PPH, from January 1997 to December 2012.  
 
In the mid-nineties, concerns about the quality of reporting RCTs resulted in the development 
of Consolidated Standards of Reporting Trial (CONSORT) (Begg et al., 1996). The statement 
was found to be associated with an improvement in the reporting of RCTs (Plint et al., 2006), 
therefore, only studies published after the first CONSORT statement were included.  
 
2. Interventions: any interventions given with the aim of preventing PPH. 
 
3. Outcomes: the percentage of different outcomes that have been used in the selected 
articles of the routine management of the third stage of labour with the aim to prevent 
PPH. 
 
Search strategy 
 
In order to optimise the probability of identifying all relevant studies, a variety of medical 
literature databases were searched. The Cochrane library database was searched (including 
Cochrane Central of Controlled Trials [CENTRAL]), as were Embase, the Ovid version of 
Medline, the Web of Knowledge, and Scopus, for relevant RCTs and systematic reviews 
using different keywords and MeSH. In order to achieve the broadest range of results 
synonyms and alternatives were also used in the search terms. Examples of the MeSH and 
keywords used are postpartum haemorrhage, any intervention used for PPH prevention such a 
oxytocin, ergometrine, misoprostol, carbetocin, oxytocin analogues, prostaglandin, uterine 
massage, cord clamping, fundal pressure, controlled cord traction, cord drainage, 
intraumbilical cord injection and others. Wildcards were used to improve the sensitivity of 
the search. Wildcard characters, denoted by a question mark, account for spelling variations. 
For example ‘postpartum h?emorrhage’ would identify the terms ‘haemorrhage’ and 
‘hemorrhage’. Boolean operators were used in the first step, using the ‘OR’ operator to 
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broaden the search, and then combining them using the ‘AND’ operator in the final step to 
narrow and focus the search. The search strategy is included in Appendix C.1. 
 
Language restrictions 
We did not apply any language restrictions. 
 
Ethical approval 
This study did not require ethical approval as the data used in this systematic review have 
been published previously and are in the public domain. 
 
The search result 
 
Search results from each of the databases were combined into the reference manager software 
program EndNote X5. Once all of the references from each of the databases had been 
uploaded into the reference manager, a search for duplicates was conducted. A duplicate 
search is necessary as many of the different databases reference the same articles when 
searched using similar criteria. Once a database that consisted of unique references was 
constructed, examination of the abstracts began for identification of eligible references for the 
review. Abstracts were identified as eligible according to the parameters described above. 
Those abstracts that appeared eligible for the review were marked for collection of a hard 
copy, and the reference hard copies underwent a final more thorough eligibility analysis and, 
if eligible, underwent data extraction. 
 
Not all references marked as relevant at the abstract stage were accessible directly as a hard 
copy via the University library. If not, we obtained interlibrary loans via the University of 
Liverpool library. As we did not apply a language restriction, the search yielded 19 articles 
which were in languages other than English. All non-English articles were sent for translation 
and translated using a translation sheet (Appendix C.2). 
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Studies excluded from the review 
 
Several types of studies were assessed as not eligible for inclusion into the review. There are 
many areas of PPH research that do not explicitly evaluate prevention of PPH. These 
alternative areas of research include cost effectiveness, or the hemodynamic effect of drugs, 
or the assessment of drug side effects within a population. Conference abstracts do not 
always reach full publication, and those that are published have been shown to be 
‘systematically different’ from those that are never published in full (Lethaby et al., 2000). 
Therefore, conference reports and abstracts were excluded because of difficulties in 
evaluating incomplete information. Nonrandomised, observational and retrospective studies 
were also not included, and neither were feasibility studies. 
 
We excluded non-systematic reviews, protocols of systematic reviews and systematic reviews 
that had been withdrawn. When more than one version of a Cochrane review was found, only 
the most recent one was included. 
 
Selection of studies for inclusion 
 
Having excluded a number of studies for the reasons outlined above, we then assessed the 
potential studies left for inclusion. The study was included if it was: 1) a full report; 2) a RCT 
or systematic review; 3) published after the first CONSORT statement; and 4) evaluating the 
efficacy of any intervention for the prevention of PPH. We also included studies that aimed to 
prevent uterine atony as a main cause of PPH. Uncertainty regarding any decision of 
inclusion was resolved with discussion with the supervisor (ZA). The full-text articles of all 
the reports meeting the inclusion criteria were analysed.   
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Data extraction and management  
 
Once a reference had undergone the eligibility checks and was considered eligible data were 
extracted using a predefined data extraction form (Appendixes C.3 and C.4). From each RCT, 
the following data were extracted: 
 
1. Reference identity data, including the type of report, name of the author and the year of 
publication.  
 
2. Other study features: information regarding the interventions used; participants and 
number of women included; study location and setting; study objectives; methods of defining 
and measuring PPH and blood loss, and others.   
 
3. All outcomes reported: outcome measure data consisted of the name of each outcome 
measure, whether the primary outcome measure was specified in the abstract or main text, 
and a list of all the stated primary and secondary outcomes. 
 
We designed a special data extraction form to collect the data from the systematic reviews 
(Appendix C.4). For each systematic review, data were extracted on reference identity data 
and a list of primary outcomes reported in each of the included reviews was organised and 
tabulated. Further categorisation of these outcomes was carried out, according to the 
definition used for PPH, maternal outcomes, neonatal outcomes, changes in blood indices and 
others. We considered the primary outcomes as the ones that were explicitly stated within the 
review.  
 
Any disagreements were resolved after discussion with the supervisor. 
 
Statistical methods 
 
All data were entered into a Microsoft access database, double-checked for accuracy, and 
analysed using Microsoft Excel 2010. For each particular outcome we calculated the 
percentage of reporting and ranked them accordingly.  
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Data analysis and presentation 
 
For each RCT the outcome was grouped into one of the two main outcome categories: 
 
A. primary outcomes 
 
The primary outcomes were further divided into subgroups as follows: 
 
1. Outcomes used for SSC and explicitly stated as primary 
 
2. Outcomes used for SSC but not explicitly stated as primary 
 
3. Primary outcomes explicitly stated but no SSC or not used for SSC (in the trials that stated 
SSC with more than one primary outcome) 
 
4. Outcomes neither used for SSC nor stated as primary but the authors stated them as their 
main outcomes 
 
5. Outcome not stated as primary or secondary, or used for SSC, but was the only one in the 
study and stated in the study objective. 
 
B. Secondary outcomes 
 
Any outcomes reported in the trials that did not fit the criteria for the primary outcomes were 
considered as secondary. For the trials that did not differentiate between the primary and 
secondary outcomes and no SSC was done, all the trial outcomes were considered as 
secondary outcomes. 
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Population stratification 
 
We considered the participants’ risk as low if this was stated explicitly in the title or text, or if 
PPH risk factors were listed in the exclusion criteria. The high risk category was assigned if 
the authors stated that they included only women with a high risk of PPH. We also 
considered the participants to be high risk if high risk factors were not considered as 
exclusion criteria. 
 
We also divided the duration of the pregnancy of the included women into different 
categories. Term studies were labelled as such when the gestational age of the participants 
included in the study was ≥ 37 weeks. Gestations below 37 weeks but ≥ 24 weeks were 
considered as preterm. 
 
We looked at the settings where the studies were conducted (e.g. hospital, home). Studies 
carried out at tertiary or university hospitals were categorised under one group, while studies 
conducted in primary care centres or rural clinics were put under a separate category. Home 
deliveries were put also under a separate group. 
 
4. Results  
 
Generation of included studies 
 
Titles and abstracts of 4170 papers were identified initially. After removal of duplicates, and 
exclusion of non-eligible studies, 466 full papers were evaluated. Further analysis reduced 
this to 138 full-text papers whose primary aim was to prevent primary PPH. We were unable 
to obtain 4 RCTs leaving 134 full-text articles for the analysis. These included 121 RCTs, 
nineteen of which were not in English so had to be translated, and 13 systematic reviews. Full 
details are shown in Figure 1. Further information on the included systematic reviews will be 
found in section B of the results. 
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Properties of the included RCTs 
 
The types of interventions assessed are listed in Table 1. The majority (88%) assessed 
pharmacological measures to prevent primary PPH, in which uterotonics accounted for 92% 
(98 out of 106). Cord management methods, including cord clamping, placental cord 
drainage, CCT and UVI, were evaluated in 7% of the trials. Only 2% assessed active versus 
expectant management, and the remaining 2% looked at a range of other interventions 
including uterine massage. 
 
Over half of the trials were conducted in the Middle East and Asia (55%; Table 2). Almost 
one fifth of the studies (17%) were carried out in Africa, and only 2% of the included trials 
were set in more than one country. The vast majority of the included studies (94%) were set 
in hospitals (Table 3). One third of included trials were conducted in high-income countries 
(33%; 40 trials), while more than half (58%) were undertaken in middle-income countries (39 
trials in upper-middle-income and 31 trials in lower middle income). Seven trials (6%) were 
conducted at low-income countries. Four trials were conducted in different countries with 
different economic incomes. The classification of countries’ income was based on the World 
Bank, July 2013. 
 
The proportion of studies carried out at primary healthcare facilities (2%) was matched by the 
proportion of studies set at home (2%). 
 
 Table 1. Type of intervention assessed in the trials  
Type of intervention No of trials Percentage 
Pharmacological measures 
106 (98 uterotonic, 6 tranexamic 
acid, 2 traditional Chinese medicine) 
88% 
Cord management 9 7% 
Active versus expectant 
management 
3 2% 
Uterine manipulation 2 2% 
Others (postpartum oxygen 
inhalation) 
1 1% 
Total trials 121 100% 
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The number of studies published every 4 years increases gradually as shown in Table 4. Most 
noticeable is that the number of published trials nearly doubled from between 2005 and 
between 2008 and 2009-2012, from 22% to 41% respectively. 
 
A SSC was described in 68% (82/121) of the included studies (Table 8). The calculated 
sample size of the included studies peaked at the range 401-500 (12% of trials), (Table 5). 
Only two of the included studies had a sample size of more than 12,000 (12,227 and 18, 530). 
 
Table 6 demonstrates the heterogeneity in the methods used for third stage blood 
measurement and diagnosis of PPH. Nearly one third of the included studies used gravimetric 
methods to measure blood loss (28%). The next popular method used by the trials was direct 
blood measurement using drape (19%). Visual estimation, despite consistently 
underestimating blood loss, was used in 14% of the included studied. A combination of more 
than one method was used by several of the included trials, as showed in Table 6. 
 
The characteristics of the included participants are shown in Table 7. The majority of women 
in the included studies underwent vaginal delivery (73%). Caesarean section was the mode of 
delivery in over one fifth (23%) of included trials. The remaining 4% of the included studies 
recruited a mixed population of women i.e. both vaginal and caesarean births. A considerable 
proportion of the included women had no risk factors for PPH (37%), while in only 9% of the 
studies they were assessed as having a high risk of PPH. Many studies (46%) did not specify 
the risk and 8% included women with or without risk factors. The duration of pregnancy for 
the included mothers was known in 70% of the included studies (30% included term and 
preterm, 40% included term pregnancies only). Nearly one third (30%) of the included trials 
did not specify the duration of pregnancy for the included participants. 
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Figure 1. Flow diagram of papers throughout the systematic review according to 
PRISMA criteria (Liberati et al., 2009) 
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Table 2. Study country  
Country No of trials Percentage 
Middle East/ Asia  66 55% 
Africa 20 17% 
Other European countries  9 7% 
USA 11 9% 
Canada 6 5% 
UK 4 3% 
Different countries  3 2% 
Latin America 1 1% 
Not stated 1 1% 
 
 
Table 3. Study setting  
Setting No of trials Percentage 
Hospital 114 94% 
Primary healthcare centre 3 2% 
Home 2 2% 
Hospital and primary healthcare centre 1 1% 
Not stated 1 1% 
 
 
Table 4. Number of published RCTs every 4 years 
Years No of trials Percentage 
1997-2000 21 17% 
2001-2004 24 20% 
2005-2008 26 22% 
2009-2012 50 41% 
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Table 5. Sample size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Methods used for diagnosis of PPH 
Method used No of trials Percentage 
Gravimetric method 34 28% 
Direct blood measurement 23 19% 
Visual estimation  17 14% 
Combining direct 
measurement and gravimetric 
methods 
13 11% 
Not stated  11 9% 
Combining gravimetric and 
visual estimations 
6 5% 
Clinical diagnosis  5 4% 
Difference in haematocrit 
value 48 hours after delivery  
4 3% 
Colorimetric method  2 2% 
Combining direct measured 
and visually estimated 
methods 
2 2% 
Combining gravimetric and 
haematocrit values 
2 2% 
More than 2 methods 2 2% 
 
 
No of subjects No of trials Percentage 
1-50 2 2% 
51-100 13 11% 
101-150 11 9% 
151-200 13 11% 
201-300 9 7% 
301-400 12 10% 
401-500 15 12% 
501-600 5 4% 
601-700 9 7% 
701-800 2 2% 
801-900 2 2% 
901-1000 5 4% 
1001-1500 9 7% 
1501-2000 9 7% 
2001-3000 3 3% 
>12, 000 2 2% 
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Table 7. Characteristics of participants included in the study 
Mode of delivery of included 
women 
Risk to PPH Duration of pregnancy 
 Vaginal Caesarean Both High Low Both 
Not 
specified 
Term 
Term 
and 
preterm 
Not 
specified 
No of 
trials 
(%) 
88 (73) 28 (23) 5 (4) 11 (9) 
45 
(37) 
10 (8) 55 (46) 48 (40) 37 (30) 36 (30) 
 
 
 
 
Table 8. Sample size calculation in relation to the study primary outcome 
SSC stated No of trials Percentage 
Yes 82 68% 
 
 
 
Table 9. Clarity of stating outcomes within the trials 
Outcome differentiation No of trials Percentage 
Clear differentiation between primary and 
secondary outcomes 
77 64% 
No differentiation  
44 
 
36% 
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A. Outcomes reporting in clinical trials 
 
One hundred and twenty-one RCTs were analysed with 68% (82/121) providing SSC. 
Seventy-seven trials clearly differentiated between primary and secondary outcomes with 
92% (71/77) describing SSC. Out of these 77 trials, 46 used one primary outcome while 31 
trials stated more than one primary outcome. Ten trials mentioned their outcomes as main 
without differentiation. In only 4 trials did we consider the ones mentioned in the objective as 
the key outcomes for the trials. One hundred and fifty-six different outcomes (primary and 
secondary) were reported by 121 RCTs; these outcomes were categorised on the basis of 
most commonly reported ones, primary outcomes (Appendix C.5) and secondary outcomes 
(Appendix C.6). The primary outcomes were not the same across all the included studies, 
with different endpoints used for SSC. Sixty-eight different primary outcomes were reported 
by 121 RCTs; 20 of these outcomes were underpinned by SSC reported by 82 trials.  
 
Postpartum blood loss 
 
The amount of postpartum blood loss and the incidence of PPH were the most commonly 
reported outcomes. Incidence of PPH ≥ 500 mls was the most frequently reported primary 
outcome mentioned in 21% (25/121) of trials. This was used for SSC in all studies except 
one. This outcome was stated as a secondary endpoint in 12% (15/121) of RCTs. Postpartum 
blood loss was measured using different methods as showed above. The time of blood 
collection was either not specified or done at different time intervals (30 minutes, 1 hr, 2 hrs, 
8 hrs, 24hrs, and 48hrs). There was no consensus about the definition of PPH based on the 
amount of blood loss. And this was true for either vaginal or caesarean delivery. The 
incidence of PPH was stated as an outcome in 12 of 28 articles with caesarean deliveries; the 
definition of PPH at caesarean delivery was not stated in 2 of them. Five of the studies, used 
blood loss > 1000 mls to define PPH, while 3 used ≥ 1000 mls, one used > 500 mls and 
strangely one study defined PPH as blood loss ≥ 400 mls. The amount of postpartum blood 
loss was used as an endpoint in many trials; however there were differences in the methods 
and times of blood collection, and different statistical measures (mean, median and 
percentage) were used to statistically measure this crucial outcome measure. 
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Maternal blood indices 
 
Differences in pre- and post-delivery haemoglobin were the most commonly used outcome 
under this category. It was mentioned as a primary outcome in 16 trials (13%), 5 of which 
used it to calculate the study sample size, whereas it was evaluated as a secondary outcome in 
29 studies (24%). However, the time of the second blood sample collection showed huge 
differences as 12, 20, 24, 36, and 48 hours postpartum were all used as cut-off points. This 
also applied to differences in pre- and post-delivery haematocrits-even though specific values 
of haemoglobin concentration were used as a primary or secondary outcome, different values 
at different time intervals were used. 
 
Other interventions used  
 
Under this grouping, additional uterotonics were used as a primary outcome in 22% (27/121) 
of RCTs. The need to treat uterine atony or PPH with uterotonics was recommended as a 
priority outcome measure for PPH by the WHO panel (WHO, 2007a). Two of the trials 
specified the use of uterotonics to treat uterine atony, while one used additional uterotonics to 
control PPH. The rest of the studies just stated the use of additional uterotonics without 
further details. Use of additional uterotonics was used for SSC in 7 studies. This important 
outcome was also used by 43% of trials (52/121) as a secondary outcome.  
 
Many other outcomes under this category were evaluated. These included manual removal of 
placenta (primary in 3% (4/121) and secondary in 18% (22/121) of RCTs) and need for blood 
transfusion (primary in 3% (4/121) and secondary in 40% (48/121) of RCTs). 
 
Duration of the third stage 
 
The outcome related to the duration of the third stage was mentioned as a primary outcome in 
9% of trials (11/121) and as a secondary endpoint in 33% (40/121). However, different 
statistical measures (mean, median, number and percentage) were used to assess this outcome 
measure. Only one of the included studies based its sample size on this outcome. 
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Intervention side effects 
 
The importance of monitoring adverse events has long been recognised as an essential 
component of all therapeutic clinical trials (Anderson and Testa, 1994). Maternal intervention 
side effects, such as nausea, vomiting, shivering, metallic taste abdominal pain, hypertension 
and others were reported by the majority (71%) of the included studies (86/121). It was 
evaluated as primary in 7% (9/121) and as secondary in 64% (77/121) of RCTs. 
 
Maternal morbidity and mortality 
 
Only one study considered maternal mortality as one of its primary outcomes. This 
particularly important outcome was not used for SSC in that study. Maternal death was 
mentioned as a secondary outcome in 7% (8/121) of trials. A composite outcome on maternal 
morbidity was mentioned as a secondary outcome in 2% (2/121) of studies. No single 
component was common to these two composite outcomes.  
 
Placenta-related outcomes 
 
The outcomes under this category were mentioned as secondary outcomes only. These 
included the incidence of retained placenta (10/121), and the mode and timing of placental 
delivery (1/121). 
 
Other maternal outcomes 
 
Other different outcomes interested a number of researchers; for example, length of hospital 
stay was mentioned as a primary outcome mentioned as a main in 2% (2/121) and as a 
secondary outcome in 8% (10/121) of the included trials. Only one study measured women’s 
and staff’s satisfaction with the third stage management and this was used as a secondary 
outcome. 
 
Neonatal outcomes 
 
Few studies were concerned with neonatal outcomes. They were more prominent as a 
secondary outcome measure. Earlier establishment of breastfeeding, and less anaemia in 
infancy were considered as important outcomes by the WHO panel (WHO, 2007a). One 
study (Ceriani Cernadas et al., 2006), had the objective of determining the effect of the timing 
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of cord clamping on neonatal venous haematocrit and clinical outcomes in term newborns 
and maternal PPH. It was the only one to mention newborn venous haematocrit at 6 hours 
after birth as its primary outcome. This outcome was used for SSC, whereas initiation of 
breast feeding was mentioned only as a secondary endpoint by 2 trials. 
 
B. Choice of primary outcomes in systematic reviews 
 
Eighty-nine reviews were retrieved and evaluated, 69 (77%) were excluded for several 
reasons (Figure 2). Twenty reviews met the inclusion criteria. A further 7 reviews were 
excluded as they did not differentiate between primary and secondary outcomes. Thirteen 
reviews were therefore included in the analysis, of which the majority were Cochrane reviews 
(85%), and only 2 were non-Cochrane.  
 
The types of intervention assessed by the systematic reviews are listed in Table 10. More than 
two thirds of the included systematic reviews (69%) assessed pharmacological measures to 
prevent primary PPH, in which uterotonics accounted for 89% (8 out of 9). Cord management 
methods were evaluated in 15 % of systematic reviews. Only 1 systematic review assessed 
active versus expectant management, and one looked at the effect of uterine massage in 
preventing PPH. 
 
Table 10. Type of interventions assessed in the included systematic reviews 
Type of intervention 
Number of SRs 
(Total=13) 
Percentage 
Pharmacological measures 9 69% 
Cord management 2 15% 
Active versus expectant management 1 8% 
Uterine massage 1 8% 
 
 
 
 
 
 
 
 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Figure 2. Flow chart of systematic review included in the review 
 
Reviews on PPH prevention identified 
(n=89) 
Articles screened for eligibility 
(n=89) 
 
Reviews excluded with reasons (n=69) 
 Not SR (n=42) 
 Summary of review (n=2) 
 Not the most recent version 
(n=16) 
 Protocol (n=4) 
 Withdrawn review (n=2) 
 Not full review (abstract) (n=2) 
 Reviews on prevention and 
treatment and not separated 
outcomes on PPH prevention 
(n=1) 
 
 
 
Systematic reviews which fit the inclusion criteria 
(n =20) 
Systematic reviews did not 
differentiate between their primary and 
secondary outcomes (n=7) 
Systematic reviews included in the analysis 
(n=13) 
Cochrane reviews  
(n=11) 
Non-Cochrane reviews  
(n=2) 
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Among 13 Cochrane and non-Cochrane reviews, 24 different primary outcomes were 
reported, and 85% (11/13) pre-specified more than one primary outcome (Table 11). They 
were categorised into maternal and neonatal. The maternal outcomes were further divided 
into five groups: (1) those that were related to postpartum blood loss and incidence of PPH, 
(2) changes in the blood indices, (3) additional interventions used (4) the length of the third 
stage of labour and (5), outcomes related to maternal morbidity and mortality. 
 
 The most common primary outcome reported by 10 reviews was PPH ≥ 1000 mls. This had 
variable definitions in terms of the methods used for blood measurement. Nine studies used 
any clinically or estimated blood loss and one review stated clinically diagnosed blood loss ≥ 
1000 mls as their primary outcome. The mode of delivery of the included participants in these 
10 reviews was vaginal in half of them, and caesarean in the other 5 reviews. Use of 
additional uterotonics and PPH ≥ 500 mls (clinically estimated or measured blood loss) were 
the second most common primary outcomes stated by third of the included systematic 
reviews (5/13). Four out of the 13 reviews (31%) listed maternal mortality as a primary 
outcome. Only two reviews (Begley et al., 2011; Rabe et al., 2012), were concerned with 
neonatal outcomes and different end points were used (Table 11). However, neonatal anaemia 
and initiation of breast feeding, as important outcomes recommended by WHO panel, were 
not among the outcomes considered. 
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Table 11. List of primary outcomes as stated in systematic reviews 
Primary outcome 
 
Number of SRs 
(Total=13) 
Percentage 
1. Maternal outcomes   
 1.a. Postpartum blood loss   
PPH ≥ 1000 mls (clinically estimated or measured blood loss) 9 69% 
PPH ≥ 500 mls (clinically estimated or measured blood loss) 5 38% 
Mean postpartum blood loss 2 15% 
PPH ≥ 1000 mls (clinically estimated blood loss) 1 8% 
PPH ≥ 500 mls (diagnosed clinically) 1 8% 
PPH > 600 mls 1 8% 
Very severe PPH ≥ 2500 mls 1 8% 
Blood loss ≥ 500 mls after enrolment 1 8% 
 1.b. Duration of the third stage  
Third stage longer than 30 minutes  2 15% 
 1.c. Blood indices  
Maternal HB concentration < 9g/dl 24 to72hrs postpartum 1 8% 
Maternal HB concentration 24-48 hrs. postpartum 1 8% 
 1.d. Interventions used 
Use of additional uterotonics 5 38% 
Maternal blood transfusion  1 8% 
Manual removal of placenta 1 8% 
 1.e. Maternal mortality and morbidity 
Maternal mortality 4 31% 
Serious maternal morbidity (organ failure, hysterectomy ICU admission) 2 15% 
Maternal postpartum anaemia 1 8% 
2. Neonatal outcomes 
Neonatal admission to ICU 1 8% 
Neonatal jaundice requiring phototherapy or exchange transfusion  1 8% 
Neonatal polycythaemia treated with delusional exchange transfusion  1 8% 
Neonatal death 1 8% 
Death or neurosensory disability at age of 2 years 1 8% 
Neonatal intraventricular haemorrhage 1 8% 
Periventricular leukomalacia 1 8% 
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We also compared the primary outcomes from the systematic reviews with the primary 
outcomes that were used for SSC in the RCTs. The main findings are summarised in Tables 
12 and 13.  
 
The most common primary outcomes, reported by at least 3 trials, were compared with the 
primary outcomes stated in the systematic reviews (Table 12). Four out of eight of the most 
common primary outcomes of the RCTs were never used as primary outcomes in reviews. 
Similarly, maternal death was reported as a primary outcome in 31% of the systematic 
reviews and never mentioned as a primary outcome in the RCTs. The most common primary 
outcome in the RCTs was the incidence of PPH of 500 mls or more while, in addition to this 
outcome, systematic reviews were also more concerned with severe blood loss, used of 
additional uterotonic (38%) and the effect of interventions on reducing maternal death (31%). 
 
Table 12. Most commonly reported primary outcomes underpinned by SSC in 
randomised trials, and proportion of systematic reviews reporting the same primary 
outcomes 
Most common primary outcomes in 
RCTs*+ 
No of RCTs (%) 
(Total=82) 
Primary outcome in 
systematic reviews  
(n=13) 
Incidence of PPH ≥ 500 mls  
 
24 (29%) 5 (38%) 
Amount of postpartum blood loss 
 
13 (16%) 2 (15%) 
Incidence of PPH > 500 mls 
 
10 (12%) 0 
Use of additional uterotonic 
 
7 (9%) 5 (38%) 
Difference in pre- and post-delivery HB 
 
6 (7%) 0 
Incidence of PPH ≥ 1000 mls 
 
5 (6%) 10 (77%) 
Incidence of severe PPH > 1000 mls 
 
3 (4%) 0 
Estimated blood loss during caesarean 
section 
 
3 (4%) 0 
*Only outcomes used for SSC are included. 
+Outcomes reported by at least 3 RCTs are listed 
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Table 13. Most commonly reported primary outcomes in systematic reviews and their 
relative frequency in randomised trials 
Most common primary 
outcomes in systematic reviews 
No systematic reviews* 
(%), (n=13) 
Primary outcomes in  
RCTls (%), (n=82) 
Severe PPH ≥ 1000 mls 
(clinically estimated or measured 
blood loss) 
10 (77%) 5 (6%) 
Use of additional uterotonics 5 (38%) 5 (6%) 
PPH ≥ 500 mls (clinically 
estimated or measured blood 
loss) 
5 (38%) 24 (29%) 
Maternal mortality 4 (31%) 0 
*More than one primary outcome in 11/13 reviews 
 
5. Discussion 
 
Well-designed clinical trials are an integral part of evidence-based medicine. Relevant and 
reliable outcomes play a crucial role in the correct interpretation and comparison of the 
results of different treatment modalities (Charman et al., 2003). Clinical trials are ‘‘only as 
credible as their outcomes’’ (Tugwell and Boers, 1993), and the decision as to which 
outcomes should be measured is crucial. The selection of inappropriate outcomes can lead to 
wasted resources or misleading information that overestimates, underestimates, or completely 
misses the potential benefits of an intervention (Holloway and Dick, 2002). Accurate 
measurement and reporting of clearly defined outcomes in RCTs and other research studies is 
a must in order to evaluate treatment effects and to provide health policy information (Moher 
et al., 2001). Information also facilitates shared decision-making, where communication 
between clinicians and patients about the risks and benefits of treatments allows an 
understanding of treatment effects and provides information on available choices (Schwartz 
et al., 1999; Alaszewski and Horlick-Jones, 2003). The difficulty of selecting the most 
appropriate outcomes for use in a clinical trial is reflected in the fact that in several fields of 
clinical research there is much heterogeneity between clinical trials of specific diseases 
regarding exactly which outcomes to select (Duncan et al., 2000; Clarke, 2007). This was 
also true regarding the outcomes of interventions for PPH prevention. 
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This systematic review has identified a wide range of outcomes which were used in PPH 
prevention studies. It shows inconsistency between studies in the way that outcomes are 
defined, measured and reported.  
 
While there were certain similarities between studies, particularly in the selection of primary 
outcomes that measure the incidence of PPH, the selection, definition and measurement of 
this particular outcome showed a wide variability. Most investigators use their own criteria to 
define the condition. Moreover, all these outcomes are frequently assessed at different times 
across trials.  
 
When comparing treatment effects, it is crucial that the outcomes being measured are relevant 
to patients, clinicians and researchers (Mease et al., 2008). Many outcomes of interventions 
to prevent PPH were considered critical for decision-making by the WHO panel (WHO, 
2007a). These included reduction in maternal mortality and reduction in maternal morbidity 
as indicated by measured blood loss of 1000 mls or more, and use of blood transfusion. These 
critically important outcomes were stated infrequently or as only secondary outcomes in the 
included trials. It has been found that RCTs of PPH prevention almost always assess the 
amount of postpartum blood loss, but do not concentrate on maternal death and morbidity as 
the import consequences of PPH. Outcomes related to the duration of the third stage of labour 
are reported as a secondary outcome. Retained placenta and neonatal outcomes tend to be 
measured uncommonly across the trials. Retained placenta could occur as a consequence of 
drug used, or could be the only cause of atony and haemorrhage. The newborn baby may be 
affected by some of the interventions used such as cord clamping; therefore researchers 
should pay special attention to, and increase the evaluation of these important outcomes. 
 
Although this review included only studies published after the first CONSORT statement to 
reduce reporting bias, a considerable number of trials showed poor reporting, including 
failure to differentiate between primary and secondary outcomes and not stating prior SSC. 
 
Our findings demonstrate that the inconsistency and lack of standardisation in the selection of 
outcomes is prevalent not only amongst RCTs but also amongst systematic reviews. This was 
not surprising in the absence of a core set of outcomes. This presents authors of systematic 
reviews with a challenging task of bringing together, and making sense of, a variety of 
studies that used a variety of outcomes and outcome measures.  
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The challenge of comparing the findings of different trials of different interventions using 
different outcomes and different ways of measurement make the identification of effective, 
ineffective and unproven treatments for this condition especially difficult. The incidence of 
PPH ≥ 1000 mls (clinically estimated or measured blood loss) was used as a primary outcome 
by 69% of included systematic reviews. However, reviewers face the problem of 
inconsistency in the method used to measure blood loss. Therefore they chose any clinically 
estimated or measured blood loss with that outcome. This was also true regarding other 
outcomes such as the incidence of PPH of 500 mls. There was also variability in the time of 
collecting the second sample for haemoglobin measurement within the trials; reviewers used 
the maternal haemoglobin level within 24-48 hours postpartum. 
 
Researchers usually use outcome measures in the context of their own trial, while reviewers 
conducting systematic reviews usually focus on outcomes that help in making clinical 
decisions about the effectiveness of interventions. Therefore, Cochrane/non-Cochrane 
systematic reviews tend to focus on more severe blood loss (≥ 1000 mls) and maternal deaths. 
It is generally accepted that an important and clinically meaningful endpoint should measure 
how a patient feels, functions or survives (Temple, 1995). Severe haemorrhage and maternal 
mortality, the most common primary outcomes in PPH prevention systematic reviews, are 
clearly important endpoints upon which conclusions about the effectiveness of an 
intervention can be made. On the other hand, incidence of PPH at blood loss of 500 mls or 
more, the most common primary outcomes in clinical trials, is more relevant in answering the 
question about the effectiveness of interventions on prevention of primary PPH, particularly 
after vaginal delivery.  
 
There is little evidence about the factors that influence the choice of primary outcomes in 
systematic reviews. Availability of data from clinical trials, previous knowledge of results, 
and the desire to publish positive results could potentially impact on outcomes reported 
(Egger and Smith, 1998). Systematic reviews are unlikely to be influenced by financial and 
time constraints in the same way as clinical trials, and therefore, it is not surprising that they 
tend to select rare endpoints that measure significant morbidity and mortality. 
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Many clinically important outcomes, as identified by the WHO panel (WHO, 2007a), were 
underrepresented in both RCTs and systematic reviews. The use of blood transfusion, one of 
the most important clinical outcomes, was used as a primary outcome by only one systematic 
review and was never used for SSC in RCTs. Although both RCTs and systematic reviews 
were concerned with the incidence of anaemia, they used different criteria to determine such 
an important outcome. It is not surprising, with the absence of a core set of outcomes, to find 
a huge variation in in the selection of primary outcomes between RCTs and systematic 
reviews. 
 
Three main problems can arise if the selection, measurement and reporting of outcomes is 
non-uniform across clinical trials. The first problem is that important outcomes can be 
overlooked.  If trialists are not required to adhere to an accepted list of mandatory outcomes, 
it is likely that factors relating to the conduct of the trial, such as feasibility, will determine 
which outcomes are measured. The importance of outcomes then becomes a secondary 
consideration. As a result, more common outcomes that are easier to collect and interpret by 
researchers may be selected, but those that are most important to patients or clinicians may be 
overlooked. 
 
The difficulty of research synthesis (meta-analysis) is the second problem associated with the 
absence of consensus on choosing outcomes. Even if the same outcomes are selected, they 
are often measured and analysed in different ways.  
 
The third obstacle is the selective reporting of results. The practice of selective reporting of a 
subset of the original recorded outcomes, based on the results, is called outcome reporting 
bias (ORB) (Hutton and Williamson, 2000). In the absence of a set of core outcomes, which 
must be reported in all clinical trials in a given condition, trialists may decide to omit certain 
results from their final study report. A systematic review of studies that examined ORB in 
published RCTs found that statistically significant results are more likely to be fully reported 
than non-significant ones. It appears to be common practice to change or omit the original 
primary outcome, or introduce a new one, as the study progresses (Dwan et al., 2008). 
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The findings of this study highlight a significant lack of consensus and standardisation that 
exists not only amongst clinical trials but also amongst systematic reviews.  The study also 
shows that systematic reviews are more likely to focus on rare, but clinically more 
meaningful endpoints such as mortality. In this study we have reviewed the available data on 
outcomes across a range of studies conducted both in high- and low-income countries, 
assessing different types of interventions used to prevent PPH. Thus any recommendations 
we draw will be applicable to these settings. In an attempt to reduce bias we did not apply 
any language restriction to the included articles. We reviewed outcomes that have been 
reported rather than those which were actually measured. ORB in published RCT reports is 
common (Chan and Altman, 2005; Dwan et al., 2008), and in order to have evaluated exactly 
which outcomes had been measured it would have been essential to assess trial protocols. 
Although ORB may lead to an underestimation of the frequency with which some outcomes 
were actually measured, it is unlikely that it would affect heterogeneity between studies. 
 
We did not make a formal assessment of the quality of included studies, as this was not the 
primary aim of the systematic review. Our overall impression is that many studies were 
poorly reported and lack detail with regards to randomisation, blinding and concealment of 
allocation. We considered only RCTs and systematic reviews in this review, based on the 
assumption that in well-designed studies careful attention would be paid to the selection of 
outcome measures. There are however number of other study designs which also report 
outcomes from PPH prevention, and the inclusion of these studies may have highlighted 
additional important outcomes. 
 
We have showed that there is a clear mismatch in the choice of primary outcomes between 
RCTs and systematic reviews. Both inappropriate selection of outcomes and a lack of 
standardisation of how to measure the selected outcomes make it difficult to design, interpret 
and meta-analyse clinical trials (Clarke, 2007) and apply their findings to clinical practice. 
Outcome measures used in trials and clinical practice need to provide a complete assessment 
of the interventions used. There is currently a movement towards the development of core 
outcome sets for trials of specific conditions, as detailed by the COMET (Core Outcome 
Measures in Effectiveness Trials) Initiative (COMET, 2012). COMET aims to standardise 
practice and enable comparison of the results of different treatment modalities in meta-
analyses. Such initiatives increase the likelihood that important outcomes are measured, 
reduce non-uniformity between studies, and reduce the risk of outcome reporting bias. The 
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information obtained from this review will provide a basis for development of core outcome 
sets, and facilitate a much-needed change towards appropriate selection and standardisation 
of clinically important outcomes in future PPH prevention studies. 
 
For prophylaxis trials, the best outcome measures would be incidence of PPH (blood loss of ≥ 
500 mls after vaginal delivery and ≥ 1000 mls after caesarean delivery), total blood loss and 
difference in pre and post-delivery HB. These outcomes were most commonly reported in 
clinical trials and can be considered more practical for use in future research.  Although use 
of additional uterotonics was one of the most commonly reported outcomes, the work in 
Chapter 3 demonstrates how uterotonic use in practice is often not linked with the standard 
500 mls definition of PPH. Therefore, this particular outcome is not recommended unless a 
very clear and rigorously enforced protocol for uterotonic use is applied (which may be very 
difficult to follow in practice). 
 
In research looking at the effects of treatment of PPH, the best outcome measures would be 
maternal mortality, amount of blood loss after uterotonic treatment received, need for 
additional intervention (blood transfusion, surgery (non—invasive or invasive surgeries) and 
hysterectomy). 
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Chapter 5  
 Preliminary studies in developing a new device to aid 
bimanual uterine compression 
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1. Background  
 
For the management of PPH, it is recommended that minimally invasive methods should be 
tried initially, if possible (WHO, 2009). Therefore, the initial treatment of uterine atony 
involves discontinuation of causative agents (inhalation anaesthetics), emptying of the 
bladder, uterine massage and uterotonic agents before BMC (ACOG, 2006). The treatment of 
PPH has for many years focused on the provision of uterotonics. However, there are frequent 
problems with the provision of the drugs to low-resource community settings. According to 
the results of a survey conducted in 37 countries between January and March 2012 to identify 
both national and global gaps in PPH and preeclampsia program priorities (Smith et al., 
2014), 4 countries reported that oxytocin was not regularly available (Bangladesh, Liberia, 
South Sudan and Yemen). A further problem is that not all women respond to oxytocics. In a 
double-blind, non-inferiority trial, where 31,055 women using prophylactic oxytocin had 
blood loss measured after vaginal delivery, 809 (3%) women were diagnosed with PPH 
(Blum et al., 2010). Of those women with a PPH, an additional blood loss of 300 mls or 
greater after treatment occurred in 123 (31%) despite receiving a rapid infusion of 40 IU 
oxytocin. 
 
Uterine massage is an attractive alternative to uterotonics. However, when used alone, it does 
not seem to be effective in reducing PPH. A trial conducted in Egypt and South Africa 
recruited 1964 women and examined the effect of uterine massage in prevention of PPH. It 
found that uterine massage alone was associated with more blood loss within 30 minutes after 
delivery than treatment with oxytocin with or without massage (Abdel-Aleem et al., 2010). In 
a Cochrane review evidence was inconclusive regarding the role of uterine massage in the 
treatment of PPH and the authors suggested further research (Hofmeyr et al., 2013). 
 
The role of BMC as a treatment of PPH has been known for many years. One early version 
was called “bimanual kneading of the uterus” where one hand was put into the uterus and the 
other placed on the abdomen with counteracting pressure from fundus (Figure 1). The birth 
attendants used to knead the uterus bimanually until it contracted (Tweedy and Wrench, 
1914). There are now two recognised methods of BMC, external BMC and internal BMC, 
which were described previously in Chapter 1. 
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Figure 1. Bimanual kneading of the uterus (Tweedy and Wrench, 1914) 
 
Care providers in resource limited settings are often limited to physical manipulation as a 
form of obstetric first aid until definitive care is secured (Hussein, 2005). The technique of 
BMC mainly treats bleeding from an atonic uterus and cervical lacerations, but should also be 
effective when there is a small amount of retained placental tissue or with clotting disorders. 
There is no published research to provide an evidence-base for this intervention (RCOG, 
2009). However, Chantrapitak and co-workers examined the efficacy of ‘lower uterine 
compression’ in the treatment of PPH, comparing the amount of blood loss between those 
treated with the ‘lower uterine compression method’ and a control group receiving 
conventional treatment (Chantrapitak et al., 2009). They also tested the same technique for 
PPH prevention. In their PPH treatment trial, both groups received PPH treatment with 
uterine massage, oxytocin (10-20 units in 1,000 mls of IV solution), intravenous ergometrine 
(methergin, 0.2 mg), a cold pack on the abdomen (fundal area), and urinary catheterisation. In 
addition, the experimental group received additional ‘lower uterine compression’ for 10 
minutes. The lower uterine compression method comprised of two techniques. The first 
technique (Figure 2) was to compress the lower segment only if the abdomen was tense. If 
the abdomen was lax, ‘compression of lower uterine segment with counteracting pressure 
from fundus’ was used (the second technique; Figure 3), which sounds very much like trans-
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abdominal wall (external) BMC. The authors found that the lower uterine compression 
method is a very effective procedure for treating PPH. The blood loss after treatment in the 
conventional group was statistically significantly higher than the blood loss in the group that 
received additional lower uterine compression (p=0.026). Lower uterine compression resulted 
in 105 mls or 47% reduction of blood loss. It also has the benefits being simple to use, safe 
and inexpensive. The authors state that the application of this technique could lead to a 
positive impact on outcomes of many PPH women over the world in either developed or 
developing countries (Chantrapitak et al., 2009). The result from this study shows the 
potential for uterine compression in the primary treatment of PPH, particularly in low- 
resource countries where it is a highly practical solution. In a second study the same team 
found that the technique was also effective for preventing PPH (Chantrapitak et al., 2011). 
However, the compression of lower segment of the uterus is not possible using this technique 
and it could be very difficult in obese women. The amount of subcutaneous fat in obese 
women could act as a barrier to effective compression of the lower segment of uterus against 
the vertebrae. The second obstacle could be the scar in women recently delivered by 
caesarean section, as compression at this point as demonstrated in the figures could be very 
painful to them. 
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Figure 2. ‘Lower uterine segment compression’ method compressing the lower uterus 
only (Chantrapitak et al., 2009)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. ‘Lower uterine segment compression’ with counteracting pressure from 
fundus (Chantrapitak et al., 2009) 
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The standard technique of BMC requires the insertion of a fist into the vagina, an act that is 
both painful and has overtones of gender-based violence (Taylor, 2015). It is therefore 
currently only used in extreme situations. The procedure should also be carried out under 
aseptic technique which is not always possible outside of healthcare facilities. Additionally, 
the traditional method of BMC needs to be performed correctly in order to be effective at 
stopping the bleeding. However, studies have found that many cannot perform it correctly. 
For example, in one study from Indonesia, less than 10% of skilled birth attendants 
(Indonesian village midwives) were able to perform BMC at an acceptable level of 
competency even after life-saving skill training (McDermott et al., 2001). BMC has been 
shown to be most effective when the attendant has been trained in how to perform the 
technique correctly. A trial carried out to evaluate the impact of simulation-based training on 
the ability of birth attendants to correctly perform BMC in response to PPH from uterine 
atony (Andreatta et al., 2011) showed promise. The study involved skilled (nurse- midwives 
and nurse midwifery students; n=111) and unskilled participants (TBA; n=14) from Ghana, 
where all participants significantly increased their BMC skills after training (P=0.001). Post-
assessment results included a significant increase in the amount of uterine compression 
(number of illuminated lights; P=0.001), and an increase in the compression time (P=0.001). 
 
If, however, BMC could be performed in a less invasive manner, then it could act as an 
effective low-cost first-line treatment for PPHs arising from either atony or cervical tears.  
This chapter reports early feasibility studies on a new device being developed in Liverpool, 
UK. Firstly, we conducted a survey to find out obstetric care provider’s views on BMC and 
conducted early feasibility studies of doing BMC in an alternative manner using a platform 
on a handle. An evaluation of 2 commercial mannequins was also carried out to assess the 
optimal model for formal testing of the device. The designing team then designed a slim-line 
intravaginal device that could be opened within the postpartum vagina to provide a platform 
against which the uterus could be compressed. Studies testing the efficacy of this device on 
the uterus of a mannequin will be described in Chapter 6. 
 
Each step with methodology and results will be described in the following pages, with a 
discussion of the whole process at the end. 
 
 
 
164 
 
2. Survey of BMC use 
 
2.1.  Introduction  
 
BMC is a well-known first aid technique for treating PPH. The method is almost always 
carried out in emergency situations, and so it is understandable that there are no randomised 
trials evaluating this method. This survey aimed to gather the opinion of practitioners about 
BMC as a method of treating PPH and to explore the importance of introducing a new tool 
that can assist in performing the manoeuvre. 
 
2.2. Methods  
 
Questions were developed by NA with collaboration with AW, and are shown in Appendix 
D.1. The questions asked were: (1) what is your job? (2) how effective do you think BMC is 
at stopping bleeding? (3) how many times have you used BMC for PPH during the last year? 
(4) why do you not use the manoeuvre of BMC more frequently? (5) if there was a rapid test 
that could tell you whether bleeding was coming from lacerations anywhere in the vagina or 
perineum or not, how helpful would it be in your management? (6) if there was a rapid test 
that could tell you whether bleeding was coming from lacerations anywhere in the vagina or 
perineum or not, do you that that it would lead to reduction in the total blood loss? 
 
The survey monkey online tool (www.surveymonkey.com) was used for distribution. The 
survey was circulated through the RCOG mailing list and midwives at Liverpool Women's 
Hospital in the period July-August 2012. All participants answered questions in relation to 
BMC and provided their view on the development of a new device that could help in treating 
PPH. Ethical approval was not needed as the survey was not considered research and it was 
anonymous and the respondents were all NHS staff (NRES., 2011). 
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2.3. Results 
 
Responses were received from 111 participants; 59% of them were consultants, 28% were 
junior doctor and 10% were midwives.  
 
As shown in Figure 4 the majority of participants thought that BMC is an effective procedure. 
Less than 1% thought it was completely ineffective. The median score was 4. 
 
One fifth of contributors have not done BMC before (Figure 5). Eleven of those surveyed had 
carried out BMC more than 5 times for treating PPH during the last year. Only 4 of 
participated midwives had previously carried out BMC, one midwife had performed BMC 4 
times and 3 midwives had done BMC once. 
 
When asked ‘Why do you not use the manoeuvre of BMC more frequently? A fifth stated 
that it was because BMC is too invasive to the woman. Many of them also believed that drugs 
such as oxytocin are more effective than BMC. None of clinicians thought that BMC was 
ineffective. The 37 participants who answered the question as ‘other’, (Figure 6), either 
already did the manoeuvre frequently or had limited opportunity due to their junior position.  
 
 
Figure 4. How effective do you think BMC is at stopping bleeding (score 1-5)?(1= 
completely ineffective, 5= very effective) 
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Figure 5. How many times have you used BMC for PPH during the last year?  
 
 
 
Figure 6. Why do you not use the manoeuvre of BMC more frequently? [Tick all that 
apply]   
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Figure 7 shows the participant’s views on the introduction of a new method that could help in 
diagnosis of the source of bleeding in PPH and control the blood loss. More than half of 
contributors thought that it would be very helpful to know the source of bleeding and the 
majority (36%) believed that the test could assist in reducing the bleeding. However, there 
were a few participants who were unenthusiastic about the introduction of a new method and 
its role in helping in the management (14%) and reduction of the total blood loss (19%).   
 
 
 
Figure 7. If there was a rapid test that could tell you whether bleeding was coming from 
lacerations anywhere in the vagina or perineum or not (A) how helpful would it be in 
your management? and (B) do you think that it would lead to a reduction in total blood 
loss?  
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3. Feasibility study 
 
3.1. Introduction 
 
The feasibility of using a mounted platform on a mannequin to generate intrauterine pressure 
was assessed in a small study. The aims were (1) to assess the suitability of a commercial 
mannequin, (2) to assess whether the placement of a pneumatic intrauterine pressure sensor 
could measure intrauterine pressures, and (3) to assess the likely pressures generated by both 
BMC and a PPH Butterfly prototype. 
 
3.2.  Materials and methods 
 
The commercial mannequin (SimMom, Limbs and Things Ltd, Bristol, UK) was supplied 
with an atonic uterus (Figure 8). A pneumatic pressure sensor (RS Components Ltd, Corby) 
was inserted into the uterus and connected to a personal computer via a data logger (Picolog 
1012 Data Logger, Pico Technologies Ltd, St Neots (Figure 8)). 
 
The equipment was assessed in May 2012 by 5 clinical academics at Liverpool Women’s 
Hospital, Liverpool, UK. They all had at least 5 years of obstetric practice and had conducted 
BMC several times in real clinical scenarios. The ethics committee at Liverpool Women’s 
Hospital stated that ethical approval was not required for this study as it involved NHS staff 
only and no patient contact. However, informed verbal consent was obtained from all 
participants who volunteered for this study.  
 
The participants were asked to perform uterine compression twice: first in the classic fashion 
using an intra-vaginal fist, and secondly using an appropriately sized platform mounted on a 
handle and inserted into the vagina. We used a commercial produced potato masher (John 
Lewis, Ltd, UK; Figure 9). Each participant was asked to carry out uterine compression on 
the mannequin model as if they were in a clinical setting for five minutes in each occasion, 
with a rest period of 5 minutes in-between. The intrauterine pressure generated by each 
participant were recorded and displayed in graphic form using the supplied Pico software 
(Picoscope 6). After finishing the procedure, the obstetrician filled in a feedback form 
(Appendix D.2). 
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Figure 8. Material used for the feasibility study, SimMom, Limbs and Things Ltd, 
Bristol, UK) 
 
 
Figurer 9. Picture of mounted platform (John Lewis, Ltd, UK) 
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3.3. Results 
 
All 5 clinicians completed the study. Typical graphic outputs are shown below, (Figure 10 
and 11). The graphs showed that the equipment was able to reliably provide a measurement 
of the intrauterine pressure and record it over a period of 5 minutes. With the classic method 
of BMC, initial pressures were good, but they rapidly decreased over time as the practitioner 
became tired (Figure 10). In contrast, the pressures could be maintained for longer when the 
PPH Butterfly was in place (Figure 11). Note that the Y-axis values are voltage and not 
pressure. They do however allow comparison of pressure between methods and over time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Using the classic method of BMC            Figure 11. Uterine compression with the                                                                                                   
mounted platform 
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Written feedback was also gathered from the participants regarding the mannequin and the 
idea of using the device. Two open questions were asked to all participants. The first was on 
the acceptability of the mannequin and the second was on the participant view of the idea of 
the device. The majority of participants (3 out of 5) like the idea of the device. A typical 
response was that “using the device was more comfortable than the traditional way of doing 
BMC and will maximise the effect of uterotonic”. The staff were less enthusiastic about the 
mannequin however, and many felt that it did not give the same feel as in real life. It was felt 
that the mannequin’s vagina was too short and inflexible making the insertion of the hand 
very difficult. One stated “difficult to get hand through the vagina, does not give the same 
feel as the in vivo situation”. Furthermore, the tone of the supplied uterus was very firm in 
comparison with the real postpartum atonic ones. A participant commented that “the uterus 
feels a bit too resistant to compress when compared to usual atonic uterus”. 
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4. Internal uterine compression on a mannequin model: a pilot study 
 
4.1. Introduction 
 
The first evaluation of uterine compression in vitro using the mounted platform documented 
considerable problems with the mannequin used. We therefore obtained further commercial 
mannequin models, each provided with an ‘atonic uterus’. The supplied uteruses were large 
but with different degrees of tone. They also varied in their anatomy, especially those areas 
relating to BMC. After several meetings and discussions with the research team, we ended up 
with 2 birthing simulators that were suitable for use in our study. The first model is Noelle
®
, 
(Figure 12), and the second model is Mama Natalie
®
 (Figure 13). Noelle
® 
is a product of 
Gaumard Ltd a company based in Miami, Florida. It is a comprehensive teaching system 
designed to provide a complete birthing experience, before, during and after delivery. One 
important application of Noelle
®
 is PPH simulation. The mannequin is supplied with an 
‘atonic uterus’ to mimic PPH. The mannequin is computerised and has a refillable internal 
blood reservoir and programmable bleeding levels to simulate postpartum bleeding. Noelle
’
s 
uterus has a cavity to teach the method of inserting and inflating a Bakri Balloon. This is 
surrounded by an air-filed sealed cavity that can be inflated to mimic an atonic uterus. 
 
This study was designed to determine which of the two models to use in a formal randomised 
trial of mannequin uterine compression. The two models were assessed in terms of their 
anatomical accuracy, realism when simulating BMC, and ability to conduct pressure 
measurements. The data from the appropriate model were also used to calculate the sample 
size needed for the randomised trial, and to assess the likely pressures generated by BMC on 
the mannequin. The average pressure generated in this study was used as the cut-off point for 
the later study. 
 
4.2. Materials and methods 
 
The two mannequins selected were Noelle
®
 (Gaumard, Ltd) and Mama Natalie (Laerdal). 
The uterus in both models contained an air-filled pressure sensor connected to a uterine 
pressure inflator to record the intrauterine pressure. This was connected to a personal 
computer via a data logger (Picolog 1012 Data Logger; (Figure 12)).  
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Noelle
®
 already has a sealed cavity on the outside of the uterus and so the air supply tube was 
cut, and connector inserted, and a pressure sensor was connected. Natalie however had no 
cavity present and so an air-filled pressure pad was inserted into the uterine cavity for 
assessment. 
 
Mama Natalie is produced by Laerdal, a major manufacturer of medical equipment and 
medical training products based in Stavanger, Norway. As with Noelle
®
, the main function of 
Mama Natalie
®
 is to provide realistic simulations in maternal and newborn care. Since 
obtaining these 2 models, we have modified them and inserted pressure sensors, so as to 
enable the measuring of intrauterine pressure, generated by BMC. We also made some 
changes to Noelle’s uterus so as to make it more realistic.  In the commercial product, the 
pressure tubes entered the uterus at the fundus, thus restricting BMC. Furthermore, the 
abdominal wall was very firm (in contrast to the postpartum abdomen). We therefore 
contacted Gaumard Ltd who adapted the mannequin, moving the pressure connectors from 
the fundus to the sides of the uterus. They also supplied us with an alternative, more lax 
abdominal wall. 
 
After discussion with Research and Development Department, it was decided that ethical 
approval was not required for this study as it involved NHS staff only and no patient contact. 
The decision on ethical approval when involving NHS staff was based on published advice 
from the National Research Ethics Service (NRES) (NRES., 2011). However, informed 
verbal consent was obtained from all participants.  
 
Ten experienced obstetricians at Liverpool Women’s Hospital were invited to participate in 
the study. They all had at least 5 years of obstetric practice and had conducted BMC several 
times in real clinical scenarios. Participants were randomised to the order in which they 
conducted compression on the models. A commercial randomisation programme was used to 
produce a random list of allocations to the two mannequins (www.sealedenvelope.com). The 
allocations list (consultant’s names and allocation) was developed by research staff not 
involved in the study.  
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Each participant was asked to carry out BMC on each mannequin model for five minutes, 
with a rest period of 5 minutes in-between. The pressure generated over a 5 minute period for 
each participant was recorded and saved. The mean pressure for each participant was then 
calculated, and an overall mean calculated out of the 10 participants’ mean pressure. After 
completing the procedure, the obstetrician filled in a feedback form related to the procedure 
and the acceptability of the mannequin models (Appendix D.3). 
 
Responses were recorded on a 10 point Likert scale (ranging from 0 (highly disagree) to 10 
(highly agree)). The following aspects were evaluated: 
 Anatomical accuracy of vagina  and cervix 
 Feel of uterus 
 Realism of conducting BMC 
 
After the optimal mannequin was chosen, data from that mannequin was analysed so as to 
device baseline data for future research. 
 
Data analysis was performed using statistical software Graphpad Prism version 6 (GraphPad 
Prism Software, Inc. San Diego, California, USA). Data from the mannequins were 
compared. The statistical significance of difference between the medians was assessed using 
the Mann–Whitney test with P < 0.05 considered significant.  
 
The main outcomes were the mean amount of uterine pressure generated by the all 
participants and the percentage of time over average for each participant and the mean of that 
value (Table 2).  
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 Figure 12. Noelle
®
 mannequin 
 
 
Figure 13. Mama Natalie mannequin 
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4.3.  Results 
 
The rating of different anatomical parts and realism of BMC on both mannequins is presented 
in Table 1. The Noelle
®
 model was superior in all variables compared with Mama Natalie, 
but, the only statistical significant difference was between the vagina of the two models. 
 
 
Table 1. Quality assessment in both mannequins (0= highly disagree, 10 = highly agree) 
Variable 
Noelle
®
 
 
Mama Natalie 
 
P-value 
 
Anatomical accuracy 
 Vagina  
 Cervix  
 
8 (2-8) 
7 (2-9) 
 
4 (2-6) 
4 (2-8) 
 
0.005 
0.07 
Feel of uterus  7 (2-8) 4 (0-7) 0.19 
Realism of BMC 7 (2-9) 4 (1-9) 0.34 
٭Data are presented as median (Range) 
 
Analysis of data from the preferred mannequin (Noelle
®
)  
 
The mean pressure from the Noelle
®
 mannequin was equal to 34 mmHg with a standard 
deviation of 10.05. The mean percentage of time over 34 mmHg was then calculated, Table 
2. 
 
Table 2. Expert percentage of time over mean pressure (34 mmHg) 
Participant 
No 
1 2 3 4 5 6 7 8 9 10 
% of time over 
34 mmHg 
94 93 91 53 35 31 19 11 0.2 0 
Average of % 
of time over 34 
mmHg (SD) 
43% (38%) 
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Sample size calculation 
 
There is no previous data on the correct pressure for BMC. We therefore used the information 
we obtained from the experts in this study, considering that they would have the best 
assessment of the correct pressure needed compress the uterine blood vessels. It can be seen 
from Table 2 that the percentage of time over average has an extreme values (0-94) and it is 
not known what the ‘correct value’ is. After discussion we decided that an increase of 17% 
(up to 60%) would be a clinically important improvement that would demonstrate the benefit 
of a new device to compress the uterus. 
 
In the expert group the percentage of time over 34 mmHg was 43% (SD=38%). A sample 
size of 42 participants is needed to improve time over average by 17% at alpha equal to 0.05 
and beta equal to 0.8. 
 
5. Discussion 
 
There are no previous human studies on the effectiveness of BMC for treating PPH. There 
have been, however; a number of simulations based studies on BMC (Andreatta et al., 2011; 
Andreatta et al., 2012). The first study evaluated the ability of simulation to train birth 
attendants to correctly perform BMC as obstetric first aid. The 2012 study examined the 
impact of team-based BMC for managing PPH from uterine atony. 
 
This new device to aid uterine compression to treat primary PPH was evaluated in several 
steps. This was first done by exploring maternity care providers’ view of BMC and this new 
tool to help provide effective uterine compression. The survey reveals that a cross section of 
maternity care providers believe that BMC is an effective method for controlling PPH. This 
fits with experts’ view - BMC is recommended in guidelines by WHO, NICE and RCOG.  As 
expected; however, their use of the procedure is limited by concerns that it is too invasive for 
the women and too tiring for the clinicians. The vast majority of clinicians also believe that a 
tool to diagnose the site of the bleeding would be very helpful in the management of PPH and 
would probably reduce overall blood loss. This survey provides evidence of the clinician’s 
need for a less invasive device that will facilitate uterine compression. 
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We believed that the above mentioned problems of BMC could be overcome by the insertion 
of a small vaginal device - the PPH Butterfly based on the shelf pessary. Initial designs were 
already in place and the survey data was used to obtain the National Institute for Health 
Research (NIHR) grant funding for formally develop the device for clinical use. 
 
The feasibility of using a mannequin model for testing the PPH Butterfly in vitro was 
evaluated. The first feasibility study of measuring uterine pressure produced by the 
participants doing uterine compression revealed that there was enthusiasm from the 
participants about the value of a PPH Butterfly prototype device. The majority of staff agreed 
that the device seems to help and that the approach is sensible as BMC can control the 
bleeding and maximise the effect of uterotonics. Furthermore, the compression using the 
device produced firm and sustained pressure on the uterus, and prevented clinician fatigue. 
Some of the practitioners using the PPH Butterfly prototype chose to let go of the handle of 
the device mid-way through and lean on the abdominal hand to prevent fatigue. This was 
made possible by wedging the handle of the PPH Butterfly prototype on the surface upon 
which the mannequin was placed. This led to a modification to the device so that it could be 
wedged into the bed. 
 
This study also showed that the use of a mannequin linked to a pressure sensor was suitable 
for testing uterine compression. However, the mannequin used was not a good model with 
respect to female anatomy. This drove us to look at different mannequin models and conduct 
a pilot randomised study included the best 2 models we have obtained. Both models were 
compared by experience clinicians in many anatomical and clinical aspects. The user 
acceptance of Noelle
®
 was an added benefit. The data obtained from Noelle
® 
was considered 
as a base-line and used for calculating the sample size for the next PPH Butterfly in vitro 
testing study.  
 
From the ten experts we noticed that there were wide variations in the pressure produced. It 
seems that there are different interpersonal factors that affect the amount of pressure. This 
could be explained by gender, age, and strength of the participants which were not assessed 
in the study. An additional point that could clarify this diversity is the lack of a standardised 
method of BMC. As has been noted previously participants differ in their BMC technique 
with some clinicians combining uterine massage and BMC as one procedure when asked to 
carry out BMC.  
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The studies in this chapter have strengths and limitations. Firstly, although the survey was 
simple and gave an overview of BMC practice amongst obstetric caregiver, it was conducted 
among clinicians in the UK only. The result could differ if obstetric care providers from low- 
income settings were included. This is particularly important in the results relating to the 
effectiveness and frequency of conducting BMC. The procedure is expected to be carried out 
more in low-resourced places where other interventions are less readily available.  
 
With regard to the survey questions we included only 6 questions so as to maximise the 
response rate. However, an additional question on how long the participants carry out BMC 
for a real clinical scenario? knowledge of this would have aided the future studies where 5 
minutes was used without prior knowledge of usual practice.  
 
The simulation studies included in the chapter show that the mannequin can be used to 
measure uterine pressure bimanually or with using a platform on a handle. The SimMom 
mannequin used in the first simulation study was neither representative nor acceptable to the 
participants. The genital parts of the mannequin bear little resemblance to a real postpartum 
woman. The study was not randomised - all participants conducted BMC followed by uterine 
compression using the device. Additionally, both forms of uterine compression were done on 
the same day. However, neither the lack of randomisation nor the same day compression are 
likely to have introduced bias to the study. This is because there was good quality 
compression using the device from most of the participants. However, the pressure readings 
from the simulation could not be used as the design and the materials were not the ideal one 
for the final PPH Butterfly design. The device material (stainless steel) could have 
contributed to the strength of the compression produced by the participants in this study. 
 
The second simulation experiment used the preferred mannequin of Noelle
®
. The model is 
very expensive (£26,500), but should be off-set by its use for clinical training. The allocation 
of participants in this study was made before the verbal consent was obtained. We admit from 
the methodological point of view that it is not the right way to allocate participants. However, 
in this situation it is less likely to introduce bias to the study. The participants in both studies 
were not blinded due to the nature of intervention but they were blinded to the pressure 
produced by each mode of compression (bimanually or using the device). 
 
 
180 
 
In summary, these feasibility studies have led to the identification and modification of the 
mannequin that is not only highly rated by clinicians but which also gives uterine pressure 
measurements. The clinicians’ survey has shown that there is the clinical need for a less-
invasive method for conducting BMC and has contributed to the development of the PPH 
Butterfly. The next phase will be a device testing stage through a formal randomised cross-
over study comparing using the PPH Butterfly device with the standard way of doing BMC 
using the preferred mannequin (Noelle
®
). 
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Chapter 6  
A randomised cross-over study of a novel device for the 
management of postpartum haemorrhage 
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The efficacy of the PPH Butterfly to facilitate uterine compression: a 
randomised cross-over study 
1. Introduction 
 
Reports from the confidential enquiries into maternal deaths (2009-2012) showed that most 
PPH deaths involved substandard care in the diagnosis and management of haemorrhage 
(Knight M et al., 2014). Up to 80% of cases are estimated to have received substandard care 
(ACOG, 2006; Rath, 2011). Examples include underestimation of blood loss, lack of local 
protocols, lack of adequate education and training (Bohlmann and Rath, 2013), poor 
communication, and deficiencies in organisation, such as staff shortages, inadequate 
equipment and insufficient teamwork and coordination (Upadhyay and Scholefield, 2008; 
Driessen et al., 2011; Rath, 2011). Much of this relates to the deficiency in organising 
transfer and complex, multi-disciplinary care at the health unit. A low-cost, effective 
intervention that can be used by first level maternity services providers could be a major 
advance in reducing maternal mortality from PPH, especially in low-resource settings where 
the majority of deaths occur. 
 
A vital step in the physiological prevention of PPH is achieving immediate contraction and 
retraction of myometrial muscle fibres during and after the third stage of labour. Uterine 
atony is a condition characterised by the inability of the uterus to contract adequately after the 
placenta has separated from the uterus. This condition is thought to be the most common 
cause of PPH (Combs et al., 1991a; Maughan et al., 2006). There are many recognised risk 
factors for uterine atony including an over-distended uterus (due to polyhydramnios, multiple 
pregnancies, or a large fetus), prolonged labour, chorioamnionitis, tocolytics and general 
anaesthesia (RCOG, 2009). Despite the attempts that have been made to identify women at 
risk of uterine atony, it has been found to occur unpredictably in women with no risk factors 
(Breathnach and Geary, 2009). The most common clinical signs of uterine atony in women 
are a flaccid, boggy uterus and genital tract bleeding. An engorged, atonic uterus can contain 
many litres of blood, and may go unrecognised except for signs of haemodynamic instability 
secondary to hypovolaemic shock (Chestnut et al, 2009). 
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The PPH Butterfly 
  
The PPH Butterfly is a simple, low cost, newly invented medical device that is designed to 
work as a management tool to assist in the diagnosis and treatment of primary PPH. The 
device was invented by Professor Andrew Weeks and the intellectual property is held by the 
University of Liverpool. The prototypes were developed in the Clinical Engineering 
Department of the University of Liverpool. The initial concept is loosely based upon the 
existing shelf pessary that is used to treat utero-vaginal prolapse. The addition of a handle 
enables the user to easily insert the device and align it into its correct position. The handle is 
large so as to limit the depth of insertion. When folded, the device can be slipped 
longitudinally into the vagina with minimal trauma. Once inserted, the device is unfolded by 
sliding the two arms of the device over each other so that the uterine platform privot into a 
horizontal position facing into the maternal abdomen. Thus the surface of the platform ends 
up perpendicular to the axis of the uterus. Upon sliding back the handle, the device will return 
to its original folded state, allowing the device to be removed without discomfort or trauma. 
The insertion process is demonstrated graphically in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. PPH Butterfly prototype - the insertion process 
Fully opened within the vagina 
Unfolded once within the vagina 
The device folded for insertion 
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The theory behind the device 
 
The idea of the device was to achieve the benefits of BMC without being so invasive, thus 
allowing it to be more widely used. The PPH Butterfly has been designed to be a slim, easily 
insertable replacement to a fist in the vagina (as occurs in BMC), thus increasing 
acceptability of uterine compression to both women and clinicians. This will make uterine 
compression available for use at a much earlier stage in the PPH treatment process, and 
provide an effective treatment without the need for medicines or advanced diagnostic skills. 
Once inserted, the uterus is compressed against the PPH Butterfly by a hand pushing against 
the woman’s abdomen. The device will be held in place by its handle, which can be wedged 
against the bed allowing the uterine compression to be achieved with one hand on the 
maternal abdomen, or be held by the clinician or an assistant. The compression of the uterus 
can therefore be provided by either an individual clinician, two clinicians, or it will be 
possible to alternate between the two. This will allow the clinicians to share the task of 
uterine compression, and also prevent the rapid fatigue that occurs when conducting BMC. 
The PPH Butterfly is also designed to work as a management tool that assists in the diagnosis 
of primary PPH. Using the PPH Butterfly to immediately stop bleeding coming from the 
uterus will assist clinicians in determining the cause and source of postpartum bleeding.  
 
Once the device is in the correct position, this can assist in the diagnosis of the source of the 
bleeding. If compressing the uterus against the device causes the blood loss to stop, then the 
user can be confident that the haemorrhage was uterine in origin and can continue uterine 
compression along with systemic oxytocics. Assessment of the bleeding will be made by 
releasing the pressure on the uterus. If the bleeding restarts, then the uterine compression can 
be continued and further oxytocics given. If, on the other hand, blood loss visibly continues 
whilst the uterus is being compressed then the user can be confident that the source of the 
haemorrhage is vaginal tears. This will allow a rapid diagnosis of the source of the bleeding 
so that appropriate steps can be taken. The surface of the platform of the device resembles a 
grill, with multiple holes. This gives a surface against which to compress the uterus, whilst 
preventing the entrapment of blood above it. 
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The three phases of the project were completed sequentially beginning with the designing 
phase, followed by the choosing and development of a usable device, and ending with an 
evaluation of the developed device. The device evaluation involved conducting a prospective 
randomised cross-over observational study at Liverpool Women’s Hospital. This current 
study tested the use of the PPH Butterfly in a mannequin model when used by delivery suite 
staff, and examined the amount of compression that can be exerted on the uterus and the 
percentage of time over the ‘effective pressure’ (34 mmHg) by the PPH Butterfly and by 
standard BMC. The choice of a level of 34 mmHg for “effective pressure” is described in 
Chapter 5. The role of PPH Butterfly in diagnosing the source of the bleeding was not tested 
in this study. 
 
Study type: randomised crossover study. 
 
Study hypotheses 
 
Three research hypotheses were examined: (1) use of the PPH Butterfly produces an 
equivalent amount of uterine pressure to standard BMC (2) uterine pressure from the PPH 
Butterfly can be sustained for a longer time than BMC, and (3) there will be no difference in 
effectiveness of uterine compression between experienced and inexperienced maternity care 
providers using PPH Butterfly. 
 
Primary outcome measures 
 
 Hypothesis 1 primary outcome: the mean area under an intrauterine pressure curve over 5 
minutes.  
Hypothesis 2 primary outcome: the percentage of time in each group for which there was 
effective compression in minutes 4 and 5 of compression. 
Hypothesis 3 primary outcomes: the percentage of time in each group for which there was 
effective compression.  
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 Secondary outcome measures 
 
• The maximum intrauterine pressure achieved in each group. 
• The mean uterine pressure over time (0-1, 1-2, 2-3, 3-4 and 4-5 minutes).  
•   The percentage of time in each group during which there was effective compression during 
the first minute and minutes 2-3. 
• The percentage of time during which there was inadequate uterine pressure (24 mmHg) 
over a period of 5 minutes in each group. Inadequate pressure was defined as ‘expert mean – 
1 SD’ (34 mmHg -10 mmHg). 
 
Materials 
 
The commercial mannequin (Noelle
®
-Gaumard) was supplied with a rubber uterus to mimic 
the postpartum atonic uterus; (see Figure 12 in Chapter 5). Some modifications were made to 
Noelle
®
 to facilitate BMC; and a full description of these is in Chapter 5. The uterus was 
supplied with air-filled pressure sensor which was connected to the uterine pressure inflator 
to record the intrauterine pressure, and connected to a personal computer via a data logger 
(Picolog 1012 Data Logger; (Figure 2)). Pressure from the uterus of the mannequin Noelle
®
 
is delivered to a piezoelectric pressure transducer ADP51A11 (Panasonic Electric Works Co., 
Ltd, Tokyo, Japan) via plastic tubing, where it is converted it into an electrical signal. The 
electrical output is directly proportional to the pressure. There is a small offset voltage at the 
output of the transducer at pressure 0 mmHg that is subtracted from the output value for 
analysis. The system includes a pressure gauge and hand pump (taken from a 
sphygmomanometer), initially pump air into the pressure pad. To calibrate the transducer, the 
tap is opened, pressure is pumped up to 10 mmHg and the value of the output noted. The 
pressure is then increased to 300 mmHg and the output value again noted. Because of the 
direct proportionality of the output to pressure, the actual pressure for any given voltage can 
be calculated. The tap to the hand pump was opened; the pressure in the pad increased to 10 
mmHg and the tap was closed. 
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The output signal is then fed into a data logger that digitises it. The data logger has a USB 
interface to allow connection to a laptop and an associated computer program (Picoscope 6; 
Pico Technology, Cambridgeshire, UK). This receives the data and converts it into both 
graphical and numerical form. The program allows mathematical manipulation and storage of 
the data so that the calibration values can be inserted into it to produce a graphical 
representation as well as and a spreadsheet of absolute pressure (mmHg) versus time. The 
pressure sensor set up and calibration was done by Mr John Porter at Electronic Product 
Supplies Ltd, Irby, Wirral, UK.  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Uterine pressure system 
 
 
 
 
 
 
 
 
 
 
Pressure pad Pressure transducer 
Laptop 
Pressure dials and pump (from a sphygmomanometer) 
  Plastic tubing 
Intrauterine 
Data logger Laptop 
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Setting 
 
The study was carried out at Liverpool Women’s Hospital, Liverpool, UK. 
 
Participants 
 
The ‘expert’ group consisted of obstetric care providers at Liverpool Women’s Hospital, 
senior obstetricians and trainees (ST3 onward) who had conducted human BMC several times 
before. The ‘novice’ group consisted of midwives who had no prior experience of conducting 
BMC. Any midwife who had previously conducted BMC was excluded. 
 
Ethical consideration and consent 
 
According to the ethics committee at Liverpool Women’s Hospital, ethical approval was not 
required for this study as it involved NHS staff only and was performed on a mannequin 
model. The decision on ethical approval when involving NHS staff was based on NRES 
advice (NRES., 2011). However, informed verbal consent was obtained from all participants 
who volunteered for this study prior to their participation.  
 
Sample size 
 
A pilot study amongst 10 experienced clinicians doing BMC on Noelle
® 
showed that the 
mean percentage of time over ‘effective pressure’ was 43% (SD=38%) (The study is reported 
in Chapter 5). It was agreed that an absolute increase of 17% to 60% would be clinically 
significant at alpha 0.05 and beta 0.8. A sample size of 42 pairs was therefore required for 
this study. The sample size calculation was done using StatsDirect software version 2.7.9 
(StatsDirect Ltd, Cheshire, UK).
 
 
Randomisation 
 
A statistical software programme (StatsDirect version 2.8.0, Cheshire, UK) was used to 
randomly allocate staff to the two methods of uterine compression. The allocations were 
written on cards and placed in consecutively numbered, sealed opaque envelopes by staff not 
involved in the study. We stratified this according to the participant experience (i.e. two 
separate randomisation lists were created for ‘novice’ and ‘expert’ providers). 
 
189 
 
2. Methods 
 
Experienced delivery suite doctors (ST3 onwards) and midwives were informed about the 
study and invited to participate. After each participant gave verbal consent, participants were 
divided into 2 groups: the expert group and the novice group according to their expertise in 
BMC. The group of midwives who had not undertaken BMC before were shown a picture 
illustrating BMC by the principal investigator (NA) before they started. Each participant was 
then asked to carry out two forms of uterine compression on a mannequin model: traditional 
BMC and uterine compression using the PPH Butterfly. As previously mentioned, the 
participants were randomised as to which form of uterine compression they undertook first. 
Some of the participants performed the standard BMC technique first, while others started 
with uterine compression using the PPH Butterfly device. This was to control the effect of 
fatigue. The participants compressed the uterus for 5 minutes on each occasion, with a 
minimum of 5 minutes rest in-between. All users were asked not to wedge the PPH Butterfly 
handle into the bed. 
 
The mannequin was supplied with an atonic uterus containing a pressure sensor. The sensor 
recorded the amount of uterine pressure produced by the participants compressing the uterus, 
and displayed it in the form of a graph. 
 
The researcher then translated the reading in the form of the time (in seconds) in which the 
participant had produced pressure of > 34 mmHg, for the whole 5 minutes. This was repeated 
with each member in each group (expert and novice group), as well as with each form of 
compression (traditional BMC, and uterine compression with the PPH Butterfly). GraphPad 
Prism version 6 software (GraphPad Prism Software, Inc. San Diego, California, USA) was 
used for data analysis. 
 
The percentage of time in each group when the pressure sensors recorded >34 mmHg was 
calculated for each group. The novice and the expert group were treated as sub-groups for the 
compression of BMC and PPH Butterfly compression.The Mann-Whitney test was used to 
compare the results within each group as well as a comparison between the 2 groups. The 
differences were considered statistically significant if the p value was ≤ 0.05.  
 
The research was funded by NIHR Invention for Innovation (i4i) programme, but they had no 
direct involvement in the study. 
190 
 
3. Results 
 
The study was conducted during June 2014 and lasted for three months. Forty two 
participants (20 doctors and 22 midwives) were enrolled and completed the study. 
 
1. Mean uterine pressure (area under the curve) 
 
There was no statistical difference between the two groups in the amount of uterine pressure 
produced over the period of 5 minutes, both between the two groups and between the 
subgroups. The mean uterine pressure produced by each group is shown in Table 1 and is 
represented graphically in Figures 3 and 4. The mean pressure for the overall data (expert and 
novice together) was 29.02 (SD=8.17) and 27.23 (SD=8.18) for the BMC and PPH Butterfly 
respectively. There were also no differences within the subgroups. The pressures were 
equivalent among the experts with the two techniques (BMC mean 28.47 (SD=8.67), PPH 
Butterfly mean 27.28 (SD=9.40)). The pressure produced by the novice group was also very 
similar when using BMC or the PPH Butterfly (P=0.34), (Figure 3). 
 
Table 1. Study outcomes 
Outcome BMC PPH Butterfly P value 
Hypothesis 1: 
Mean uterine pressure of a period 
of 5 minutes (SD) 
All 29.02 (8.2) 27.23 (8.2) 0.26 
Expert 28.47 (8.7) 27.28 (9.4) 0.51 
Novice 29.52 (7.9) 27.18 (7.1) 0.34 
Hypothesis 2: 
% of time over 34 mmHg over 
minutes 4 and 5 (Mean, SD) 
All 22.55 (38) 17.21 (32.2) 0.50 
Expert 21(37.8) 17.4 (34.1) 0.63 
Novice 24 (24.1) 17.1 (31.2) 0.15 
Hypothesis 3:  
% of time over effective pressure 
(34 mmHg) of a period of 5 
minutes (Median, IQR) 
All  14.5 (0-53.8) 9 (1-41) 0.73 
Expert  13 (0-49.3) 8.5 (0.25-32.3) 0.51 
Novice 14.5 (0.75-64) 9 (1-52) 0.62 
Secondary outcomes: 
% of time over 34 mmHg in minute 
1(Mean, SD) 
All 47.19 (42.8) 40.33(41.1) 0.78 
Expert 38.5 (41.1) 38 (39.6) 0.83 
Novice 55 (43.6) 43(43.1) 0.58 
% of time over 34 mmHg in 
minutes 2 and 3 (Mean, SD) 
All 30.26 (37.4) 27.43(37.7) 0.54 
Expert 28 (37.9) 26 (39.5) 0.78 
Novice 32 (37.7) 25 (34.4) 0.45 
Maximum pressure (Median, IQR) 
All 41.15 (34.2-53.8) 35.4 (28.1-446) 0.008* 
Expert 41.5 (34.7-53.5) 38 (29.6-44.7) 0.20 
Novice 41.15 (33.8-55.1) 33.11(27.9-41) 0.02* 
% of time over of inadequate 
pressure (24 mmHg) of a period of 
5 minutes (Mean, SD) 
All 35.8 (37.4) 43.2 (37) 0.52 
Expert 44 (41) 48 (36.7) 0.79 
Novice  28.3 (32.9) 39 (37.8) 0.52 
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Figure 3. Mean pressure produced by each method 
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Figure 4. Mean pressure produced by the subgroups 
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2. The percentage of time in each group over recommended pressure (34 mmHg) 
during minutes 4 and 5. 
The percentage of time that each group was over the recommended pressure (34 mmHg) was 
slightly lower when comparing the last 2 minutes with time minutes 2 and 3. The trend of a 
decrease in the amount of time above the recommended pressure was observed in both 
groups, but was more considerable with PPH Butterfly compression. However, these 
differences were not statistically significant. Both groups kept the pressure over 34 mmHg for 
exactly the same duration with the PPH Butterfly. The values for this outcome are 
summarised in Table 1. 
 
3. Percentage of  time of effective pressure (34 mmHg) 
 
The percentage of time that the participants achieved effective pressure over a period of five 
minutes was calculated. This was then compared according to the method of compression and 
the experience of the participants, and between the groups. This is explained below. 
 
A.  Effect of technique 
 
There was no statistical difference in the percentage of effective pressure within each group 
over a period of 5 minutes, (expert and novice), when looking at both of the methods of 
uterine compression. The median percentage of time over effective pressure during period of 
5 minutes was 14.5 (IQR=0-53.8) in the BMC group (expert and novice) and 9 (IQR=1-41) in 
the PPH Butterfly group (expert and novice), P= 0.73. In the expert group the median 
percentage of time over effective pressure was 13 (IQR=0-49.25) with BMC and 8.5 
(IQR=0.25-32.25) with the PPH Butterfly (P=0.96). Whereas in the novice group the median 
percentage of time over effective pressure was 14.5 (IQR=0.75-64) with BMC and 9 (IQR=1-
52) with the PPH Butterfly (P=0.55).  
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Figure 5. Percentage of time over recommended pressure over 5 minutes in subgroups 
 
 
B. Effect of experience 
 
There was no statistical difference between the experts and novices when performing each 
method of uterine compression. Both groups were able to keep the pressure over the 
recommended 34 mmHg at the same level regardless of experience. The majority of 
participants kept the pressure over the recommended value for only 20-25% of time. The 
median percentage of time over effective pressure during a period of 5 minutes was 13 
(IQR=0-49.25) among expert and 14.5 (IQR=0.75-64) amongst novice doing BMC, P= 0.52. 
Expert using PPH Butterfly produced a median of 8.5 (IQR=0.25-32.25) versus 9 (IQR=1-52) 
in the novice PPH Butterfly group (P=0.84). 
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Figure 6. Percentage of time over recommended pressure over 5 minutes in subgroups 
 
 
4. Maximum uterine pressure produced 
 
Figure 7 demonstrates the maximum amount of uterine pressure produced by the two 
methods. The participants were able to produce a higher amount of uterine pressure with 
BMC than PPH Butterfly (P=0.008). The maximum value of uterine pressure in the BMC 
group was 88 mmHg and this was produced by one of the expert group. The maximum value 
of uterine pressure in the PPH Butterfly group was 65 mmHg, and again was among the 
expert group. The maximum pressure produced by a novice was 79 mmHg and 51 mmHg 
using BMC and PPH Butterfly respectively, (Figure 8). There was no difference among 
experts using either method of compression in relation to this outcome (P=0.20). The 
maximum uterine pressure produced by the two methods of compression was significantly 
different in the novice group (P=0.02). 
195 
 
B M C P P H  B utte rfly
0
2 0
4 0
6 0
8 0
1 0 0
M
a
x
im
u
m
 p
r
e
ss
u
r
e
 i
n
 m
m
H
g
 
Figure 7. Maximum uterine pressure produced 
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Figure 8. Maximum pressure produced in subgroups 
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5. The percentage of time in each group over recommended pressure (34 mmHg) 
during minute 1 and minutes 2 and 3. 
 
The percentage of time that each group was over the recommended pressure (34 mmHg) over 
the initial 2 time intervals (minute 1 and minutes 2 and 3) was sustained at a similar level 
among the expert using either method of compression. Midwives kept the pressure over 34 
mmHg for a slightly higher duration with the BMC than the PPH Butterfly. The values of this 
outcome are summarised in Table 1. 
 
6. Mean pressure over time 
 
Participants were unable to maintain the same level of pressure over 5 minute periods, using 
either form of compression. It can be noted from Figures 9 and 10 that the mean uterine 
pressure produced by the participants reduced slowly over the 5 minutes.   
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Figure 9. Mean pressure over time in the BMC group 
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Figure 10. Mean pressure over time in the PPH Butterfly group 
 
 
 
 
7. Percentage of time of inadequate pressure (< 24 mmHg) 
 
The percentage of time of ineffective pressure over a period of 5 minutes was also calculated 
and presented in Figures 11 and 12. In the BMC group the mean was 35.8 (SD=37.4), in the 
PPH Butterfly group the mean was 43.2 (SD=37.1). Generally, using either method of uterine 
compression, both groups had almost the same percentage of time below the ineffective 
pressure of 24 mmHg, Figure 11. Novices were able to keep the pressure in the effective zone 
more than the expert, and this was more with BMC (Figure 12). 
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Figure 11. Percentage of time of inadequate pressure (< 24 mmHg) with the two 
methods 
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Figure 12. Percentage of time of inadequate pressure (< 24 mmHg) in the subgroups 
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Informal verbal feedback from the two groups on the use of the PPH Butterfly (ease of use, 
comfort, fatigue) during the time of performing uterine compression was varied. The majority 
of participants, especially the midwives, felt comfort able when holding the device, and stated 
that the compression was much easier using the PPH Butterfly and less tiring. Many of the 
clinicians felt comfortable with the device size but some felt that, it needed to be smaller. 
Following participant feedback the device was subsequently reduced in size with the platform 
reduced in size from 76.5 x 43.5 x 90 mm to 65 x 40 x 90 mm. Some doctors felt that when 
using the device they lost the tactile sensation that they had with traditional BMC.  
 
4. Discussion  
 
As countries strive to meet the MDGs before the 2015 deadline, rapid and urgent action is 
needed to ensure that communities, particularly women, have equitable access to high-quality 
health supplies and services. Whilst the goal of MDG 5 to improve maternal health has 
witnessed impressive reductions in the global number of maternal deaths (Fathalla, 2012; 
WHO et al., 2012). BMC is one of the emergency methods used to control PPH and prevent 
maternal mortality. The ICM, FIGO, and WHO all have recommended its inclusion as a 
treatment alternative of atonic PPH (Lalonde, 2012; WHO, 2012). The PPH Butterfly is 
designed to be as effective as BMC, but to be less invasive, easily used by less experienced 
health workers and to be more easily sustained for longer period. However, there have been 
concern raised about the ‘violence’ of the technique and suggestions that this may violate 
human rights (Taylor, 2015). 
 
There are no previous human studies on the effectiveness of BMC in treating PPH. There are 
only 2 mannequin studies, and these evaluate the ability of simulation to train birth attendants 
to correctly perform BMC as obstetric first aid (Andreatta et al., 2011) and examined the 
impact of team-based BMC for managing PPH from uterine atony (Andreatta et al., 2012). 
 
 In this study we have found that the PPH Butterfly is simple to use on a mannequin model, 
even among obstetric care providers with little experience. It produces an equivalent amount 
of pressure to BMC, but feedback from focus group (data not shown) suggested an 
appropriate size and this would be less invasive than the standard BMC. It has also 
demonstrated the feasibility of using a mannequin model for teaching and performing BMC. 
However, uterine compression is not sustainable by the majority of participants.  
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There was a huge diversity within the group in all measured outcomes. Experts were able to 
produce the same amount of uterine pressure using either method of uterine compression. 
Novices produced a slightly higher pressure with BMC. This was a surprising finding, but it 
may relate to the lack of previous BMC experience. Those inexperienced in uterine 
compression will not be aware of how hard to compress the uterus in order to stop the 
bleeding and so will simply compress as hard as possible. Those experienced in compression 
may understand that the amount of pressure needed is only enough to compress the 
intramyometrial arterioles. This may have led to the experienced group not using too much 
pressure. It could also relate to the build of the participants. It has been suggested that a large 
body mass is required to produce effective pressure, as it has been found on a feasibility 
study that the level of pressure reached through compression was directly proportional to the 
clinician's body weight (Douma and Brindley, 2014). Finally, it may relate to the way doctors 
conducted BMC. This was not constant and some carried out BMC and uterine massage at 
the same time.  
 
The majority of participants (experts and novices) kept the pressure over the recommended 
value for only around 10% of time. It seems that BMC is poorly taught and more attention 
should be paid to training on the correct way of carrying BMC. From the study we noted that 
BMC is easy to teach but the amount of pressure produced by the compression is difficult to 
standardise. Standardisation of pressure is possible on a mannequin model but would not be 
easy in human subjects. In one evaluation of simulation-based training on the ability of birth 
attendants to correctly perform BMC as obstetric first aid, researchers used six light pressure 
sensors to give biofeedback on the amount of uterine compression. The better level of uterine 
compression would be achieved the more lights were lit up (Andreatta et al., 2011). The 
authors found significant differences in the post-assessment quality of compression (P= 0.04) 
and the length of sustained compression (P= 0.001). All these studies are affected by a lack of 
knowledge about what the ‘correct’ pressure is when BMC is performed. In this study we 
used the pressure produced by (10) clinical academics as gold standard (see Chapter 5). 
However, these levels of compression were rarely achieved again, even by experienced 
practitioners, and retrospect they may have over-estimated the amount of force needed. 
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Almost all participants verbally indicated how tiring and hard it was to maintain uterine 
compression by either method. Use of the new handle of the device to wedge into the bed 
when a woman is lying in lithotomy may help to maintain pressure as it will allow 
practitioners to ‘lean’ on the uterus whilst merely stabilising the device with the other hand. 
This should be less tiring. It has also been suggested that BMC is more effective when 
performed by a team, with a primary attendant maintaining internal lower uterine segment 
pressure and monitoring the patient's condition, and a partner applying external pressure to 
the uterine fundus (Andreatta et al., 2012). This could also be true when using the PPH 
Butterfly. However, researchers need to be very careful when testing this on humans, as the 
amount of pressure produced using this method could harm the uterus if the compression was  
too high. 
 
One drawback of using the device would be losing the vaginal hand as a ‘biosensor’. This 
limitation could be lessened by vaginal examination before insertion of the device to assess 
the area of insertion, presence of injuries and for removal of blood clots. 
 
The risk of trauma cannot be eliminated until the device is assessed in vivo and its safety is 
evaluated in women immediately after delivery. However, as protective measures, the edges 
of the device that will be used in the human study will be round in shape in order to reduce 
the risk of injuries to lower genital tract. Additionally, lubricant will be used to facilitate the 
process of insertion. 
 
The study is strengthened by being a randomised trial, but does have several limitations 
related to the simulation method. Firstly, even the modified abdominal wall of the mannequin 
was much firmer than a postnatal woman’s abdominal wall, making external compression 
hard to do. Participants may have under/overestimated their maintainable and maximum 
effort in the absence of clinical urgency. That is, given the absence of a conscious, 
haemorrhaging woman, participants were able to undertake uterine compression in whatever 
position they felt comfortable, without the potential restrictions of a conscious woman. This 
may have affected how long they were able to sustain the uterine pressure, and thus what 
level of pressure they were able to achieve. Also, the lack of clinical feedback in response to 
uterine compression in the form of amount of bleeding and uterine tone could have 
contributed to the value of the pressure produced by the participants. Another limitation is 
that we needed to limit the time that participants were asked to maintain compression to just 5 
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minutes. Human studies need to be conducted to assess how long the clinician can sustain the 
pressure. Because of the nature of the intervention, staff could not be blinded to the group 
allocation, although they were blinded to the amount of uterine pressure they produced. We 
had to ask the participant to perform both methods of uterine compression on the same day. 
This was tiring however, and having the compression methods carried out on two separate 
days could possibly have given a better result, especially in term of sustainability. The results 
from this study are transitional in nature and may not apply in actual clinical settings. We did 
not formally collected feedback from the participants on the device usage, fatigue and 
comfortability. Having a structured questionnaire would have allowed us to gain further 
information on the device shape, size and ease of usage, and to formally assess this. 
However, the PPH Butterfly project has other focus group meetings that dealt with such 
feedback and assessment. 
 
BMC is performed by applying external pressure to the uterine fundus with one hand and 
internal lower uterine pressure with the other hand in order to compress the uterus. Finding 
that the uterine pressure produced by both the PPH Butterfly and BMC was not sustained and 
BMC is easy to teach, one may argue that using two hands to compress the uterus rather than 
the device is still cheaper. However; from the feminine point of view the use of device rather 
than insertion a fist would be more acceptable and less invasive. Additionally, the traditional 
method of BMC requires clinicians to come in direct contact with maternal blood which may 
increase the risk of transmission of blood borne diseases, namely HIV. It also may increase 
the potential introduction of infection to the mother. Although wearing gloves may allay 
some of these concerns, the availability of sterile gloves may be a problem in low-resource 
settings. In clinical practice, BMC often needs to be carried out for long periods of time. This 
is very tiring and it is impossible for the same person to maintain an effective level of 
pressure. With traditional BMC the tiredness would make the clinician need to remove their 
hand and this would make the pressure drop to zero. Using the PPH Butterfly will allow the 
clinician to alter their position more easily, whilst allowing the pressure to be maintained. 
The device has also the capability to be wedged into the bed and this would add more 
sustainability to the compression. 
 
One advantage to using the device in low-resource countries is that a re-usable device will be 
of low cost compared to the other available early use PPH therapies such as balloon 
technologies. In these countries it is envisaged that the device will be reusable as opposed to 
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disposable, and thus will reduce the cost, as an individual device will not be required for each 
haemorrhaging woman.  The new device will be available for only the cost of re-sterilisation. 
Also by using the device as a first line of defence, the costs of other later stage interventions 
such as additional drugs and theatre-based interventions could also be substantially 
diminished. 
 
It will be importance to assess the efficacy of the PPH Butterfly in vivo studies, especially in 
the developing world. Human studies are needed to ascertain with more precision the size and 
efficacy of the PPH Butterfly, and also its effectiveness in the presence and the absence of 
injectable uterotonics. This intervention, if efficacious, may become a vital tool to be 
implemented in all public healthcare centres, and could especially have applicability in 
under-resourced areas of developing nations. 
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Chapter 7 
General discussion and future research 
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1. Final discussion 
 
This thesis is devoted to critical evaluation of the standard methods available to prevent and 
early treat PPH mainly due to uterine atony. Failure of the uterus to contract and retract 
following childbirth has for centuries been recognised as the most important cause of PPH. In 
the developing world, PPH is responsible for ten maternal deaths every hour. For more than 
50 years AMTSL has been proposed for the prevention of PPH and is still recommended in 
current guidelines. The 3 key components of AMTSL have been the prophylactic 
administration of oxytocin, clamping and cutting of the umbilical cord and CCT, and the 
combination has been shown to reduce the rate of severe PPH by 70%. However, it has taken 
50 years to become clear that prophylactic oxytocin is the most important component of 
AMTSL.  
 
1. Bimanual uterine compression  
 
While primary PPH can occur in spite of AMTSL, maternal death from PPH is an 
unforgivable tragedy. In order to optimise the prevention and treatment of PPH, different 
approaches have been introduced and modified over the last century. The importance of BMC 
in treating PPH has increased gradually, moving from third to first treatment option in the 
PPH treatment process (Chapter 2). 
 
Physical measures are thought to be important in the early treatment of PPH. However, with a 
lack of research into the effectiveness of BMC, the procedure is rarely used by clinicians 
(Chapter 5). Whilst BMC is thought to be effective, obstetric care providers consider BMC to 
be tiring and too invasive to the women (Chapter 5). A commercial mannequin was therefore 
used to evaluate a new intervention that might contribute to the early physical management of 
PPH by making uterine compression available at very early stages of management. The PPH 
Butterfly is a new low cost device that is designed to make uterine compression simpler, less 
tiring and less invasive (Chapter 6). The device was initially compared to standard BMC. The 
study revealed that the PPH Butterfly is simple to use on a mannequin model, even among 
obstetric care providers with little experience. It also demonstrates the feasibility of using a 
mannequin model for teaching and performing BMC.  
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If proven efficient, using the PPH Butterfly would replace many of today’s first aid measures. 
In comparison with anti-shock garment, the device would be much simpler and cheaper to 
use. Additionally, the effect of device can be seen immediately by assessing the patient’s 
responsiveness through the amount of blood loss and uterine contractility.  
 
One potential disadvantage of the device in comparison with the garment would be the 
invasiveness of the PPH Butterfly that can result in genital trauma but using lubricated 
appropriate sized device would reduce this risk. 
 
2. Choosing the right outcomes for PPH clinical trials 
 
The first step in reducing maternal morbidity and mortality associated with PPH is to improve 
methods of prevention. PPH prevention is an important subject and research is going on all 
over the world to improve the current management and medications. Historically, PPH care is 
not evidence based (Chapter 2). Studies commonly use PPH of 500 mls or additional 
uterotonic use (Chapter 4) as their primary outcome, but the evidence from the histogram 
study suggested that these do not correlate in the research context (Chapter 3). In a systematic 
review including 121 studies conducted to identify the outcome measures for prevention of 
PPH, there was a huge diversity in choice of outcomes (Chapter 4). There is strong need for 
development of a clear core set of outcomes in clinical trials. This would best be done 
through a Delphi technique or other methods, so as to reach a consensus around the optimal 
outcomes. This, however, is very challenging especially when it related to PPH outcomes. 
The dilemma around PPH definition, varying maternal haemoglobin at the time of delivery, 
differences in the  time of  postnatal haemoglobin measurement and methods of blood 
measurement make it very difficult to to produce a core set. In their 2009 PPH guidelines, 
WHO attempted to reach consensus around optimal postpartum care (WHO, 2009). WHO 
staff drafted questions on interventions and listed all possible outcomes for the treatment of 
atonic PPH and retained placenta. The draft questions and list of outcomes relating to the 
treatment of PPH and management of retained placenta were sent to 144 experts from all over 
of the world. They included a multidisciplinary panel of international health workers and 
consumers (including physicians, midwives, and non-clinicians (policy-makers, researchers 
and consumers)). The WHO team applied a similar methodology on various interventions 
described for the prevention of atonic PPH (WHO, 2007a).  
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3. How effective are uterotonics for PPH treatment? 
 
Clinical trials evaluating the efficacy of uterotonics in treating PPH are rare. Where present 
they usually compare two uterotonics with an absence of control group, as it is unethical to 
leave a bleeding woman untreated. Historically, uterotonics use were taught as first line in 
PPH pathway of care (Chapter 2), but evidence for their use as a treatment largely came from 
PPH prevention studies. With the lack of placebo-controlled randomised trials the 
effectiveness of uterotonics in treatment of PPH is still questioned. Although treatment 
studies are very difficult, repeated doses of uterotonics appear to be ineffective (Widmer et 
al., 2010; Sheehan et al., 2011; Weeks et al., 2014). A recent innovation is to model the likely 
outcomes in the absence of uterotonic therapy through histograms (Weeks et al., 2014). This 
worked well in the presence of a clearly defined and implemented pathway for PPH diagnosis 
and treatment. Examination of 4 other PPH datasets from PPH prophylaxis studies however 
found that histogram analysis was unhelpful – largely due to the fact that women were given 
PPH treatment at a wide variety of blood losses (Chapter 3). Based on this evidence it is clear 
now that a new methodology is required. This could be either by conducting cluster RCTs or 
reviewing ‘large data’. All of these solutions are not without obstacles including lack of 
power and consent issues.  
 
 
2. Future research  
 
It is well-recognised phenomenon that whenever research questions are answered, more 
questions arise. This increases the researchers’ interest and may lead them to continue their 
investigations and improve the methodology, or to replicate their previous findings. The 
work in this thesis is no different and opens new avenues in several aspects of research. 
 
The third stage blood loss histogram study, in Chapter 3, could be replicated using datasets 
from large RCTs with a clearly defined treatment point and policy. This would result in a 
clearer picture of the benefit of using uterotonics for treating PPH at a blood loss > 700 mls 
and give adequate power to confirm or contradict the findings. From reviewing the data 
from the included studies in the histogram study in Chapter 3, it is clear that there is 
massive heterogeneity with a lack of consistency in methods used for data collection, 
abbreviations and code using. The production and use of a predefined data extraction sheet 
with standard code and definitions for use in all clinical trials would be highly beneficial. 
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The work in Chapter 4 about the clinical outcomes of PPH prevention studies has already 
been taken further by Dr. Shireen Meher, Clinical Lecturer in Obstetrics and Gynaecology 
University of Liverpool. The development of core outcome sets for PPH future studies will 
help in reaching a clear conclusion on the effect of intervention. A study is ongoing to 
examine the status of outcomes within PPH treatment trials to facilitate the development of 
COS. As mentioned above, different aspects of PPH (including its definition and method of 
blood loss measurements) need to be agreed at least in the context of research. 
 
The work in Chapter 2 could be linked to other sources of evidence based such as RCOG 
and CEMD recommendations. 
 
PPH remains a major cause of maternal mortality especially in low resource settings, where 
the majority of deaths take place. Providing affordable and effective intervention is essential 
for reducing maternal mortality from PPH. Although BMC is a well-known first aid 
procedure in treating PPH more research is required to establish its efficiency. This may 
also include research on how long it should be conducted for. The invention of the PPH 
Butterfly could help in treating PPH and preventing the tiredness caused by the standard 
method of BMC. However, this device now needs to be tested in women; first to test the 
device size and acceptability, and then to test its efficacy in vivo.  
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Appendix B.1.Third stage management prophylaxis as stated in ‘Obstetric by Ten Teachers’ editions 
Year Edition 
Third stage management prophylaxis 
Drug  Placental delivery  Cord clamping Other  
1917 1 
E oral liquid extract one teaspoonful 
in a wine-glass of water or    
hypodermic injection of some ergot 
preparation after delivery of placenta   
(Good practice not essential) 
Maternal straining 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward 
1920 2 
E oral liquid extract one teaspoonful 
in a wine-glass of water or    
hypodermic injection of some ergot 
preparation after delivery of placenta   
(Good practice not essential) 
Maternal straining 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward 
1925 3 
E oral (liquid extract) one 
teaspoonful in a wine-glass of water  
or hypodermic injection of ergtin 
after delivery of placenta   (good 
practice not essential)  
Maternal effort 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward then directly downward  
 
1931 
 
 
 
 
4 
E oral(liquid extract) one teaspoonful 
in a wine-glass of water  or 
hypodermic injection of ergtin after 
delivery of placenta   (good practice 
not essential) 
 
Maternal effort 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward then following the curve of 
genital canal direct the pressure downward 
and forward toward the vulval outlet  
 
1935 5 
E oral(liquid extract of ergot) one 
teaspoonful in a wine-glass of water  
or hypodermic injection of ergtin 
after delivery of placenta   (good 
practice not essential) 
Maternal effort 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward then following the curve of 
genital canal direct the pressure downward 
and forward toward the vulval outlet  
240 
 
1938 6 
E oral (liquid extract of ergot) one 
teaspoonful in a wine-glass of water  
or intramuscular injection of 
ergometrine 0.25 mg after delivery of 
placenta (good practice not essential) 
Maternal effort 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward then following the curve of 
genital canal direct the pressure downward 
and forward toward the vulval outlet  
1942 7 
E oral(liquid extract of ergot) one 
teaspoonful in a wine-glass of water  
or intramuscular injection of 
ergometrine, 0.25 mg  after delivery 
of placenta   (good practice not 
essential) 
Maternal effort 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward then following the curve of 
genital canal direct the pressure downward 
and forward toward the vulval outlet 
 
 
 
 
1948 
 
 
 
 
 
8 E oral or IM or OX IM 
Maternal effort 
 
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein  collapse 
(after few minutes) 
 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
gently and stead 
1955 9 
E 0.5 mg, IM immediately after 
delivery of baby 
Maternal straining  
  
Until baby cried  vigorously  
and pulsation stop and the 
umbilical vein collapse (after 
few minutes) 
 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward gently and steady 
 
 
1961 
 
 
 
 
10 
 
 
 
E IM 0.5 mg after delivery of baby 
If patient had anaesthesia  E IV 
0.3mg after head is crowned 
Maternal effort or 
cord traction  if the 
placenta not 
delivered (some 
clinics) 
Until  baby cried vigorously 
and pulsation stop  and the 
umbilical vein collapse (few 
minutes) 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, make it 
contract by stimulation with the tip of 
fingers and then press the uterus downward 
and backward gently and steady 
241 
 
 
 
 
 
 
1966 
 
 
 
11 
Physiological method: 
 NM 
Maternal 
effort/obstetrician 
pressing on the 
fundus of 
contracted 
uterus/CT/ B-A 
method 
Until  baby cried vigorously 
and pulsation stop  and the 
umbilical vein collapse (few 
minutes) Placing the baby 
below the level of placenta  
to facilitate blood flow by 
the aid of gravity 
Divide third stage management to 
conservative and active method (first 
mentioned) 
If the mother not able to expel the placenta, 
grasp the uterus with left hand, wait for a 
contraction then press the uterus downward 
and backward gently and steady 
 
Active method:  
E 0.5 mg IV or IM after delivery of 
anterior shoulder 
E/OX IM 
 
 
 
Combination of 
fundal pressure and 
CT or by B-A 
method   
Early 
 
 
 
 
 
1972 
 
 
 
 
 
12 
E 0.5 mg IV or IM after delivery of 
anterior shoulder or E/OX IM  (in the 
active method) 
 
Maternal 
effort(conservative 
method) if mother 
fail the placenta 
will be delivered by 
B-A method  
Until baby cried vigorously 
and pulsation stop and the 
umbilical vein collapse. 
Placing the baby below the 
level of placenta to facilitate 
blood flow by the aid of 
gravity 
Immediately in active 
method 
Divide third stage management to 
conservative and active method 
 
 
 
 
1980 
 
 
 
 
 
13 
E0.5 mg IV after delivery of anterior 
shoulder or E/OX IM 
B-A method 
If baby well: Until  baby 
cried vigorously and 
pulsation, keep the baby 
same level as the placenta, 
no milking, not to hold the 
baby too low or too high 
If resuscitation needed 
immediate (early) cord 
clamping 
Active management advocated by nearly all 
obstetricians 
 
242 
 
1985 14 
(Preferred) OX, IM 5 units within the 
delivery of anterior shoulder in 
primigravida 
While the head is crowing in 
multipara 
 or E/OX 
B-A method 
If baby well: Until  baby 
cried vigorously and 
pulsation, keep the baby 
same level as the placenta or 
a little low but not  o held 
high 
If resuscitation needed 
immediate (early) cord 
clamping 
Can be treated by simple observation but, 
active management advocated by nearly all 
obstetricians 
Mention side effects of erogmetrine nausea 
vomiting and high blood pressure 
1990 
 
 
 
 
15 
OX 5 units IM or IV with the 
delivery of anterior shoulder in 
primigravida 
While the head is crowing in 
multipara 
 or E/OX 
B-A method/NM 
If baby well: Until  baby 
cried vigorously and 
pulsation, keep the baby 
same level as the placenta or 
a little low but not to held 
high 
If resuscitation needed 
immediate (early) cord 
clamping 
 
Can be treated by simple observation but, 
active management advocated by nearly all 
obstetricians 
 
 
 
 
1995 
 
 
 
 
16 
OX 5 units IM or IV with the 
delivery of anterior shoulder in 
primigravida 
While the head is crowing in 
multipara 
 or E/OX 
B-A method/NM 
If baby well: Until  baby 
cried vigorously and 
pulsation, keep the baby 
same level as the placenta or 
a little low but not  o held 
high 
If resuscitation needed 
immediate (early) cord 
clamping 
Can be treated by simple observation but, 
active management advocated by nearly all 
obstetricians 
 
2000 17 
OX 10 IU or E/OX,  IM after 
delivery of anterior shoulder 
CCT 
Delayed  (until cord 
pulsation cease),  baby 
between the mother’s legs 
Active management  
Suckling to simulate oxytocin release 
E/OX contraindicated in hypertension 
 
2006 
 
 
18 
OX 10 IU or E/OX,  IM after 
delivery of anterior shoulder 
CCT 
Delayed, baby between the 
mother’s legs  
Active management 
Suckling to simulate oxytocin release 
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2011 
 
 
 
 
19 
 
 
 
Active management: OX, 10 IU IM 
with the delivery of anterior shoulder 
or immediately after delivery of  
baby 
CCT 
Early , baby between 
mother’s legs 
Active or physiological management 
Recommended active management to all 
women 
 
 
 Physiological management: no 
uterotonic 
Maternal effort  
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Appendix B.2. Summary on PPH treatment as stated in ‘Obstetric by Ten Teachers’ editions 
Year Edition 
Drug 
Type/dose 
Expulsion of the 
placenta/Crede’s  
manoeuvre 
Bimanual 
compression 
Aortic 
compression 
Uterine 
massage 
Surgery 
Other 
 
1917 1 
Ergot glass ampoules 
containing one dose 
IM (Ergotin) and 
pituitary extract IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
manual removal 
Third:  Yes 
but if case of 
severe flooding 
start with it  
Yes (difficult 
in obese 
women, may 
cause damage 
to intestines) 
First: 
Squeezing 
the uterus  
 
Last resource: 
Plugging the uterus 
using gauze 
(Surgical non- 
invasive) 
Second:  Intrauterine 
douche at a temperature 
180° F 
 
1920 2 
Ergot glass ampoules 
containing one dose 
IM (Ergotin) and 
pituitary extract IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
manual removal 
Third:  Yes 
but if case of 
severe flooding 
start with it 
Yes (difficult 
in obese 
women, may 
cause  damage 
to intestines) 
First: 
Squeezing 
the uterus  
 
Last resource: 
Plugging the uterus 
using gauze 
(Surgical non- 
invasive) 
Second: Intrauterine 
douche at a temperature 
180° F 
 
1925 3 
Ergot glass ampoules 
containing one dose 
IM (Ergotin) and 
pituitary extract IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
manual removal 
Third:  Yes 
but if case of 
severe flooding 
start with it 
Yes (difficult 
in obese 
women, may 
cause  damage 
to intestines) 
First: 
Squeezing 
the uterus  
 
Last resource: 
Plugging the uterus 
using gauze 
(Surgical non -
invasive) 
Second: Intrauterine 
douche at a temperature 
180° F 
 
1931 
 
 
4 
Ergot glass ampoules 
containing one dose 
IM (Ergotin) and 
pituitary extract IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
manual removal 
Third:  Yes 
but if case of 
severe flooding 
start with it 
Yes (difficult 
in obese 
women, may 
cause  damage 
to intestines) 
First: 
Squeezing 
the uterus 
 
Last resource: 
Plugging the uterus 
using gauze 
(Surgical non- 
invasive) 
Second: Intrauterine 
douche at a temperature 
180° F 
 
 
 
 
 
1935 
 
 
 
 
5 
Ergot glass ampoules 
containing one dose 
IM (Ergotin) and 
pituitary extract IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
manual removal 
Third: Yes but 
if case of 
severe flooding 
start with it 
Yes (difficult 
in obese 
women, may 
cause  damage 
to intestines) 
First: 
Squeezing 
the uterus  
 
Last resource: 
Plugging the uterus 
using gauze 
(Surgical non- 
invasive) 
Second: Intrauterine 
douche at a temperature 
180° F 
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1938 6 
E,  glass ampoules 
containing one dose 
IM (Ergometrine) and 
pitocin IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted,(first 
time mention and 
description of Cred’s 
manoeuvre), if fail 
manual removal 
Second:  Yes 
but if case of 
severe flooding 
start with it 
NM 
Yes, First: 
Squeezing 
the uterus 
(mentioned 
the word 
uterine 
massage) 
 
NM 
Third: ( after uterus 
gained contractility): 
Intrauterine douche at a 
temperature 180° F of 
dettol, or inject sterile 
glycerine intrauterine 
 
 
1942 
 
 
 
 
 
7 
IM or IV 0.5 mg E 
(asap) 
 
E,  glass ampoules 
containing 0.5 mg IM 
(Ergometrine) and 
pitocin IM 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
expression under 
anaesthesia if not manual 
removal(Ergot 8 hr for 3-4 
days) 
Second:  Yes 
but if case of 
severe flooding 
start with it 
NM  
Yes, First: 
Squeezing 
the uterus 
  
NM  
Third:( if the uterus 
unable to maintain 
tone): Intrauterine 
douche  of dettol, at a 
temperature 180° F  
 
 
 
1948 
 
 
 
 
 
8 
Before the  birth of 
placenta 
0.5 mg E, IM 
After the  birth of 
placenta 
5 units OX IM  or E 
0.5 mg IM 
 
 
Before the  birth of 
placenta 
Fundal squeezing while 
uterus contracted, if fail 
expression under 
anaesthesia if not manual 
removal 
Second:  Yes 
but if case of 
severe flooding 
start with it 
NM 
Yes, First: 
Squeezing 
the uterus 
In addition 
to drug 
NM 
Third:  
Repeat ergot if uterine 
contractility not achieved 
 
 
 
 
1955 
 
 
 
 
 
9 
After the  birth of 
placenta  and 
patient not received 
E 
E 0.5 mg IV 
 
Before the  birth of 
placenta 
One attempt of Crede’s 
manoeuvre,  fundal 
squeezing while uterus 
contracted, if fail and in 
hospital expression under 
anaesthesia if not manual 
removal, If patient in poor 
facility place: E 0.5MG IV 
Second:  Yes 
but if case of 
severe bleeding 
start with it  
NM 
Yes, First: 
Rub the 
uterus 
 
NM 
Divide the treatment 
according to: 
1. Placenta delivered or 
not 
2. Patient received E  or 
not 
3.  Available facility 
such as    anaesthesia and 
blood transfusion 
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if failed transfers to 
hospital for manual 
removal 
Third:  Repeat ergot or 
give 10 IU OX if uterine 
contractility not achieved  
with bimanual  
compression  
1961 10 
After the  birth of 
placenta  and 
patient not received 
E 
E 0.5 mg IV 
Before the  birth of 
placenta 
Crede’s  manoeuvre,  
(become unpopular) , cord 
traction if fail  manual 
removal 
 
Second:  Yes 
but if case of 
severe bleeding 
start with it 
while waiting 
for E to act 
NM 
Yes, First: 
Rub the 
uterus 
 
NM 
Third: Repeat E IMM,  
transabdominally if 
uterine contractility not 
achieved  with bimanual  
compression 
1966 
11 
 
 
 
 
 
 
 
 
After the  birth of 
placenta  and 
patient not received 
E 
E 0.5 mg IV 
Before the  birth of 
placenta 
If separated:  Backward 
and downward pressure or 
CT 
If not separated:  
B-A method 
Crede’s  manoeuvre if 
uterus contracted one 
attempt if failed manual 
removal 
Second:  Yes 
but if case of 
severe bleeding 
start with it  
NM 
Yes, First: 
Rub the 
uterus,  
 
Hysterectomy if 
sever bleeding 
Third: Repeat E 
injection if uterine 
contractility not achieved  
with bimanual  
compression 
 
 
 
 
 
1972 
 
 
 
 
 
 
12 
After the  birth of 
placenta  and 
patient not received 
E 
E 0.5 mg IV 
Before the  birth of 
placenta 
If separated:  Backward 
and downward pressure or 
CT 
If not separated:  
B-A method, if uterus 
contracted one attempt if 
failed manual removal  
(Crede’s manoeuvre NM) 
Second:  Yes 
but if case of 
severe bleeding 
start with it 
NM 
Yes, First: 
Rub the 
uterus 
 
Hysterectomy if 
sever bleeding 
Third:  Repeat E 
injection if uterine 
contractility not achieved  
with bimanual  
compression 
247 
 
 
 
1980 
 
 
13 
After the  birth of 
placenta   
First: E 0.5 mg IV 
even the patient  
received E 
 
Before the  birth of 
placenta 
Manual removal under GA 
 
Second:  Yes  NM NM 
Last resource: 
Hysterectomy 
Divide  treatment of PPH 
into 2 principles arrest 
the bleeding restore 
blood volume) 
Taking in consideration 
bleeding disorders 
 
 
1985 
 
 
 
 
14 
After the  birth of 
placenta   
First: E 0.5 mg IV  
Before the  birth of 
placenta 
If separated:  B-A method, 
if uterus contracted  
If not separated:  
Manual removal under 
GA.  
Second:  Yes NM 
Yes, First:  
with fundal 
pressure 
Last resource: 
Hysterectomy 
 
1990 
 
 
 
 
 
15 
After the  birth of 
placenta   
First: E 0.5 mg IV 
Before the  birth of 
placenta 
If separated:  B-A method, 
if uterus contracted  
If not separated:  
Manual removal under 
GA. 
Second:  Yes NM 
Yes, First:  
with fundal 
pressure 
Last resource: 
Hysterectomy, in 
case of 
uncontrolled 
bleeding 
 
1995 16 
After the  birth of 
placenta   
First: E/OX 0.5 mg 
IV 
Before the  birth of 
placenta 
If separated:  B-A method, 
if uterus contracted  
If not separated:  
Manual removal under 
GA. 
Second:  Yes NM 
Yes, First:  
with fundal 
pressure 
Last resource: In 
case of 
uncontrolled 
bleeding, internal 
iliac artery ligation 
or  hysterectomy, 
 
 
 
 
2000 
 
 
17 
First : 1. E 0.5 mg 
IM(repeat with IV if 
bleeding continue)  
2. OX 100 IU in 1 
litre of normal saline, 
20 drops/min (these 
as first line ), 
 NM NM Yes, First   
Third: Arterial 
ligation if possible 
 
To avoid 
hysterectomy: 
-Uterine packing 
 
Treatment of atonic PPH 
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Second: PGF2  
alpha(second line) IM 
or intramyometrial 
  
-Balloon 
tamponade 
(Sengstaken-
blahemore tube) 
-Embolisation of 
pelvic vasculature 
2006 
 
18 
E and OX IV (to 
maintain contraction) 
PGF2  alpha(second 
line) IM or IMM  
 
 Yes, First   NM Yes, First   
If medical 
treatment fail 
Balloon tamponade 
(Rusch urological 
catheter) 
-Rarely, bilateral 
IIAL or 
hysterectomy  
Treatment of atonic PPH 
 
Empty the bladder 
2011 
 
 
 
 
19 
 
 
 
First:  
OX bouls, E/OX 
And OX 40 IU IN 
500 ml  saline over 4 
hr 
Or E, PGF2  alpha or 
PG E2 
 Yes, First   NM Yes, First   
If medical 
treatment fail 
Balloon tamponade 
Radiological 
occlusion of 
uterine vessels 
Laporatomy for 
bilateral IIA 
ligation 
Uterine 
compression 
sutures 
  Last resource:  
Hysterectomy 
Empty the bladder as an 
empty bladder aid uterine 
contraction 
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Appendix C.1. Search strategy  
 
(Same search strategy was used for all databases (Cochrane library, the Embase, the 
Ovid version of Midline, the Web of Knowledge and Scopus) 
 
A. Any intervention used 
• Pharmacological 
#1 oxytocin   
#2 pitocin  
#3 misoprostol 
#4 ergometrine 
#5 ergonovine 
#6 methergine 
#7 ergot alkaloid 
#8 methyl ergometrine 
#9 syntometrine 
#10 prostaglandin 
#11 tranexamic acid 
#12 traditional Chinese medicine 
#13 oxytocin agonist 
#14 carbetocin 
• Cord management 
#15 cord clamp 
#16 placental cord drainage 
#17 controlled cord traction 
#18 umbilical cord injection 
• Uterine manipulation 
#19 uterine massage 
#20 fundal pressure 
• Others 
#21nipple stimulation 
#22 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 
or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21) 
 
 
B. Third stage labour/ postpartum haemorrhage 
#23 postpartum h?emorrhage 
#24 third stage labo?r 
#25(#23 or#24) 
 
C. (#22 and #25) 
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Appendix C.2. Translation form 
 
To be completed by the translator. 
 
Please note: full translations of papers are not necessary. The following questions 
are designed to assist in the extraction of necessary information for the inclusion of 
randomised controlled trials in a systematic review.  
Date of translation:  
Translator:  
Language of the paper:   
A. Publication details:  
1. Authors:  
2. English title 
3. Original title:  
4. Journal Name:  
5. Year:   Volume:                      Issue:                  Pages:  
 
B. Introduction/abstract 
 
1. What is the objective of the study? 
 
C. Materials and methods 
 
2. Is this study described as being a randomised control trial? 
 
If Yes,  please continue with Sections C-D below.  
 
If No – we do not need any further information, but please give a description of the 
study (e.g. a review article, a case-controlled study, a cohort study, a letter to a 
journal, a controlled before and after study, etc). 
 
3. What is the total number of patients participating in the trial?  
4. Were the participant described as low or high risk to postpartum  
haemorrhage? 
5. Stage of pregnancy (in weeks) 
6. Mode of delivery (vaginal or caesarean)  
7.  In which country the study was conducted? 
8. Where were the patients recruited from (e.g. community centre, hospital, 
outpatients clinic, emergency department, city, rural setting)? 
9. What were the inclusion criteria?   
10. What were the exclusion criteria? 
11. Is there any information on the measurement of blood loss?  if yes,  (What 
method used to measure it, when they start measuring it and for how long) 
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12. What was the definition of postpartum haemorrhage in the paper? 
 
13. Is there any outcome that clearly stated as primary? If NO go to Q 16 
14. Did the authors clearly differentiate between primary and secondary 
outcomes? 
• If Yes (please answer Q 15)  
• If No (go to Q16) 
 
15. What were the primary outcome measures?  
16. What were the secondary (other) outcome measures? 
17. Is there any outcomes that mentioned as main or key outcomes?( If yes 
please list them) 
18. If the haemoglobin or the haematocrit level were mentioned in the outcome 
measures, when was (in hours) the second postpartum sample of blood taken? 
19. Is there any information on sample size calculation? If yes, what outcome is 
used for sample size calculation? 
D. Results  
 
20.  Were the results reported in tables/graphs? If so, please indicate if the term 
primary or secondary outcomes used for the table title or subtitle and list the 
outcomes that considered as primary and the one that considered as secondary within 
the result table? 
      E. Is there any additional information which you consider significant?  
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Appendix C.3. RCT data extraction form  
Serial No Extractor Nasreen  
Year of publication 
 
 
Reference 
 
 
Number of 
participants included  
 
Type of intervention 
 
Setting   
Location   
Type of participants  
Study objective  
Primary outcomes 
Not pre-specified  
Explicitly pre-specified 
Not explicitly pre-specified 
 
Primary outcome (define) 
 
SSC  
Not pre-specified  
pre-specified  based on primary outcomes 
pre-specified  not based on primary outcomes 
 
Outcome used for 
SSC if different 
 
Secondary outcomes  
Does the outcomes 
stated clearly in the 
abstract and/or the 
main text 
 
How was the blood 
loss measured 
 
Subgroups 
Mode of delivery: 
Duration of pregnancy: 
Risk of women for PPH :  
ID= identification number; SSC= sample size calculation; PPH= postpartum 
haemorrhage. 
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Appendix C.4. Systematic review data extraction form  
Serial No Extractor Nasreen  
Reference  
 
 
 
 
What is the type of 
review? 
 
     Cochrane review                             Non-Cochrane review 
What was the type of 
intervention assessed? 
 
Outcomes 
Dose the study differentiate between primary and secondary outcomes? 
    Yes                                                        No (exclude) 
Primary outcomes  
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Appendix C.5. RCTs primary outcomes 
 
 
Number of trials 
(n=121) 
SSC/ 
clearly 
stated 
SSC/ 
not 
clearly 
stated 
clearly 
stated/no 
SSC 
Mentioned 
as main 
Mentioned 
as objective 
Total     
(%) 
(n=121) 
A. Maternal outcomes 
1. Blood loss 
1. 1. Incidence of Postpartum haemorrhage 
1.1.1  Incidence of PPH > 500 mls 
Incidence of PPH > 500 mls (time 
of blood collection not defined) 
5 3  2  10 (8%) 
Incidence of PPH > 500 mls, 48hrs 
after delivery 
1  1   2 (2%) 
Incidence of PPH > 500 mls within 
24 hrs. after delivery 
1     
1 
(0.8%) 
1.1.2.  Incidence of PPH ≥ 500 mls 
Incidence of PPH ≥ 500  mls  
(time of blood collection not 
defined)  
7     7 (6%) 
Incidence of PPH ≥ 500  mls  up to 
1 hr. after delivery 
6 1    7 (6%) 
Incidence of PPH ≥ 500 mls within 
2 hrs. after delivery 
1 2 1   4 (3%) 
Incidence of PPH ≥ 500 mls within 
24 hrs. after delivery 
4     4 (3%) 
Incidence of PPH ≥ 500  mls  up to 
1 hr. after delivery of placenta 
2     2 (2%) 
Incidence of PPH ≥ 500  mls (until 
active bleeding stop for minimum 
of 1 hr. after delivery) 
1     
1 
(0.8%) 
1.1.3.  Incidence of PPH >1000 mls 
Incidence of PPH > 1000  mls  
(time of blood collection not 
defined) 
2   1  3 (2%) 
Incidence of PPH > 1000  mls (up 
to 2hrs after delivery of baby) 
1     1(0.8%) 
Incidence of PPH > 1000 mls 
within 24 hrs. of delivery 
  1   1(0.8%) 
A.1.1.4.  Incidence of PPH ≥ 1000 mls 
Incidence of PPH ≥ 1000 mls 
within1 hr. after delivery 
3  1   4 (3%) 
Incidence of PPH ≥ 1000 mls   
(time of blood collection not 
defined) 
1  2   3 (2%) 
Incidence of PPH ≥ 1000 mls 
within 2 hrs. after delivery 
 
 
 
1     1(0.8%) 
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1.1.5.  Other incidence of PPH 
Incidence of PPH (amount and 
time of blood collection not 
defined) 
1  2   3 (2%) 
Incidence of PPH > 800 mls (time 
of blood collection not defined) 
1     1(0.8%) 
Incidence of primary PPH (amount 
not defined) within 1 hr. of 
delivery 
  1   1(0.8%) 
Incidence of PPH (> 500 mls  OR 
10% drop in haematocrit value [ 
24 hrs. after delivery]) 
1     1(0.8%) 
Delayed haemorrhage within the 
first 24hrs 
  1   1(0.8%) 
1. 2. Amount of blood loss 
1.2.1. Measured blood loss 
Mean measured blood loss up to 1 
hrs. post delivery 
3  2  1 6 (5%) 
Mean measured postpartum blood 
loss within 24hrs of delivery   
1  1 1 1 4 (3%) 
Mean measured postpartum blood 
loss (time  of blood collection not 
defined) 
  2 2  4 (3%) 
Mean measured blood loss (within 
2hrs  after delivery of baby) 
3    1 3 (2%) 
Mean measured blood loss, total 
before and after placental delivery 
(time  of blood collection not 
defined) 
   1  1(0.8%) 
Amount of measured blood loss 
(1-2 hrs. after delivery) (median) 
1     1(0.8%) 
Median measured postpartum 
blood loss over 72hrs 
 1    
1 
(0.8%) 
Mean measured blood loss (2 
hours after delivery of placenta) 
    1 
1 
(0.8%) 
Measured blood loss of 300 mls  
or more within 30 minutes after 
delivery 
1     1(0.8%) 
1.2.2. Estimated blood loss 
Estimated blood loss during 
caesarean section 
3  1   4 (3%) 
Mean estimated blood loss (time  
of blood collection not defined) 
2    1 3 (2%) 
Mean estimated blood loss 2hrs. 
after delivery 
1     
1 
(0.8%) 
Mean estimated blood loss for 8 
hrs. post delivery 
1     
1 
(0.8%) 
Mean estimated blood loss within 
48hrs post-delivery 
1     
1 
(0.8%) 
Median estimated blood loss (4 
hours post-operative) 
1     
1 
(0.8%) 
2. Maternal blood indices  
Difference in pre and post-delivery 
HB (24 hrs.) 
1  4 2  7 (6%) 
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Difference in pre and post-delivery 
HB (12 hrs.) 
3     3 (2%) 
Difference in pre and post-delivery 
HB (72 hrs.) 
 1  1  2 (2%) 
Decrease in HB and haematocrit 
from baseline to 24hrs after 
delivery 
1  1   2 (2%) 
Drop in HB > 2 g/dl from before to 
3 -5 days post- delivery 
  1   
1 
(0.8%) 
Postpartum anaemia (HB <  8 g/dl) 
3-5 days post-delivery 
  1   
1 
(0.8%) 
Postpartum HB < 10 g/dl 
 
   1  
1 
(0.8%) 
Changes in HB and haematocrit 
during postpartum period (at 24 
and 36 hrs.) 
   1  
1 
(0.8%) 
Difference in pre and post-delivery 
haematocrit (time of blood 
collection not defined) 
  1   
1 
(0.8%) 
Difference in pre and post-delivery 
HB time of blood collection not 
defined) 
 1    
1 
(0.8%) 
Difference in pre and post-delivery 
haematocrit (24 hrs.) 
   1  1(0.8%) 
Difference in pre and post-delivery 
haematocrit (48hrs.) 
1     
1 
(0.8%) 
Haematocrit drop 10% or greater 
24 hrs postpartum 
  1   
1 
(0.8%) 
Postpartum HB ≥ 2 g/dl lower than 
pre-delivery HB 
 
  1   
1 
(0.8%) 
3. Maternal assessment/ intervention side effect 
Maternal side effect of 
intervention  
   8 1 9 (7%) 
Change in blood pressure 
 
   2  2 (2%) 
Atony or haemorrhage requiring 
treatment (medical or surgical) 
(composite outcome) 
1     
1 
(0.8%) 
4. Other interventions used 
Use of additional uterotonics 
 
4 1 12 6  23 
Manual removal of placenta 
 
 1 2 1  4(3%) 
Need for blood transfusion 
 
  3 1  4 (3%) 
Proportion of patient requiring 
additional uterotonic for uterine 
atony (48hrs.) 
1  1   2(2%) 
Additional uterotonic to control 
PPH 
  1   
1 
(0.8%) 
Need for additional uterotonic in 
the first 24 hrs. 
 
1     1(0.8%) 
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Number of women need uterine 
massage 
  1   
1 
(0.8%) 
5. Duration of the third stage 
Mean duration of the third stage of 
labour 
 
1  2 4 2 9 (7%) 
Duration of the third 
stage(median) 
   1  
1 
(0.8%) 
Duration of the third stage 
(number, percentage) 
  1   
1 
(0.8%) 
Third stage equal to or > 30 
minutes 
  1   
1 
(0.8%) 
6. Maternal mortality and morbidity  
Maternal mortality 
 
  1   
1 
(0.8%) 
Endometritis 
 
   1  
1 
(0.8%) 
7. Others 
Length of hospital stays for the 
mother. 
   2  2 (2%) 
Consumption of paracetamol 
 
   1  
1 
(0.8%) 
B. Neonatal outcomes 
Newborne venous haematocrit 6 
hrs. after birth 
1     
1 
(0.8%) 
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Appendix C.6. RCTs secondary outcomes 
 
Secondary outcome Number of trails (%)   
(n=121) 
A. Maternal outcomes  
A.1.  Blood loss 
A.1.1.Incidence of postpartum haemorrhage 
A.1.1.1Incidence of PPH > 500 mls 
 PPH > 500 mls (time of blood collection not defined) 6 (5%) 
PPH > 500 mls within 2 hrs. after delivery 2 (2%) 
PPH > 500mls (within the first hr. after delivery) 1(0.8%) 
A.1.1.2 Incidence of PPH ≥ 500 mls 
Incidence of PPH ≥ 500 mls within 24hrs after delivery 4 (3%) 
Incidence of PPH ≥ 500 mls (time of blood collection not defined)  4 (3%) 
Incidence of PPH ≥ 500 mls within 2 hrs. after delivery 3 (2%) 
Incidence of PPH ≥ 500 mls up to 1 hr. after delivery of baby 2 (2%) 
Incidence of PPH ≥ 500 mls in 30 minutes 1(0.8%) 
Incidence of PPH ≥ 500 mls up to 1 hr. after delivery of placenta 1(0.8%) 
A.1.1.3 Incidence of PPH > 1000 mls 
Sever haemorrhage > 1000 mls  (time  of blood collection not defined) 5 (4%) 
A.1.1.4 Incidence of PPH ≥ 1000 mls 
Incidence of PPH ≥ 1000 mls within 2 hrs. of delivery of baby 8 (7%) 
Incidence PPH ≥ 1000 mls (time of blood collection not defined) 4 (3%) 
Incidence of PPH ≥ 1000 mls within1 hr. after delivery 4 (3%) 
Incidence of PPH ≥ 1000 mls within 1 hrs. from delivery of placenta 2 (2%) 
Incidence of PPH ≥ 1000 mls in 30 minutes 1(0.8%) 
A.1.1.5  Other incidence of PPH 
Incidence of primary PPH (amount not defined) within 1 hr. of delivery 4 (3%) 
Delayed haemorrhage within the first 24hrs 4 (3%) 
Clinical diagnosis of PPH (visually estimated blood loss, amount of blood loss 
and  time of diagnosis not defined) 
2 (2%) 
Incidence of blood loss  ≥ 1500 mls within 1 hr. after delivery 1(0.8%) 
Intermediate and severe PPH (≥ 750 and  ≥ 1000 mls; until active bleeding stop 
for minimum of 1 hr. after delivery) 
1(0.8%) 
Intermediate and severe PPH (≥ 750 and  ≥ 1000 mls) 1 hr. after delivery 1(0.8%) 
Incidence of blood loss ≥ 1500 mls within 1 hr. after delivery 1(0.8%) 
Incidence of PPH defined as blood loss of > 400 mls within 2 hrs. after birth 1(0.8%) 
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Severe haemorrhage (amount not defined) in 48hrs 1 (0.8%) 
A.1.2. Amount of blood loss 
A.1.2.1. Measured blood loss 
Mean measured blood loss (within 2hrs of delivery) 11 (9%) 
Mean measured blood loss (time of blood collection not defined) 7 (6%) 
Mean measured blood loss up to 1 hrs. after delivery of baby 6 (5%) 
Mean measured blood loss up to 1 hrs. after delivery of placenta  4 (3%) 
Mean measured postpartum blood loss over 72hrs 2 (2%) 
Mean and median measured blood loss within 1 hr. postpartum 1 (0.8%) 
Mean measured blood loss (until active bleeding stop for minimum of 1 hr. after 
delivery) 
1 (0.8%) 
Mean measured blood loss within 24hrs of delivery  1 (0.8%) 
Measured blood loss of from ≥ 500-999 mls 1 (0.8%) 
A.1.2.2. Estimated blood loss 
Mean estimated blood loss (time of blood estimation not defined) 12 (10%) 
Mean estimated blood loss within 24hrs post-delivery 2 (2%) 
Amount of blood loss from placental delivery to end of CS 1 (0.8%) 
Estimated blood loss (%) (time not defined) 1 (0.8%) 
Estimated blood loss during caesarean section    1 (0.8%) 
Median estimated blood loss (time not defined) 1 (0.8%) 
Median estimated blood loss (4 hours post-operative) 1 (0.8%) 
Amount of blood loss from end of CS to 2hrs. after delivery 3 (2%) 
A. 2. Maternal blood indices 
Difference in pre and post-delivery HB (24 hrs.) 14 (12%) 
Difference in pre and post-delivery HB (48 hrs.) 11 (9%) 
Haemoglobin concentration 24hrs postpartum 7 (6%) 
Difference in pre and post-delivery haematocrit (48 hrs.) 5 (4%) 
Difference in pre and post-delivery haematocrit (24 hrs.) 4 (3%) 
Change in HB concentration in pre and 12 hrs. post-delivery  3 (2%) 
Incidence of a 10% decrease in HB between pre and 24 hrs. post-delivery 2 (2%) 
Difference in pre and post-delivery haematocrit (12 hrs.) 1 (0.8%) 
Difference in pre and post-delivery HB (20 hrs.) 1 (0.8%) 
Haemoglobin < 9g/dl and < 11g/dl (3-5 days post-delivery) 1 (0.8%) 
Haemoglobin < 8 g/dl and < 10g/dl (12-24 post-delivery) 1(0.8%) 
Decline of 6% unit or more in haematocrit (8-24 hrs.) post-delivery 1 (0.8%) 
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HB concentration < 6 g/dl 24 hrs. after delivery 1 (0.8%) 
HB concentration 24-48hrs postpartum 1 (0.8%) 
Haematocrit drop 10% or greater 24hrs postpartum 1 (0.8%) 
Mean drop in HB (3-5 days post-delivery) 1 (0.8%) 
Percentage of women with >10% decline in postpartum HB (12-48 hrs.) 1 (0.8%) 
Reduction in HB > 20% (severe anaemia) 48hrs after delivery 1 (0.8%) 
A haemoglobin drop of 30 mg/L or greater(24-36hrs) 1 (0.8%) 
Postpartum HB  ≥ 2g/dl lower than pre-delivery HB 1 (0.8%) 
Drop in haemoglobin concentration (time not defined) 1 (0.8%) 
Difference in postoperative blood chemistry (creatinine, alkaline .phos. Na) 1 (0.8%) 
A. 3. Assessment of mother/Intervention side effect 
Maternal side effect of intervention  77 (64%) 
Change in blood pressure  8 (7%) 
Uterine tone 6 (5%) 
Change in clinical parameter (pulse, T, BP) 5 (4%) 
Uterine fundal position over time 2 (2%) 
Frequency of postpartum pain 2 (2%) 
Severity of maternal side effect of intervention 1 (0.8%) 
Vital signs during and after the operation 1 (0.8%) 
Acceptability of misoprostol sublingually my the women 1 (0.8%) 
Postpartum uterine involution over 24hrs 1 (0.8%) 
General health at 6 weeks 1 (0.8%) 
A. 4. Duration of the third stage 
Mean duration of the third stage of labour 30 (25%) 
Duration/length of the third stage (median) 5 (4%) 
Duration/length of the third stage (number, percentage) 5 (4%) 
Third stage > 30 minutes 3 (2%) 
Third stage equal to or > 30 minutes 1 (0.8%) 
A. 5. Intervention used 
Use of additional uterotonic 52 (43%) 
Need for blood transfusion 48 (40%) 
Manual removal of placenta 22 (18%) 
Subsequent evacuation of uterus 7 (6%) 
Surgical intervention to control PPH  5 (4%) 
Maternal admission ICU 2 (2%) 
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Need to transfer to high facility 2 (2%) 
Need for uterine massage 2 (2%) 
Additional uterotonic to treat uterine atony 1 (0.8%) 
Additional uterotonic to control PPH 1 (0.8%) 
Other procedure to treat PPH 1 (0.8%) 
Other procedure to treat uterine atony 1 (0.8%) 
Bimanual compression  1 (0.8%) 
Exploration under general anaesthesia 1 (0.8%) 
Infused fluid volume 1 (0.8%) 
A. 6. Placenta-related outcomes 
Frequency / incidence of retained placenta 10 (8 %) 
Time from bolus/ injection to delivery of placenta 2 (2%) 
Mode and timing of delivery of placenta 1 (0.8%) 
Percentage of placenta remained undelivered beyond 15 minutes 1 (0.8%) 
Placenta delivered spontaneously 1 (0.8%) 
A. 7. Maternal mortality and morbidity 
Maternal mortality 8 (7%) 
Hysterectomy 3 (2%) 
Maternal morbidity (e.g. admission to ICU, prolonged hospitalisation) 1 (0.8%) 
Maternal morbidity (composite outcome, hysterectomy, blood loss ≥ 2000 mls, 
uterine inversion) 
1 (0.8%) 
Morbidity requiring admission  1 (0.8%) 
Endometritis 1 (0.8%) 
Laporatomy 1 (0.8%) 
Frequency of haemorrhagic shock 1 (0.8%) 
Number of patient with major complication (not defined) 1 (0.8%) 
Third and fourth degree tear 1 (0.8%) 
A. 8. Others 
Length of hospital stays for the mother. 10 (8 %) 
Cost of oxytocic 2 (2%) 
Women and staff satisfaction with the third stage management  1 (0.8%) 
Duration of surgery (minutes) 1 (0.8%) 
Delay before need for additional uterotonic 1 (0.8%) 
Safety outcomes (e.g. fluid overload requiring diuretics) 
 
1 (0.8%) 
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B. Neonatal outcomes 
Neonatal outcomes(Apgar score, arterial blood pressure, heart rate, oxygen 
saturation) 
2 (2%) 
Initiating breastfeeding 2 (2%) 
Birth weight 2 (2%) 
Apgar score 1 (0.8%) 
Admission to special baby unit 1 (0.8%) 
Infant health (admission to intensive care unit, Phototherapy for jaundice, no 
problem reported)  
1 (0.8%) 
Neonatal haematocrit at 24-48 hr. of age 1 (0.8%) 
Early neonatal morbidity and mortality (e.g. jaundice, sepsis, necrotizing colitis 
and death) 
1 (0.8%) 
Admission to neonatal  ICU 1 (0.8%) 
Newborn length of hospital stay 1 (0.8%) 
Any neonatal disease that occurred between birth and one month of age 1 (0.8%) 
Type of feeding at 1 month of age 1 (0.8%) 
Neonatal side effect of intervention 1 (0.8%) 
Need for supplement lactation 1 (0.8%) 
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Appendix D.1. Survey on bimanual uterine compression 
 
1. What is your job? 
 
2. How effective do you think bimanual compression is at stopping bleeding (score 1-5)?  
 
[1= completely ineffective, 5= very effective] 
 
3. How many times have you used bimanual compression for PPH during the last year? 
None 
1 
2 
3 
4 
5 
More 
 
4. Why do you not use the manoeuvre of bimanual compression more frequently? (Tick all 
that apply)  
• Not effective 
• It is too invasive to the woman 
• It is too tiring to do 
• There are more effective methods to stop the bleeding 
• Fear of harming the woman 
• Other 
 
5. If there was a rapid test that could tell you whether bleeding was coming from 
lacerations anywhere in the vagina or perineum or not, how helpful would it be in your 
management? 
 
a) Very helpful 
b) A little bit helpful 
c) Not helpful at all 
 
6. If there was a rapid test that could tell you whether bleeding was coming from 
lacerations anywhere in the vagina or perineum or not, do you that that it would lead to 
reduction in the total blood loss? 
 
a) Yes 
b) May be 
c) No 
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Appendix D.2. Staff feedback on the first mannequin study 
 
1. What do you think of the mannequin? 
 
 
 
 
 
 
 
 
2. Please write your comment about the ideas. 
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Appendix D.3. Feedback sheet for the feasibility study on BMC 
 
1. Noelle
® 
 
 
 What do you think of Noelle
®
? 
        0= highly disagree                    10 = highly agree 
• Anatomical accuracy of vagina and cervix (0-10) 
• Feel of uterus (0-10) 
• Realism when conducting BMC (0-10) 
 
 Would you suggest any modification to the uterus? 
 
2. Mama Natalie 
 
 What do you think of Mama Natalie? 
         0= highly disagree                    10 = highly agree 
• Anatomical accuracy of vagina and cervix (0-10) 
• Feel of uterus (0-10) 
• Realism when conducting BMC (0-10) 
 
 Would you suggest any modification to the uterus? 
 
 
 
  
 
 
 
 
 
 
 
 
 
